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ABSTRACT
The EU Medicinal Products Directive (65/65/EEC) has been amended to require an environ­
mental risk assessment (ERA) for human pharmaceuticals effective January 1995. At pre­
sent, official ERA guidelines have yet to be finalised. Previous discussions about their nature 
have taken place in the absence of a systematic analysis of the potential environmental im­
pacts of pharmaceuticals. This study attempts to address this deficiency via a review of ex­
isting ecotoxicity data. Acute ecotoxicity data relating to >100 human pharmaceuticals have 
been collated. They suggest a lack of acute effects at <100 pg/\ in standard tests. Relative 
sensitivity based on acute effects was algae (most sensitive) > Daphnia > fish. Chronic ef­
fects data were limited and this was identified as a shortcoming. This was reinforced by ob­
servations of large differences between acute and chronic responses to steroids in fish. The 
availability of UK usage data permitted risk characterisation i.e., calculation of PEC/PNEO
ratios for >60 compounds. Under "worst-casé1 fate assumptions of no human metabolism, 
passage of all material to drain, no removal during wastewater treatment and no surface wa­
ter dilution of effluent, the large majority of pharmaceuticals yielded PEC/PNEC ratios <i (in 
theory implying environmental safety). For the remainder, a consideration of surface water 
dilution and expected wastewater treatment removal was sufficient to yield PEC/PNEC <1. 
PNEC was based on acute effects data with an assessment factor of 1,000. These assess­
ments ignore the potential for multiple exposure/mixture effects. Calculation of potential 
lifetime ingestion via drinking water employing * worst-case'' assumptions (as above and no re­
moval during drinking water treatment) revealed I 70 values (based on ingestion of 2 li­
tres/day for 70 years) generally equivalent to <Z days of the corresponding daily therapeutic 
doses. Refinement of the exposure calculations or comparisons with monitoring data con­
firmed the degree of conservatism associated with the * worst-case" exposure estimations.
i Predicted Environmental Concentration (PEC) and Predicted No-Effect Concentration (PNEC).
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CHAPTER 1 
INTRODUCTION
INTRODUCTION
There is a growing literature in relation to observations of human pharmaceuticals in the en­
vironment, in particular from sewage and surface waters. These have been reviewed else­
where (Daughton A Ternes, 1999: EA, 2000). Discussions about the environmental conse­
quences (i.e., safety or risk) of the presence of such compounds have taken place in the gen­
eral absence of a systematic analysis of the potential risk, with only a few notable exceptions 
(Halling-Sarensen et al., 1998; Stuer-Lauridsen et ai, 2000). This can partly be attributed to 
the lack of public domain information relating to the ecotoxicity of pharmaceuticals. Concur­
rently, there have been various regulatory developments in the USA and EU relating to re­
quirements for environmental risk assessment (ERA) of new drug actives as part of their 
registration process. The lack of such an analysis means that to date, decisions concerning 
ERA criteria have been somewhat arbitrary or based on comparisons with inappropriate 
groups of industrial chemicals such as pesticides. This study aims to address that deficiency 
and collates examples of data relating to the environmental fate/concentration (Chapter 2) 
and ecotoxicity (Chapter 3) of existing pharmaceuticals. W here possible, these data are em­
ployed i^environmental risk assessments of compounds in the aquatic compartment (Chapter 
4). Quantitative 'worst-case" estimates of indirect human exposure via drinking water are 
similarly benchmarked against potential effects endpoints such as daily therapeutic dosage 
(Chapter 5). These elements and others are considered further in the General Discussion 
(Chapter 6). The overall intention is to provide perspective that will prove useful during the 
further development of regulatory assessment criteria.
REFERENCES
Daughton CG, Ternes TA (1999) Pharmaceuticals and personal care products in the environment. Envi­
ronmental Health Perspectives 107 (Supplement. 6): 907-938.
8
EA (2000) Review o f Human Pharmaceuticals in the Environment. R A D  Technical Report P390 (Ay- 
scough NJ, Fawell J, Franklin G 4  Young VV). Research Contractor WRc_NSF Ltd. Environment Agency.
Hailing-Sorenson B, Mors Nielsen S, Lanzky PF, Ingerslev F, Holten-Uitzhoft HC, Jorgensen SE (1998) 
Occurrence, fate and effects of pharmaceutical substances in the environment - A review Chemos- 
phere 36(2): 357-393.
Stuer-Lauridsen F, Birkved M, Hansen LP, Ho I ten Lützhoft HC, Hailing-Sorensen B (2000) Environ­
mental risk assessment o f human pharmaceuticals in Denmark a fter normal therapeutic use. Chemos- 
phere 40(7): 7 8 3 -7 9 3 .
9
CHAPTER 2 
FATE A EXPOSURE DATA
INTRODUCTION
An increasing number of human pharmaceuticals have been reported in the environment (e.g., 
Stumpf et a/., 1996; Heberer etal., 1997; Ternes, 1998; Hirsch etal., 1999). Data relating to 
observations in sewage, surface waters, groundwater and drinking water are collated here. 
Similarly, data influencing the fate of pharmaceuticals in the environment such as physico­
chemical properties, biodégradation profile or fate during wastewater treatment have also 
been collated. An extensive discussion of fate and observed environmental concentrations 
per se will not be undertaken here. This has adequately been dealt with elsewhere (e.g., EA, 
2000). The main thrust of this study is the benchmarking of predicted and observed concen­
trations against available ecotoxicity data. The data in this chapter have been collated to as­
sist in this purpose.
PHYSICO -CHEMICAL DATA
The physico-chemical characteristics of pharmaceuticals help to determine their fate, e f­
fects and bioaccumulation. Of particular importance in this respect are the molecular weight 
(M W ), the octanol/water partition coefficient (Kq w ) and the acid dissociation constant (pKa). 
Details of Chemical Abstracts Service numbers (CAS # ), molecular weight, octanol/water 
partition coefficients (as log Kqw) and dissociation constants (Table 1).
The octanol/water partition coefficient (K q w )  is a  surrogate measure of hydrophobicity/ 
lipophilicity. Hydrophobicity in turn helps to determine adsorption to organic solids (Karick- 
hoff 1981), ecotoxicity (Clements et al., 1993; Kaiser & Esterby, 1991; Kdnemann, 1981) and 
bioconcentration/bioaccumulation (Mackay, 1982; Veith A Kosian, 1983; Geyer et al., 1991). 
The acid dissociation constant (pKa), together with ambient pH, determines the extent to 
which medicinal compounds exist in the unionised or ionised form. When the pKa of a drug and
the pH of the aqueous phase is known, the proportion of ionised/unionised moieties can be 
calculated Via the familiar Henderson-Hasselbach equations (see Bowman A Rand, 1980).
Table 1. - Physico-chemical characteristics of selected pharmaceuticals [from 
Bowman & Rand (1980); Dollery (1991); Hansch et al.. (1995); Newton & Kluza, 
(1978); Raymond & Born (1986); Hoekman, (1997)].
Compound CAS# MW log Kow2 pKo3
Acarbose 56180-94-0 645 2.40 5.1
. Acriflavine 86-40-8 224.27 -1.78
Aiendromc Acid 66376-36-1 249.1
Aminosidin/Neomycin E 7542-37-2 615.56
Amitriptyline 50-48-6 277.44 5.04* 9.4c
Amobarbital 57-43-2 226.27 2.11/2.07 7.94a
Amopyroquin 550-81-2 353.83 2.57(7.4)
Amphetamine 300-62-9 135.21 1.76* 9.8c
Aprotinin 9087-70-1 6500
Aspirin 50-78-2 180.17 1.19* 3.5a
Atropine 55-55-8 289.38 1.83* 9.9c
Azithromycin 83905-01-5 748.99
Bacitracin 1405-87-4 1422.59 -0.92
Bicalutamide 90357-06-5 430.4
Budesonide 51333-22-3 430.55 3.28
2 Preferred values from Hansch e t al. (1995) are denoted by an asterisk. Values in parenthesis denote 
the pH at which KoW was determined.
3 Anion forming (i.e., acidic) denoted by a and cation forming (i.e., basic) by c.
Caffeine 58-08-2 194.22 -0.07* 0.6 c, 13.9a
Carved i loi 72956-09-3 406.48
Cefprozil 92665-29-7 389.4
Ceftibuten 97519-39-6 410.42
Cetirizine 83881-51-0 388.89 1.70*
Chloramine T 127-65-1 227.67
Chloramphenicol 56-75-7 323.15 1.14* 5.5
Chloroquine 54-05-7 319.89 4.63* 8.4c, 10.8c
Cimetidine 51481-61-9 252.34 0.40* 6.8c
Cisapride 81098-60-4 465.95
Cladribine 4291-63-8 285.69
Clofibric Acid 882-09-7 214.66 2.57* 2.95a
Cyclophosphamide 50-18-0 261.10 0.63*
Cyclosporin A 59865-13-3 1202.6 2.92 (7.4)
Dextroproproxyphene 469-62-5 33048 418 (9 2)* 63c
Diazepam 439-14-5 284.76 2.99 (7.4)* 3.2c
Didanosine 69655-05-6 236.2 -1.24 (7.0)
Diethylstilbestrol 56-53-1 268.34 5.07*
Digoxin 20830-75-5 780.92 1.26*
Dirithromycin 62013-04-1 835.1
Dorzolamide 120279-96-1 324.4
Erythromycin 114-07-8 733.95 2.54 (8.0)* 8.8c
Ethinyl Oestradiol 57-63-6 296.41 3.67* 10.5
Famciclovir 104227-87-4 321.3
Famotidine 768224-35-6 337.43 -0.57(9.2) 7.1
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Finasteride 98319-26-7 372.55 3.03
Flumazenil 78755-81-4 303.29 1.15 1.7
Flumequine 42835-25-6 261.26 1.11 (7.2)
Fluoxetine 54910-89-3 309.3 1.82 (7.4)
Fluticasone 80474-14-2 500.6
Gabapentin 60142-96-3 171.2
Ibuprofen 15687-27-1 206.27 3.50(2.0)* 5.2a
Ifosamide 3778-73-2 261.07 0.86*
lopromide 73334-07-3 791.12 -2.33
Isoniazid 54-85-3 137.16 -0.70* 2.0c, 3.85c
Ketoprofen 22071-15-4 254.29 2.76
Ketorolac 74103-06-3 255.27 2.72 3.54
Lansoprazole 103577-45-3 369.4
Li neomycin 154-21-2 406.56 0.20* 7.6c
Lithium Carbonate 554-13-2 73.89
Lithium Citrate 6080-59-6 281.99
Lomefloxacin 98079-51-7 351.35 -0.80*
Loracarbef 76470-66-1 349.8
Losartan 114798-26-4 461.0
Methotrexate 59-05-2 454.47 2.28
Metformin 657-24-9 129.17 -1.43 2.8c, 11.5
Metronidazole 443-48-1 171.16 -0.02* 2.62c
Midazolam 59467-70-8 325.77 1.53(7.4) 6.2
Milrinone 78415-72-2 211.22
Naproxen 22204-53-1 230.26 3.24 (2.0)* 4.39a
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Nefazodone 83366-66-9
Nicotine 54-11-5 162.23 1.17(11.0)* 3.2c, 8.0c
Nitrofurazone 59-87-0 198.14 0.23 (7.4)*
Omeprazole 73590-58-6 345.42 2.23* 4.0, 8.7
Ondanestron 103639-04-9 293.37 7.4
Orphenadrine 83-98-7 269.36 3.77* 9.0c
Oxolinic Acid 14698-29-4 261.2
Oxytetracycline 79-57-2 460.44 -0.89 (5.5) 
-0.92 (6.6) 
-1.60 (7.5)
3.3c, 7.3a, 
9.1c
Paclitaxel 33069-62-4 853.9"
Paracetamol 103-90-2 151.18 0.51 (2.0)* 9.5a
Paroxetine 61869-08-7 329.37
Perindopril 82834-16-0 368.47
Pentobarbital 57-33-0/
76-74-4
226.27 2.07V2.10* 8.11a
Phénobarbital 50-06-6 232.26 1.47 (2.0)* 7.2a
Porfirmer Sodium 87806-31-3
Propranolol 525-66-6 259.35 2.98 (10.2)* 9.5c
Quinacrine 83-89-6 399.93 1.91(7.4)
Quinidine 56-54-4 324.43 2.88 (7.4)* 4.2c, 8.8c
Quinine 130-95-0 324.43 2.64 (7.4)* 4.1c, 8.5c
Ranitidine 66357-35-5 314.41 0.27(10.5)* 2.7c, 8.2c
Risperidone 106266-06-2 410.5
Salicylic Acid 69-72-7 138.12 2.26* 3.0a, 13.4a
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Salmeterol 89365-50-4 415.8
Secobarbital 76-73-3 238.3 1.97 7.92a,12.60a
Simethicone 8050-81-5 15k - 26k >12 .54
Spirapril 83647-97-6 467.1 -1.10(7.4)
Stavudine 3056-17-5 224.2 -0.81*
Streptomycin 57-92-1 581.6
Sulfadiazine 68-35-9 250.3
Sulfadimethoxine 121-11-2 310.33 1.63 (4.0)* 5.9a
Sulfamerazine 127-79-7 264.30 0.14* 7.1a
Sulfamethazine 57-68-1 278.33 0.28 (4.0)* 2.36c, 7.38a
Sulfisoxazole 127-69-5 267.30 1:01* 5.0a
Sumatriptan 103628-46-2 295.40 -1.17
Tetracycline 60-54-8 444.45 -1.05 (5.3) 
-1.44 (7.5)
3.3a, 7.7a, 
9.7c
Theophylline 58-55-9 180.19 -0.02* 0.7c, 8.8a
Thiopental 76-75-5 2.85* 7.45a
Thioridazine 50-52-2 370.56 5.90 9.5c
Thiotepa 52-24-4 189.2 0.53*
Tolazoline 59-98-3 160.21 2.65 10.3c
Tramadol 27203-92-5 263.39 2.63(7.4)*
Verapamil 52-53-9 454.59 3.79 (9.0)* 8.75c
Warfarin 81-81-2 308.35 2.70* 5.0a
Zalcitabine 7481-89-2 211:2 -1.30*
4 Bruggemcm e f al. (1984);
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When pH is equal to the pKa, unionised and ionised moieties exist in equal proportion. The de­
gree of ionisation of acidic drugs increases with increasing pH and acidic drugs with lower pKa 
values will tend to ionise more easily. In the case of basic drugs, the converse is true and the 
degree of ionisation decreases with increasing pH and drugs with higher pKa values will tend 
to ionise more easily. This phenomenon is important as the degree of ionisation will influence 
lipid solubility. In  turn, lipid solubility is relevant to important fate and effects processes 
such as adsorption, volatilisation, ecotoxicity and bio-accumulation. In general, neutral com­
pounds will be more lipid soluble and consequently more highly adsorbed to organic solids, 
more toxic and bioconcentrated to a greater degree than their ionised counterparts. I t  is 
notable that most medicinal compounds are either weak acids or weak bases One evident 
shortcoming in the consideration of the effective environmental exposure of pharamaceuti- 
cals is the general lack of experience in dealing with the fate of ionisable compounds. This is 
particularly the case for wastewater treatment processes. Whereas the predominant influ­
ence upon the adsorption of neutral compounds to organic solids during wastewater treat­
ment is hydrophobicity, interactions with ionised compounds are less well understood. Under 
circumstances where a significant proportion of a compound is present as the ionised moiety, 
actual adsorption to organic solids (Koc) will deviate from that predicted for the neutral moi­
ety from hydrophobicity alone (i.e., log Kqw) and adsorption will therefore also be a function 
of pKa and ambient pH. Following a consideration of the pKa values, it is likely that the degree 
of removal via adsorption during wastewater treatment of many pharmaceuticals will deviate 
from that predicted from hydrophobicity alone. Biomass/bacterial matter within wastewater 
treatment plants is negatively charged. As such anionically charged compounds (i.e., acids) will 
tend to be repulsed by negatively charged bacteria. The corollary is that cationically charged 
compounds (i.e., bases) will tend to be attracted by the biomass. For reference, the typical 
operational pH of activated sludge treatment plants is ~6.5. Under such conditions, acidic 
compounds with pKa values <6.5 will be present predominantly as the anionic moiety, whereas
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basic compounds with pKa >6.5 will be present as the cationic moiety. One of the few empiri­
cal studies to deal with the effects of pH upon the sludge/water distribution coefficient 
(kd) of an ionisable compound is Ziegenfuss and Hannah (1994). Their study demonstrated 
how adsorption of 2,4,5-Trichlorophenol (pKa 7.4) to activated sludge solids was positively re­
lated to the proportion of unionised (i.e., neutral compound). Overall, this is an area that re­
quires further research.
BIODEGRADATION DATA
Richardson A Bowron (1985) selected 25 human pharmaceutical compounds for biodégrada­
tion studies "on the basis of high quantity in use, potential for being noxious or because on 
reviewing the literature the drug seemed to survive sewage treatment". The results from 
these studies are presented below (Table 2). Compounds highlighted as 'Non-biodegradable' 
failed to comply with test criteria (Ready Biodégradation Test) and are not necessary totally 
recalcitrant and persistent. However, no information on by-products or metabolites was re­
ported. In  the case of the anti-microbials, test concentration may have influenced the out­
come of the testing. The relevance or applicability of the tests per se may also be questioned 
as they are typically conducted at relatively high concentrations (mg/1 range). This is greatly 
in excess of likely real-world concentrations. In addition to biodégradation, other degrada­
tion/removal process may apply (i.e., photodegradation, adsorption, hydrolysis, volatilisation 
etc.). For example, the photodegradation half-life of aqueous Tetracycline is reported to 
range from 88 - 130 hours (Peterson et al., 1993). Likewise, the photodegradation half-life of 
Diclofenac is reported as <1 hour in a Swiss lake (Buser et ai, 1998a).
Henschel et al. (1997) reports on the ready biodegradability (OECD 301F) of Salicylic Acid, 
Paracetamol, Clofibrinic Acid and Methotrexate. Only Salicylic Acid yielded a categorical 
positive result. Paracetamol was borderline and both Clofibrinic acid and Methotrxate failed.
Table 2. - Biodégradation results for 25 selected human pharmaceutical com­
pounds (from Richardson & Bowron, 1985).
Drug Category Biodegradability5
Amitriptyline Anti-depressant 'Non-biodegradable*
Ampicillin Anti-bacterial . Inherently biodegradable'
Aspirin Analgesic; Anti-pyretic; 
Anti-inflammatory
'Readily biodegradable*
Caffeine CN5 stimulant 'Readily biodegradable'
Chlorhexidine Topical anti-bacterial; Dis­
infectant
'Non-biodegradable'
Clofibrate Anti-hyperlipoproteinemic ' No n-b iodegradab le '
Codeine Phosphate Narcotic analgesic; Anti- 
tussive
' Ndn-b iodegradab le '
Dextroproproxyphene Narcotic analgesic 'Non-biodegradable*
Ephedrine Bronchodilator; Deconges­
tant
'RB + acclimation'
Erythromycin Anti-bacterial 'Non-biodegradable'
Ibuprofen Anti-inflammatory Inherently biodegradable'
Menthol Topical anti-pruritic 'Readily biodegradable’
Meprobamate Anxiolytic ' Non-b iodegradab le '
Methyldopa Anti-hypertensive Non-biodegradable'
Metronidazole Anti-protozoal 'Non-biodegradable*
Naproxen» Anti-inflammatory; Analge­
sic; Anti-pyretic
'Non-biodegradable'
s 1RB ♦ acclimation' denotes readily biodegradable a fter acclimation.
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Nicotinamide Vasodilator 'Readily biodegradable'
Paracetamol Analgesic; Anti-pyretic 'RB + acclimation'
Phenylpropanolamine Decongestant: Anorexic 'RB + acclimation'
Su 1 phamet hoxazo le Anti-bacterial; Anti- 
pneumocystis
'Non-biodegradable'
Sulphasalazine Treatment of ulcerative co­
litis A Crohn's disease
'Non-biodegradable'
Tetracycline Anti-amoebic; Anti­
bacterial; Anti-ricketettsial
'Non-biodegradable'
Theobromine Diuretic; Bronchodilator; 
Cardiotonic
RB + acclimation'
Theophylline Bronchodilator 'Readily biodegradable'
Tolbutamide Anti-diabetic 'Non-biodegradable'
Another study has demonstrated that both lopromide and Ethinyl Oestradiol are non-readily 
biodegradable (Schweinfurth et ai, 1996). Ingerslev et al. (1998) similarly reports that both 
Oxytetracycline and Metronidazole are non-readily biodegradable. Kümmerer et al. (1996) 
reports limited biodégradation of Ifosfamide and Cyclophosphamide in the Closed Bottle 
Test (CBT - OECD 301D). Similarly, the limited biodégradation of Cefotiam, Ciprofloxacin, 
Ifosf amide, Meropenem, Metronidazole, Ofloxacin, Penicillin and Sulphamethoxazole is de­
scribed by Kümmerer et al. (1997), Al-Ahmad et al. (1999) and Kümmerer et al. (2000). The 
biodégradation profile of 12 sulfonamides is reported by Ingersleev & Halling-Sorensen 
(2000). None were degraded in screening tests conducted at concentrations below microbial
6 Van e t al. (1995) reports a marked degree of biodégradation of Naproxen.
7 Wotzka e t al. (1994) reports a BODg/COD ratio of 73.68% for Paracetamol following adaption 
(BODg/COD >50% = 'Readily Biodegradable').
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inhibitory thresholds. Al-Ahmad et al. (2001) report that Vinca alkaloid antineoplastics are 
not readily biodegrab le in the CBT test. The anti neoplasties Mitoxantron and Treosulfane are 
similarly reported as non-readily biodegradable by Al-Ahmad (1997). The general lack of bio­
dégradation of iodinated x-ray contrast media is highlighted in Steger-Hartmann et al. 
(1998; 1999). Ready biodégradation test methodologies (i.e., OECD 301A-F) are given in 
OECD (1992).
ENVIRONMENTAL CONCENTRATIONS
Possible routes of environmental exposure to human pharmaceuticals are depicted in Figure 1. 
A certain proportion of drugs will typically be excreted from the body via urine or faeces 
following administration as the parent material or as a metabolite. This will enter the sewage 
before arriving at the sewage treatment plant (STP). A proportion of unused drugs may also 
be present in sewage following disposal to drain. During sewage treatment, a certain propor­
tion of any compound will be typically be removed by biodégradation and/or adsorption to 
sewage sludge solids. Adsorbed compounds will typically be applied to land during sludge ap­
plication, incinerated or landfilled. Landfill is also a sink for medicines diposed of via the solid 
waste stream. Discharges from sewage treatment plants will contribute to surface water and 
sediment loadings. Groundwater is potentially contaminated via landfill leachate or exchange 
with sludge amended soils or surface waters. Surface waters will also be potentially subject 
to contamination from surface run-off. Potable water is extracted from surface waters or 
groundwater.
In considering the fate of pharmaceuticals, Richardson and Bowron (1985) paid particular at­
tention to anti-neoplastic agents, immunosuppresants, compounds with morphinian sub­
structure, oral contraceptives, Penicillins and Aspirin. Environmental concentrations of such 
pharmaceuticals that were observed or summarised by Richardson and Bowron (1985) are
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presented below (see Table 3) together with observations from other subsequent studies. 
Most notable amongst these is Ternes (1998) who conducted a comprehensive survey of the 
occurrence 32 drugs in German sewage effluent discharges and rivers. In  total, over 60 com­
pounds are listed.
Figure 1. - Routes of environmental exposure for human pharmaceuticals.
Sewage Treat­
ment Plant
Sediment
Soil
Ground WaterSurface Water
Disposal
Landfill
Excretion
(faeces/urine)
Sewage
Water Treatment Plant
Drinking Water
Human Drugs
Overall, most observations from the various studies were in the ng/l range with maximal con­
centrations for some compounds in the low /jg/l range. The highest concentrations were un­
surprisingly associated with untreated influent (i.e., raw sewage) from hospitals. Observa­
tions of Caffeine were attributed to beverages,'rather than drugs (Richardson & Bowron, 
1985). The presence of Aspirin in effluent has at least partly been attributed to microbial 
degradation of naphthalene oils from oil spillages, rather than pharmaceuticals (Richardson & 
Bowron 1985). I t  is notable that Paracetamol, the most frequently consumed pharmaceutical, 
was not recorded as being detected in surface waters by Richardson A Bowron (1985) or 
Ternes (1998). Rogers et al. (1986) report the detection of Ibuprofen, Naproxen and Clofi-
bric Acid in primary treated sewage effluent without details of concentrations. The ex­
tremely high values (i.e., pg/\ range) for Ethinyl Oestradiol reported by Tabak et al. (1981) 
contrast markedly with other reported observations (i.e., ng/l range) and should therefore 
be treated with some caution.
Table 3. - Observed environmental concentrations (ng/l) of human pharmaceuticals 
in raw sewage, sewage effluent, river water and potable water.
Drug Sewage
Influent
Sewage
Effluent
River
Waters
Potable 
& Ground 
Waters
Reference
Aspirin ~ 1,000 Richardson A 
Bowron 
(1985)
Aspirin <50 -1510 Stumpf et 
ai (1996)
Aspirin (i) median 
220 (ii) 
maximum 
1500
(i) median 
<20 (ii) 
maximum 
340
Ternes
(1998)
Betaxolol (i) median 
57 (ii) 
maximum 
190
(i) median 
<10 (ii) 
maximum 
28
Ternes
(1998)
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Bezafibrate (i) median 
2,200 (ii) 
maximum 
4,600
(i) median 
350 (ii) 
maximum 
3,100
Ternes
(1998)
Bisoprolol (i) median 
57 (ii) 
maximum 
370
(i) median 
<10 (ii) 
maximum 
2,900
Ternes
(1998)
Bleomycin (i) range 11 
19 (ii) 
mean 15.8
(i) range 
<5 -17 (ii) 
mean 8 5
(i) range 
5 - 1 3  (ii) 
mean 8.7
Aherne et al. 
(1990)
Caffeine ~ 1,000 > 1,000 Richardson & 
Bowron 
(1985)
Caffeine 16 - 292 Rogers et al. 
(1986)
Caffeine 2,000 - 
33,000
Paxéus
(1996)
Carazolol (i) median 
<25 (ii) 
maximum 
120
(i) median 
<10 (ii) 
maximum 
110
Ternes
(1998)
Carbamazepine (i) median 
2,100 (ii) 
maximum 
6,300
(i) median 
250 (ii) 
maximum 
1,100
Ternes
(1998)
24
Chloramphenicol (i) median 
<20 (ii) 
maximum 
560
(i) median 
<20 (ii) 
maximum 
60
<20 Hirsch et al. 
(1999)
Ch lorotetracyc 1 i ne <50 <50 <50 Hirsch et al. 
(1999)
Ciprofloxacin 8,000 - 
87,000 
(hospital)
Hartmann et 
al. (1998)
Ciprofloxacin range
5.000 -
90.000 
(hospital)
primary 
250 - 370 
final 70 - 
80
Alder et al. 
(1998)
Clarithromycin 240 (i) median 
<20 (ii) 
maximum 
260
<20 Hirsch et al. 
(1999)
Clenbuterol (i) median 
<50 (ii) 
maximum 
80
<10 Ternes
(1998)
Clofibric Acid ~ 40 Richardson <& 
Bowron 
(1985)
Clofibric Acid Detected Rogers et a/. 
(1986)
25
Clofibric Acid <222 10 - 165 Stan et al. 
(1994)
Clofibrinic Acid <1 - 100 Kalbfus
(1995b)
Clofibric Acid <0.5 - 
1,750 
(Berlin)
Heberer
(1995)
Clofibric Acid <0.5 - 220 
(Europe)
Heberer
(1995)
Clof ibric Acid <50 - 1560 <5 - 180 Stumpf et 
al. (1996)
Clofibric Acid
-
7 0 -
7,300
Heberer et 
a/. (1997)
Clofibric Acid Swiss 
Lakes <1 - 
9
North Sea 
-0.5 - 7.8
Baser et al. 
(1998b)
Clofibrote <100 <30 Ternes
(1998)
Clofibric Acid (i) median 
360 (ii) 
maximum 
1,600
(i) median 
66 (ii) 
maximum 
550
Ternes
(1998)
Cloxacillin <20 <20 <20 Hirsch etal. 
(1999)
26
Cyclophosphamide 146
(hospital)
Steger- 
Hartmann et 
al. (1996)
Cyclophosphamide (i) median 
<10 (ii) 
maximum 
20
<10 Ternes
(1998)
Dextropropoxyphene ~ 1,000 Richardson & 
Bowron 
(1985)
Diazepam < 1,000 ~ 10 : ~ 10 Waggott
(1981)
Diazepam (i) median 
<30 (ii) 
maximum 
50
<30 Ternes
(1998)
Dichlorfenac
•
<2,000 15-304  
(Rhine) 
38 - 489
Stumpf et 
al. (1996)
Dichlorfenac nd- 380 Heberer et 
a/. (1997)
Diclofenac range <1 - 
12 (lakes) 
range 11- 
310 (riv­
ers)
Buser et al. 
(1998a)
27
Diclofenac (i) median 
810 (ii) 
maximum 
2,100
(i) median 
150 (ii) 
maximum 
1,200
Ternes
(1998)
Dicloxacillin <20 <20 <20 Hirsch etal. 
(1999)
Diethylstilbestrol (i) range 
0 - 0.8
(ii) mean 
0.11 
0.24
Rurainski et 
al. (1977)
Dimethylamino-
phenazone
(i) median 
<100 (ii) 
maximum 
1,000
(i) median 
<30 (ii) 
maximum 
340
Ternes
(1998)
Doxcycline <50 <50 <50 Hirsch etal. 
(1999)
Erythromycin ~ 1,000 Watts et al. 
(1983)
Erythromycin
"
(i) median 
2500 (ii) 
maximum 
6,000
(i) median 
150 (ii) 
maximum 
1,700
<20 Hirsch et al. 
(1999)
28
Ethinyl Oestradiol (i) range 
0 - 22.5
(ii) mean 
0.69-
3.18
Rurainski et 
al. (1977)
Ethinyl Oestradiol (i) mean 
1210
(ii) range 
500 - 2250
(sic)
(i) mean 
810
(ii) range 
250 - 1780
(sic)
Tabak et al. 
(1981)
Ethinyl Oestradiol <5 <5 Aherne, Eng­
lish <5t Marks 
(1985)
Ethinyl Oestradiol <1-7 2 - 1 5 <1-4 . Aherne A 
Briggs 
(1989)
Ethinyl Oestradiol - 0.5 - 1.1 - - FWR (1992)
Ethinyl Oestradiol 0.3 - 0.5 <0.2 <0.2 Kalbfus
(1995)
Ethinyl Oestradiol (i) over 
half <0.2 
(ii) where 
detected 
0.2 - 7.0
Desbrow et 
al. (1996)
Ethinyl Oestradiol -10 Be If ro id et • 
al. (1998)
29
Ethinyl Oestradiol 0.76 Snyder et al. 
(1998)
Ethinyl Oestradiol <0.4 James et al. 
(1998)
Ethinyl Oestradiol (i) median 
[D]&9  
[Can] (ii) 
maximum 
15 [D] A 42 
[Can]
<0.5 [D] Ternes et al. 
(1999)
Etofibrate <100 <30 Ternes
(1998)
Fenofibrate nd - 45 Heberer et 
al. (1997)
Fenofibrate <50 <10 Ternes
(1998)
Fenof ibric Acid (i) median 
380 (ii) 
maximum 
1,200
[i) median 
45 (ii) 
maximum 
280
Ternes
(1998)
Fenoprofen <50 <10 Ternes
(1998)
Fenoterol (i) median 
<50 (ii) 
maximum 
60
[i) median 
<10 (ii) 
maximum 
61
Ternes
(1998)
30
Gembibrozil (i) median 
400 (ii) 
maximum 
1,500
(i) median 
52 (ii) 
maximum 
510
Ternes
(1998)
Ibuprofen Detected Rogers et al. 
(1986)
Ibuprofen <12,000 <5-41
(Rhine)
17-139
Stumpf et 
al. (1996)
Ibuprofen nd - 200 Heberer et 
al. (1997)
Ibuprofen (i) median 
370 (ii) 
maximum 
3,400
(i) median 
70 (ii) 
maximum 
530
Ternes
(1998)
Ibuprofen 990-
3,300
2 - 8 1 <0.2 - 7.8 Buser et al. 
(1999)
Ifosomide 24
(hospital)
Steger- 
Hartmann et 
al. (1996)
Ifosamide Median 109 
(hospital) 
Median 6.2 
- 8.5 
(communal)
Median 6.5 
-9.3 
(communal)
Kümmerer et 
a/. (1997)
31
Ifosamide (i) median 
<10 (ii) 
maximum 
2,900
<10 Ternes
(1998)
Indometacine (i) median 
270 (ii) 
maximum 
600
(i) median 
40 (ii) 
maximum 
200
Ternes
(1998)
Ketoprofen (i) median 
200 (ii) 
maximum 
280
(i) median 
<10 (ii) 
maximum 
120
Ternes
(1998)
AAeclofenamic Acid <50 <10 Ternes
(1998)
Methaqualone ~ 1,000 
(hospital)
Richardson & 
Bowron 
(1985)
Methicillin <20 <20 <20 Hirsch etal. 
(1999)
Methotrexate ~ 1,000 
(oncology 
clinic)
<6.25 <6.25 Aherne, Eng­
lish 4 Marks 
(1985)
Metoprolol (i) median 
730 (ii) 
maximum 
2,200
(i) median 
45 (ii) 
maximum 
2,200
Ternes
(1998)
32
"Morphinian Sub­
structure"
< 1,000 Richardson & 
Bowron 
(1985)
Nadolol (i) median 
25 (ii) 
maximum 
60
<10 Ternes
(1998)
Nafcillinn <20 <20 <20 Hirsch et al. 
(1999)
Naproxen Detected Rogers et al. 
(1986)
Naproxen (i) median 
300 (ii) 
maximum 
520
(i) median 
70 (ii) 
maximum 
390
Ternes
(1998)
Norethisterone < 10 Aherne, Eng­
lish & Marks 
(1985)
Norethisterone 8 - 2 0 <2-17 <2 - <10 Aherne & 
Briggs 
(1989)
"Oral Contracep­
tives"
<100 <200 Aherne, Eng­
lish A Marks 
(1985)
Oxacillin <20 <20 <20 Hirsch etal. 
(1999)
33
Oxytetracycline <50 <50 <50 Hirsch etal. 
(1999)
Paraceta­
mol/Acetaminophen
(i) median 
<500 (ii) 
maximum 
6,000
<150 Ternes
(1998)
"Penicilloyl Groups" <25 < 10 Richardson A 
Bowron 
(1985)
Penicillin G <20 <20 <20 Hirsch et al. 
(1999)
Penicillin V <20 <20 <20 Hirsch etal. 
(1999)
Phenazone <10 - 
1,250
Heberer et 
al. (1997)
Phenazone (i) median 
160
(ii) maxi­
mum 410
(i) median 
24 (ii) 
maximum 
950
Ternes
(1998)
Propranolol (i) median 
170 (ii) 
maximum 
290
(i) median 
12 00 
maximum 
590
Ternes
(1998)
Propyphenazone nd - 
1,465
Heberer et 
a/. (1997)
34
Roxithromycin (i) median 
680 (ii) 
maximum 
1,000
(i) median 
<20 (ii) 
maximum 
560
<20 Hirsch etal. 
(1999)
Salbutomol (i) median 
<50 (ii) 
maximum 
170
(i) median 
<10 (ii) 
maximum 
35
Ternes
(1998)
Sulfamethazine <20 <20 (i) me­
dian <20
(ii)
maximum
160
Hirsch et al. 
(1999)
Sulfamethoxazole ~ 1,000 Watts et al. 
(1983)
Sulfamethoxazole (i) median 
400 (ii) 
maximum 
2,000
(i) median 
30 (ii) 
maximum 
480
(i) me­
dian <20
(ü)
maximum
470
Hirsch etal. 
(1999)
Terbutalin (i) median 
<50 (ii) 
maximum 
120
<10 Ternes
(1998)
Tetracycline ~ 1,000 Watts et a/. 
(1983)
35
Tetracycline <50 <50 <50 Hirsch et al. 
(1999)
Theophylline ~ 1,000 Watts et al. 
(1983)
Timolol (i) median 
<25 (ii) 
maximum 
70
(i) median 
<10 (ii) 
maximum 
10
Ternes
(1998)
Tolfenamic Acid <50 <10 Ternes
(1998)
Trimethoprim (i) median 
320 (ii) 
maximum 
660
(i) median 
<20 (ii) 
maximum 
200
<20 Hirsch etal. 
(1999)
WASTEWATER TREATMENT REMOVAL
Several publications deal with the fate of human pharmaceuticals during wastewater treat­
ment. This is an important consideration as most sewage influent containing drug residues 
excreted via faeces and/or urine will be subject to wastewater treatment. The degree of 
removal during wastewater treatment is a major determinand of aquatic exposure. Reported 
observations are presented in Table 4 (AS denotes activated sludge and TF trickling filter).
Table 4. - Reported removal of pharmaceutical residues during wastewater treatment.
Compound WWTP Removal (%) WWTP Type Reference
Acetylsalicyclic Acid 81 AS Ternes (1998)
36
Bezafibrate 83 AS Ternes (1998)
Bezafibrate 27 TF Stumpf etal. (1999)
50 AS
Carbamazepine 7 AS Ternes (1998)
Clofibric Acid 51 AS Ternes (1998)
Clofibric Acid 15 TF Stumpf et al. (1999)
34 AS
Diclofenac 69 AS Ternes (1998)
Diclofenac 9 TF Stumpf et al. (1999)
75 AS
Dimethylaminophenazoen 38 AS Ternes (1998)
Ethinyl Oestradiol 64 TF Ternes etal. (1999)
78 AS
0 AS
Fenof ibric Acid 64 AS Ternes (1998)
Fenof ibric Acid 6 TF Stumpf et al. (1999)
45 AS
Gemfibrozil 69 AS Ternes (1998)
Gemfibrozil 16 TF Stumpf et al. (1999)
46 AS
Ibuprofen 22 TF Stumpf et al. (1999)
75 AS
Ibuprofen 90 AS Ternes (1998)
Ibuprofen 96 - 99.9 AS Buser et al. (1999)
Indometacine 75 AS Ternes (1998)
37
Indometacine 71 TF Stumpf et al. (1999)
83 AS
Ketoprofen 48 TF Stumpf et al. (1999)
69 AS
AAetroprolol 83 AS Ternes (1998)
Naproxen 66 AS Ternes (1998)
Naproxen 15 TF Stumpf et al. (1999)
78 AS
Phenazone 33 AS Ternes (1998)
Propranolol 96 AS Ternes (1998)
DISCUSSION
The presence of pharmaceuticals in the environment may arise from various sources such as 
manufacture, use or disposal. Within the current context, the key route of entry of human 
pharmaceuticals into the environment is a consequence of use by patients within the commu­
nity or within hospitals or clinics etc. Patients may excrete pharmaceuticals (or their 
metabolites) in urine or faeces or dispose of unused medicines via the sewage system. 
Emissions from pharmaceutical production facilities are typically highly controlled and are 
not thought to be responsible for the diffuse distribution of the wide range of compounds 
observed in the environment as highlighted here. The environmental exposure pathways 
(including potential transformation and depletion/removal mechanisms) of drugs in general 
have been reviewed by Velagaleti (1997).
Once within the sewage system drug residues will typically be subject to wastewater treat­
ment. Likely fate during waste water treatment will be dependent upon a variety of parame­
ters relating to physico-chemistry (i.e., Kg*, pKa, water solubility) and degradation via biologic
38
cal (i.e., biodégradation) or chemical (i.e., hydrolysis) pathways. Type of treatment will also be 
a major consideration. For example, Stumpf et al. (1999) demonstrate the higher efficiency 
of activated sludge treatment relative to trickling filter for all compounds considered. Dif­
ferences in fate during wastewater treatment can be illustrated by reference to different 
compounds. Compounds which are easily biodegraded show near complete removal (via miner­
alisation) during wastewater treatment e.g., 98% for Paracetamol (Ternes 1998). Other rela­
tively hydrophilic compounds (which may include conjugates) which are also more resistant to 
biodégradation will pass through the wastewater treatment plant so that overall removal is 
more limited e.g., 34% for Clofibric acid (Stumpf et al., 1999). The possibility for microbially 
mediated deconjugation of conjugates during wastewater treatment should also be consid­
ered as a factor potentially influencing ultimate environmental release. Other more hydro- 
phobic substances may exhibit relatively high removal during treatment due to absorption to 
solids rather than via biodégradation eg:. Penicillins (Halling-Serensen etal., 1998).
The large number of compounds that have been detected in the environment is amply illus­
trated in Table 3. Chief amongst these are analgesics, lipid regulators, antibiotics, steroids 
and anti-neoplastics. Concentrations vary according to the medium analysed. As expected, 
higher concentrations are associated with sewage influents and effluents than surface wa­
ters. This is well illustrated by the observations of Ternes (1998). Most observations in sur­
face waters are in the ng/l range, although a few compounds have been measured in the //g/l 
range e.g., Clof ibric Acid (Herberer et al., 1997). A major determ inand of drug residue con­
centration in surface waters will be the extent of dilution of the sewage effluent following 
discharge from the treatment plant. Ternes (1998) clearly demonstrates how drug concen­
tration is a function of river/stream size. There are relatively few reports of pharmaceuti­
cals in water supplies or drinking water (e.g., Heberer et al., 1997). Others have typically 
failed to detect pharmaceuticals in such water supplies (e.g., Hirsch et ai, 1999); An exten­
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sive discussion of fate and observed environmental concentrations per se will not be under­
taken here. This has adequately been dealt with elsewhere (e.g., EA, 2000). The main thrust 
of this study is the benchmarking of predicted and observed concentrations against available 
ecotoxicity data. The data in this chapter have been collated to assist in this purpose.
CONCLUSIONS
The increasing number of observations of pharmaceutical compounds in sewage, surface wa­
ters and drinking water supplies mean that the environmental fate of pharmaceuticals cannot 
and should not be ignored. These observations are associated with use of medicinal products 
by patients rather than emissions from manufacturing facilities. They imply exposure of 
aquatic biota and potentially indirect human exposure. This necessitates risk assessment. 
Risk assessment requires effects data against which to benchmark exposure. These points 
are addressed in the subsequent chapters.
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CHAPTER 3
ECOTOXICITY DATA
This chapter has been published in 'Pharmactuticals in Hu Environment - Sources. Fate. 
Effects and Risk? (Ed. K. Kümmerer) under the title ‘A Data Based Perspective on the 
Environmental Risk Assessment of Human Pharmaceuticals I  -  Collation of Available 
Ecotoxicity Ùata" pp 175-201 (Springer. 2001).
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INTRODUCTION
There is a growing literature relating to observations of human pharmaceuticals in the 
environment (see review by Halling-Serenson e t al., 1998). Discussions about the 
environmental consequences of the presence of such compounds have taken place in the 
general absence of a systematic analysis of the potential risk. This can partly be attributed 
to the lack of public domain information relating to the ecotoxicity of pharmaceuticals. The 
lack of such an analysis means that to date, decisions concerning Environmental Risk 
Assessment criteria and/or regulatory thresholds have been somewhat arbitrary or based 
upon inappropriate groups of industrial chemicals such as pesticides. This study attempts to 
address that deficiency and collates examples of data relating to the ecotoxicity of existing 
human pharmaceuticals. The intention is to provide perspective that will prove useful during 
the further development of assessment criteria. The database may also prove useful in the 
context of the risk assessment of individual substances.
METHODS
A review of available acute ecotoxicity data for macro-invertebrates, fish and algae was con­
ducted. Results of studies from searches of the published scientific literature were supple­
mented with details of studies from the grey-literature or regulatory submissions secured 
via contacts with colleagues from industry and academia. In  collating the data, attempts were 
made to ensure that the original sources of data were consulted. In many cases it was not al­
ways possible to establish if concentrations at the reported endpoints relate to nominal or 
measured concentrations. Inclusion of data does not imply endorsement - in terms of quality 
- of the study in question. A list of test of species is given in the Appendix (page 108).
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RESULTS 
Acute Ecotoxicity Data
The available acute ecotoxicity database for macro-invertebrates, fish and algae is 
presented in Table 1. There are over 360 endpoints for over 100 human pharmaceuticals.
Table 1. - Acute ecotoxicity data for human pharmaceuticals.
Compound Category* Value
(mg/l)
Endpoint/
Duration*
Species Reference
Acarbose Anti-diabetic >1000 EC50 Unspecified fish FDA-CDER (1996)
Acarbose Anti-diabetic >1000 EC50 Daphnia spp. FDA-CDER (1996)
Acriflavine Anti-infective 5 96h LC50 Morone saxatilis 
(larvae)
Hughes (1973)
Acriflavine Anti-infective 30.0 48h LC50 Morone saxatilis 
(fingerling)
Hughes (1973)
Acriflavine Anti-infective 28.0 72h LC50 Morone saxatilis 
(fingerling)
Hughes (1973)
Acriflavine Anti-infective 27.5 96h LC50 Morone saxatilis 
(fingerling)
Hughes (1973)
8 Therapeutic category is as detailed in the Merck Index (Budavari, 1989).
9 LC50 values relate to lethality in all organisms. EC50 values in Daphnia typically relate to immobilisation. 
In  the case of algae, EC50 values relate to effects upon growth (i.e., biomass or cell number).. US FDA 
test guidelines include 4,01 algal assay, 4,08 Oaphm  acute toxicity (48h), 4 09 Daphnia chronic test­
ing, 4.10 Hyalella azteca acute toxicity and 4.11 freshwater fish acute toxicity.
Acriflavine Anti-infective 30.1 24h LC50 Oncorhynchus my- 
kiss
Wilford (1966)
Acriflavine Anti-infective 19.9 48h LC50 Oncorhynchus my- 
kiss
Wilford (1966)
Acriflavine Anti-infective 37.5 24b LC50 Salve linus namay- 
cush
Wilford (1966)
Acriflavine Anti-infective 28.0 48b LC50 Salvelinus namay- 
cush
Wilford (1966)
Acriflavine Anti-infective 40.0 24b LC50 Salmo truffa Wilford (1966)
Acriflavine Anti-infective 27.0 48b LC50 Salma truffa Wilford (1966)
Acriflavine Anti-infective 43.5 24b LC50 Ictalurus punctatus Wilford (1966)
Acriflavine Anti-infective 33.2 48b LC50 Ictalurus punctatus Wilford (1966)
Acriflavine Anti-infective 48.0 24b LC50 Salvelinus fon- 
tinalis
Wilford (1966)
Acriflavine Anti-infective 14.8 48b LC50 Salvelinus fon- 
tinalis
Wilford (1966)
Acriflavine Anti-infective 18.0 24b LC50 Lepomis macrochi- 
rus
Wilford (1966)
Acriflavine Anti-infective 13.5 48b LC50 Lepomis macrochi- 
rus
Wilford (1966)
Alendronate So­
dium
Metabolic Bone 
Disease
1450 LC50 Pimephales prome- 
las
FDA-CDER (1996)
Alendronate So­
dium
Metabolic Bone 
Disease
>1000 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
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Alendronate So­
dium
Metabolic Bone 
Disease
22 LC50 Daphnia spp. FDA-CDER (1996)
Alendronate So­
dium
Metabolic Bone 
Disease
>0.5 MIC Green Algae FDA-CDER (1996)
Aminosidine Anti-bacterial; 
Anti-amebic
2,220 48h EC50 Artemia Migliore et al. 
(1997)
Aminosidine Anti-bacterial;
Anti-amébic
847 72h EC50 Artemia Migliore et al. 
(1997)
Aminosidine Sul­
phate (Neomycin
E)
Anti-bacterial;
Anti-amebic
1,055 24h LC50 D. magna Di Delupis et al. 
(1992)
Aminosidine Sul­
phate (Neomycin 
E)
Anti-bacterial;
Anti-amebic
503 48h LC50 D. magna Di Delupis et al. 
(1992)
Amitriptyline Anti-
depressant
1.2 24h EC50 D. magna Lilius et al. (1994)
Amitriptyline Anti-
depressant
36.9 24h LC50 Artemia salina Calleja et al. 
(1994a)
Amitriptyline Anti-
depressant
0.78 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Amitriptyline Anti-
depressant
5.55 24h EC50 D. magna Calleja et al. 
(1994a)
Amitriptyline Anti-
depressant
0.80 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Amobarbital Sedative; Hyp­
notic
85.4 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
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Amopyroquin Di­
hydrochloride
Anti-malarial 47.0 24h LC50 Oncorhynchus my- 
kiss
WiIlford (1966)
Amopyroquin Di­
hydrochloride
Anti-malarial 35.3 48h LC50 Oncorhynchus my- 
kiss
Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 15.5 24h LC50 Salvelinus namay- 
cush
Wi Ilford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 14.0 48h LC50 Salvelinus namay- 
cush
Willford (1966)
Amopyroquin Di­
hydrochloride
Anti-malarial 42.0 24h LC50 Salmo trutta Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 36.0 48h LC50 Salmo trutta Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 19.8 24h LC50 Ictalurus punctatus Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 12.5 48h LC50 Ictalurus punctatus Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 52.0 24h LC50 Salvelinus fon- 
tinalis
Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 40.0 48h LC50 Salvelinus fon- 
tinalis
Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 33.0 24h LC50 Lepomis macrochi- 
rus
Willford (1966)
Amopyroquin Di- 
hydrochloride
Anti-malarial 18.5 48h LC50 Lepomis macrochi- 
rus
Willford (1966)
Amphetamine Sul­
phate
CNS stimulant; 
Anorexic
28.8 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
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Amphetamine Sul­
phate
CNS stimulant; 
Anorexic
60 24h EC50 D. magna Lilius et al. (1994)
Amphetamine Sul­
phate
CNS stimulant; 
Anorexic
1515 24h LC50 Artemia salina Calleja et al. 
(1994a)
Amphetamine Sul­
phate
CNS stimulant; 
Anorexic
55 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Amphetamine Sul­
phate
CNS stimulant; 
Anorexic
270 24h EC50 0. magna Calleja et al. 
(1994a)
Amphetamine Sul­
phate
CNS stimulant; 
Anorexic
4.90 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Aprotinin Enzyme Inhibi­
tor (proteose)
>1,000 EC50 Daphnia spp. FDA-CDER (1996)
Aspirin Analgesic;
Anti-pyretic;
Anti­
inflammatory
1468 24h EC50 0. magna Lilius et al. (1994)
Aspirin Analgesic;
Anti-pyretic;
Anti­
inflammatory
382 24h LC50 Artemia salina Calleja et al. 
(1994a)
Aspirin Analgesic;
Anti-pyretic;
Anti­
inflammatory
178 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
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Aspirin Analgesic; 
Anti-pyretic;
Anti­
inflammatory
168 24h EC50 0. magna Calleja et al. 
(1994a)
Aspirin Analgesic; 
Anti-pyretic;
Anti­
inflammatory
141 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Atropine Sulphate Anti­
cholinergic;
Mydriatic
258 24h EC50 0. magna Lilius et al. (1994)
Atropine Sulphate Antir
cholinergic;
Mydriatic
15,773 24h LC50 Artemia salina Calleja et al. 
(1994a)
Atropine Sulphate Anti­
cholinergic;
Mydriatic
661 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Atropine Sulphate Anti­
cholinergic;
Mydriatic
356 24h EC50 0. magna Calleja et al. 
(1994a)
Atropine Sulphate Anti­
cholinergic;
Mydriatic
334 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Azithromycin Anti-bacterial >120 LC50 Unspecified amphi- 
pod
FDA-CDER (1996)
Azithromycin Anti-bacterial 120 EC50 Daphnia spp. FDA-CDER (1996)
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Bacitracin Anti-bacterial 34.1 24h EC50 Artemia salina 
(nauplii)
Migliore et al. 
(1997)
Bacitracin Anti-bacterial 21.8 48h EC50 Artemia salina 
(nauplii)
Migliore et al. 
(1997)
Bacitracin Anti-bacterial .34.1 24h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Bacitracin Anti-bacterial 21.8 48h LC50 Artemia salina 
(nauplii)
Brambilla etal. 
(1994)
Bacitracin Anti-bacterial 126.4 24h LC50 b. magna Brambilla et al. 
(1994)
Bacitracin Anti-bacterial 30.5 48h LC50 0;magna Brambilla et al. 
(1994)
Bacitracin Anti-bacterial 126.4 24h LC50 b. magna Di Delupis et al. 
(1992)
Bacitracin Anti-bacterial 30.5 48h LC50 b.magna Di Delupis et al. 
(1992)
Bicalutamide Non-steroidal
Anti-androgen
>5 EC50 baphnia spp. FDA-CDER (1996)
Bicalutamide Non-steroidal
Anti-androgen
>1 EC50 Unspecified green 
algae
FDA-CDER (1996)
Bicalutamide Non-steroidal
Anti-androgen
>1 EC50 Unspecified blue- 
green algae
FDA-CDER (1996)
Budesonide Anti­
inflammatory
20 EC50 baphnia spp. FDA-CDER (1996)
Budesonide Anti­
inflammatory
>19 LC50 Unspecified fish FDA-CDER (1996)
57
Caffeine CNS stimulant 151 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Caffeine CNS stimulant 684 24h EC50 Ù. magna Lilius etal. (1994)
Caffeine CNS stimulant 3,457 24h LC50 Artemia salina Calleja et al. 
(1994a)
Caffeine CNS stimulant 410 24h LC50 5  treptocephalus 
proboscideus
Calleja et al. 
(1994a)
Caffeine CNS stimulant 160 24h EC50 0. magna Calleja et al. 
(1994a)
Caffeine CNS stimulant 4,661 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Carved i loi Anti-
hypertensive;
Anti-anginal
>3 EC50 baphnia spp. FDA-CDER (1996)
Carved i loi Anti-
hypertensive;
Anti-anginal
1 LC50 Unspecified fish FDA-CDER (1996)
Cefprozil Anti-bacterial >642 EC50 baphnia spp. FDA-CDER (1996)
Ceftibuten Anti-bacterial >600 EC50 baphnia spp. FDA-CDER (1996)
Ceftibuten Anti-bacterial >520 LC50 Amphipod FDA-CDER (1996)
Cetirizine HCI Anti-histaminic 330 EC50 baphnia spp. FDA-CDER (1996)
Chloramine T Anti-bacterial 23.6 24h LC50 Penaeus setiferus Johnson (1976)
Chloramine T Anti-bacterial 22 96h LC50 Rasbora hetero- 
morpha
Tooby et al. 
(1975)
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Chloramphenicol Anti-bacterial;
Anti-
rickettsial
543 24h EC50 0. magna Jlius et al. (1994)
Chloramphenicol Anti-bacterial;
Anti-
rickettsial
2,042 24h LC50 Artemia salina Calleja et al. 
(1994a)
Chloramphenicol Anti-bacterial;
Anti-
rickettsial
305 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Chloramphenicol Anti-bacterial;
Anti-
rickettsial
1,086 24h EC30 D. magna Calleja et al. 
(1994a)
Chloramphenicol Anti-bacterial;
Anti-
rickettsial
2,074 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Chloroquine Phos­
phate
Anti-malarial; 
Anti-amebic; 
Anti-rheumatic
50 24h EC50 D. magna Lilius etal. (1994)
Chloroquine Phos­
phate
Anti-malarial; 
Anti-amebic; 
Anti-rheumatic
2,043 24h LC50 Artemia salina Calleja et al. 
(1994a)
Chloroquine Phos­
phate
Anti-malarial;
Anti-amebic;
Anti-rheumatic
11.7 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
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Chloroquine Phos­
phate
Anti-malarial;
Anti-amebic;
Anti-rheumatic
43.5 24h EC50 D. magna Calleja et al. 
(1994a)
Chloroquine Phos­
phate
Anti-malarial;
Anti-amebic;
Anti-rheumatic
4.39 24h LC50 Brachionus caty- 
ciflorus
Calleja et al. 
(1994a)
Cimetidine Anti-ulcerative 740 EC50 Daphnia spp. FDA-CDER (1996)
Cimetidine Anti-ulcerative >1000 LC50 Lepomis macrochi- 
rus
FDA-CDER (1996)
Cisapride Peristaltic
Stimulant
>1000 EC50 baphnia spp. FDA-CDER (1996)
Cisapride Peristaltic
Stimulant
>1000 LC50 Lepomis macrochi- 
rus
FDA-CDER (1996)
Cladribine Anti-neoplastic 233 EC50 baphnia spp. FDA-CDER (1996)
Clofibrate Anti-
hyperlipopro-
tein-emic
28.2 24h ECgo b, magna Kdpf (1995)
Clofibrate Anti- 
hyper lipopro- 
tein-emic
12.0 EC50 Unspecified algae Kdpf (1995)
Clof ibrinic Acid Anti-
hyperlipopro-
tein-emic
106 EC50 D. magna Henschel et al. 
(1997)
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Clofibrinic Acid Anti-
lyperlipopro-
tein-emic
86.0 18h EC50 Brachydanio rerio 
(embryos)
Henschel et al. 
(1997)
Clof ibrinic Acid Anti-
lyperlipopro-
tein-emic
89 72h EC50 Scenedesmus sub- 
spicatus
Henschel et al. 
(1997)
Cyclosporine Immuno­
suppressant
>100 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
Cyclosporine Immuno­
suppressant
20 EC50 baphnia spp. FDA-CDER (1996)
Dextroproproxy- 
phene HCI
Narcotic anal­
gesic
14.6 24b EC50 b. magna Lilius et al. (1994)
Dextroproproxy- 
phene HCI
Narcotic anal­
gesic
308 24b LC50 Artemia salina Calleja et al. 
(1994a)
Dextroproproxy- 
phene HCI
Narcotic anal­
gesic
7.6 24b LC50 Streptocephalus
proboscideus
Calleja et al. 
. (1994a)
Dextroproproxy- 
phene HCI
Narcotic anal­
gesic
19 24b EC50 b. magna Calleja et al. 
(1994a)
Dextroproproxy- 
phene HCI
Narcotic anal­
gesic
4.2 24b LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Diazepam Anxiolytic; 
Muscle Relax­
ant
65.4 24b LC50 Artemia salina Calleja et al. 
(1994a)
Diazepam Anxiolytic; 
Muscle Relax­
ant
103 24b LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
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Diazepam Anxiolytic; 
Muscle Relax­
ant
14.1 24h EC50 D. magna Calleja et a l.. 
(1994a)
Diazepam Anxiolytic; 
Muscle Relax­
ant
>10,00
0
24h LC50 Brachionus caly- 
ciflorus
Calleja etal. 
(1994a)
Diazepam Anxiolytic; 
Muscle Relax­
ant
4.3 24h EC50 D. magna Lilius et al. (1994)
Didanosine Anti-
(retro)viral
>1,020 ECSO Ù. magna FDA-CDER (1996)
Diethylstilbestrol Estrogen 4.0 LC50 b. magna Coats et al. (1976)
Diethylstijbestrol Estrogen >10 LC50 Physa spp. Coats et al. (1976)
Diethylstilbestrol Estrogen >1 48h LC50 Gambusia affinis Coats et al. (1976)
Diethylstilbestrol Estrogen 1.09 48h LC50 D. magna Zou A Fingerman 
(1997)
Diethylstilbestrol Estrogen 1.2 48h LC50 b. magna Baldwin et al. 
(1995)
Diethylstilbestrol Estrogen 316 14d LC50 Pimephales prome- 
las
Ranter et al. 
(1999)
Digoxin Cardio-tonic 24 24h EC50 b. magna Lilius et al. (1994)
Dirithromycin Anti-bacterial >2,880 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
Dirithromycin Anti-bacterial >48 EC50 b. magna FDA-CDER (1996)
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Dorzolamide HCI Carbonic anhy- 
drase inhibitor, 
treatment of 
glaucoma
>1,000 LC50 Pimephales prome- 
las
FDA-CDER (1996)
Dorzolamide HCI Carbonic anhy- 
drase inhibitor, 
treatment of 
glaucoma
699 EC50 b. magna FDA-CDER (1996)
Erythromycin Anti-bacterial 388 24h LC50 b.magna Di Delupis et al. 
(1992)
Erythromycin Anti-bacterial 211 48h LC50 b.magna Di Delupis et al. 
(1992)
Erythromycin
Phosphate
Anti-bacterial 818 24h LC50 Salvelinus namay- 
cush
Marking ef al. 
(1988)
Erythromycin
Phosphate
Anti-bacterial 410 96h LC50 Salvelinus namay- 
cush
Marking et al. 
(1988)
Erythromycin
Thiocyanate
Anti-bacterial >80 48h LC50 Oncorhynchus my- 
kiss, Salmo trutta, 
Salvelinus 
fontinalis, Ictalu­
rus punctatus, Le­
pomis macrochi rus 
A Salvelinus namay- 
cush
Wilford (1966)
Ethinyl Oestradiol Estrogen 5.7 24h EC50 b. magna Kdpf (1995)
Ethinyl Oestradiol Estrogen 0.84 EC50 Unspecified algae Kdpf (1995)
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Ethinyl Oestradiol Estrogen 6.4 48h EC50 D. magna Schweinfurth et 
al. (1996)
Ethinyl Oestradiol Estrogen 1.6 96h EC50 Oncorhynchus my- 
kiss
Schweinfurth et 
al. (1996)
Etidronic Acid Metabolic Bone 
Disease
200 96h LC50 Oncorhynchus my- 
kiss
Gledhill A Feijtel 
(1992)
Etidronic Acid Metabolic Bone 
Disease
868 96h LC50 Lepomis macrochi- 
rus
Gledhill A Feijtel 
(1992)
Etidronic Acid Metabolic Bone 
Disease
695 48h LC50 Ictalurus punctatus Gledhill A Feijtel 
(1992)
Etidronic Acid Metabolic Bone 
Disease
3.0 96h EC50 Unspecified algae Gledhill A Feijtel 
(1992)
Etidronic Acid Metabolic Bone 
Disease
527 48h EC50 D. magna Sledhill A Feijtel 
(1992)
Famciclovir Anti-viral >986 LC50 Lepomis macrochi- 
rus
FDA-CDER (1996)
Famciclovir Anti-viral 820 EC50 D. magna FDA-CDER (1996)
Famotidine Anti-ulcerative >680 LC50 Pimephales prome- 
las
FDA-CDER (1996)
Famotidine Anti-ulcerative 398 EC50 D. magna FDA-CDER (1996)
Finasteride Treatment of 
benign 
prostatic hy­
pertrophy
21 EC50 Daphnia spp. FDA-CDER (1996)
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Finasteride Treatment of 
benign 
prostatic hy­
pertrophy
20 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
Flumazenil Benzodiazepine
Antagonist
>500 EC50 0 . magna FDA-CDER (1996)
Flumequine Anti-bacterial 476.8 24h EC50 Artemia salina 
(nauplii)
Migliore etal. 
(1997)
Flumequine Anti-bacterial 307.7 48h EC50 Artemia salina 
(nauplii)
Migliore etal. 
(1997)
Flumequine Anti-bacterial 96.4 72h EC50 Artemia salina 
(nauplii)
Migliore etal. 
(1997)
Flumequine Anti-bacterial 477 24h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Flumequine Anti-bacterial 308 48h LC50 Artemia salina 
(nauplii)
Brambilla etal. 
(1994)
Flumequine Anti-bacterial 96.4 72h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Flut amide Androgen >1,000 14d LC50 Pimephales prome- 
las
Panter et al. 
(1999)
Fluticasone Propi­
onate
Corticosteroid
anti-asthmatic
0.55 EC50 baphnia spp. FDA-CDER (1996)
Fluoxetine HCI Anti-
depressant
0.94 EC50 baphnia spp. FDA-CDER (1996)
Fluoxetine HCI Anti­
depressant
2.0 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
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Fluoxetine HCI Anti­
depressant
0.031 EC50 Unspecified green 
algae
FDA-CDER (1996)
Fluoxetine Anti-
depressant
1.55 4h LOEC Sphaerium spp. Fong et al. (1998)
Fluvoxamine Male- 
ate
Anti-
Depressant
63 MIC Unspecified algae FDA-CDER (1996)
Fluvoxamine Anti-
Depressant
0.003 4h LOEC Sphaerium striati- 
num
Fong et al. (1998)
Gabapentin Anti-epileptic
adjunctive
>1,100 EC50 Daphnia spp. FDA-CDER (1996)
Ibuprofen Analgesic; anti­
inflammatory
7.1 96b EC50 Skeletonema co- 
sfatum
Knoll/BASF (1995)
Ibuprofen Analgesic; anti­
inflammatory
9.06 48h EC50 D. magna Knoll/BASF (1995)
Ibuprofen Analgesic; anti­
inflammatory
173 96b LC50 Lepomis macrochi* 
rus
Knoll/BASF (1995)
lopromide Diagnostic Aid 
(radiopaque 
medium)
>962 LC50 Oncorhynchus my* 
kiss
FDA-CDER (1996)
lopromide Diagnostic Aid 
(radiopaque 
medium)
>973 LC50 Lepomis macrochi* 
rus
FDA-CDER (1996)
lopromide Diagnostic Aid 
(radiopaque 
medium)
137 MIC Unspecified green 
algae
FDA-CDER (1996)
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lopromide Diagnostic Aid 
(radiopaque 
medium)
>1,016 EC50 baphnia FDA-CDER (1996)
lopromide Diagnostic Aid 
(radiopaque 
medium)
>10,00
0
24h EC50 b. magna Schweinfurth et 
a/. (1996a)
lopromide Diagnostic Aid 
(radiopaque 
medium)
>10,00
0
48h EC50 Unspecified fish Schweinfurth et 
al. (1996a)
Isoniazid Anti-bacterial 85 24h EÇgo b. magna Lilius etal. (1994)
Isoniazid Anti-bacterial 322 24h LC50 Artemia salina Calleja et al. 
(1994a)
Isoniazid Anti-bacterial 24.4 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Isoniazid Anti-bacterial 125.5 24h EC50 b. magna Calleja et al. 
(1994a)
Isoniazid Anti-bacterial 3,045 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Ketorolac Tro- 
methpmine
Analgesic;
Anti­
inflammatory
1480 96h LC50 Lepomis macrochi- 
rus
Anon (1993)
Lansoprazole Proton pump 
inhibitor (Anti- 
ulcerative)
>22 EC50 baphnia spp. FDA-CDER (1996)
67
Lansoprazole Proton pump 
inhibitor (Anti- 
ulcerative)
18 LCSO Oncorhynchus my- 
kiss
FDA-CDER (1996)
Lincomys(c)in Anti-bacterial 283.1 72h BC50 Artemia Migliore et al. 
(1997)
Lincomys(c)in Anti-bacterial 379.3
9
72h LC50 b.magna Di Delupis et al. 
(1992)
Lithium Sulphate Anti-
depressant
197 24h EC50 b. magna Lilius et al. (1994)
Lithium Sulphate A nti-
depressant
4,318 24h LC5 0 Artemia salina Calleja et al. 
(1994a)
Lithium Sulphate Anti-
depressant
112 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Lithium Sulphate Anti-
depressant
33.1 24h EC50 b. magna Calleja et al. 
(1994a)
Lithium Sulphate Anti-
depressant
712 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Lomef loxacin Anti-bacterial 130 EC50 baphnia spp. FDA-CDER (1996)
Lomefloxacin Anti-bacterial 170 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
Lomef loxacin Anti-bacterial 2.4 EC50 Unspecified green 
algae
FDA-CDER (1996)
Loracarbef Anti-infective >963 EC50 baphnia spp. FDA-CDER (1996)
Losartan K Anti-
hypertensive
331 EC50 baphnia spp. FDA-CDER (1996)
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Losartan K Anti-
hypertensive
>929 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
Losartan K Anti-
hypertensive
>1000 LC50 Pimephales prome- 
las
FDA-CDER (1996)
Losartan K Anti-
hypertensive
245 MIC Unspecified green 
alage
FDA-CDER (1996)
Losartan K Anti-
hypertensive
949 MIC Unspecified blue- 
green alage
FDA-CDER (1996)
Merthiolate (Thi- 
m eroS al)
Anti-infective 60.5 24h LC50 Oncorhynchus my- 
kiss
Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 21.2 48h LC50 Oncorhynchus my- 
kiss
Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 13.0 24h LC50 Salvelinus namay- 
cush
Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 2.13 48h LC50 Salvelinus namay- 
cush
Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 110 24h LC50 Salmo trutta Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 54.0 48h LC50 Salmo trutta Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 7.50 24h LC50 Ictalurus punctatus Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 5.65 48h LC50 Ictalurus punctatus Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 89.5 24h LC50 Salvelinus fon­
tinalis
Wilford (1966)
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Merthiolate (Thi- 
merosal)
Anti-infective 74.5 48h LC50 Salvelinus fon­
tinalis
Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 110 24h LC50 Lepomis macrochi- 
rus
Wilford (1966)
Merthiolate (Thi- 
merosal)
Anti-infective 64.5 48h LC50 Lepomis macrochi- 
rus
Wilford (1966)
Metformin HCI Anti-diabetic >982 LC50 Lepomis macrochi- 
rus
FDA-CDER (1996)
Metformin HCI Anti-diabetic 130 EC50 baphnia spp. FDA-CDER (1996)
Methotrexate Anti­
neoplastic;
Anti-rheumatic
>1,000 ÉC50 0. magna Henschel et al. 
(1997)
Methotrexate Anti­
neoplastic; 
Anti-rheumatic
85.0 48h EC50 Brachydanio rerio 
(embryos)
Henschel et al. 
(1997)
Methotrexate Anti­
neoplastic;
Anti-rheumatic
260 72h EC50 Scenedesmus sub- 
spicatus
Henschel et al. 
(1997)
Metronidazole Anti-protozoal >100 72h EC50 Acartia tonsa Lanzky A Halling- 
Sorenson (1997)
Metronidazole Anti-protozoal >500 96h EC50 Brachydanio rerio Lanzky A Halling- 
Sorenson (1997)
Metronidazole Anti-protozoal 39.1 72h EC50 Selenastrum capri- 
cornutum
Lanzky A Halling- 
Sorenson (1997)
Metronidazole Anti-protozoal 12.5 72h EC50 Chlorella spp. Lanzky A Halling- 
Serenson (1997)
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Metronidazole Anti-protozoal >100 48h LC50 Oncorhynchus my- 
kiss, Salmo trutta, 
Salvelinus 
fontinalis, Ictalu­
rus punctatus, Le­
pomis macrochirus 
A Salvelinus namay- 
cush
Wilford (1966)
Midazolam Anesthetic (in­
travenous)
0.2 EC50 D. magna FDA-CDER (1996)
Milrinone Lactate Cardiotonic 414 EC50 baphnia spp. FDA-CDER (1996)
Moexipril HCI 
(pro-drug)
Anti-
hypertensive
800 EC50 baphnia spp. FDA-CDER (1996)
Moexiprilat 
(active metabo­
lite)
Anti-
hypertensive
>1000 EC50 baphnia spp. FDA-CDER (1996)
Naproxen Sodium Anti­
inflammatory;
Analgesic;
Anti-pyretic
140 24h EC50 b. magna Rodriguez et al. 
(1992)
Naproxen Sodium Anti­
inflammatory;
Analgesic;
Anti-pyretic
383 96h LC50 Hyalella azteca Rodriguez et al. 
(1992)
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Naproxen Sodium Anti­
inflammatory;
Analgesic;
Anti-pyretic
560 96h LC50 Lepomis macrochi­
rus
Rodriguez et al. 
(1992)
Naproxen Sodium Anti­
inflammatory;
Analgesic;
Anti-pyretic
690 96h LC50 Oncorhynchus my- 
kiss
Rodriguez et al. 
(1992)
Nefazodone HCI Anti-
depressant
7 EC50 Daphnia spp. FDA-CDER (1996)
Nicotine Sulphate Cholinergic
agonist
13.8 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Nicotine Cholinergic
agonist
3.0 EC50 D. magna FDA-CDER (1996)
Nicotine Cholinergic
agonist
7.0 LC50 Oncorhynchus my- 
kiss
FDA-CDER (1996)
Nicotine Cholinergic
agonist
20.0 LC50 Pimephales prome- 
las
FDA-CDER (1996)
Nicotine Cholinergic
agonist
4.0 LC50 Lepomis macrochi­
rus
FDA-CDER (1996)
Nicotine Cholinergic
agonist
13 LC50 'Goldfish" FDA-CDER (1996)
Nisoldipine Anti-
hypertensive;
Anti-anginql
33 EC50 Daphnia spp. FDA-CDER (1996)
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Nisoldipine Anti­
hypertensive;
Anti-anginal
3 EC50 Unspecified fish FDA-CDER (1996)
Nitrofurazone Topical Anti- 
infective
1.45 EC50 Selenastrum capri- 
cornutum
Macri à Sbardella 
(1984)
Nitrofurazone Topical Anti- 
infective
28.7 LC50 0. magna Macri à Sbardella 
(1984)
Nitrofurazone Topical Anti- 
infective
10 96h LC50 Morone saxatilis 
(larvae)
Hughes (1973)
Nitrofurazone Topical Anti- 
infective
>5 24h LC50 PenaeuS SetiferuS Johnson (1976)
Omeprazole Anti-ulcerative 88 EC50 Daphnia spp. FDA-CDER (1996)
Ondansetron HCI Anti-emetic 28 EC50 Daphnia spp. FDA-CDER (1996)
Orphenadrine HCI 
(Mephenamin)
Relaxant; Anti- 
histaminic
8.9 24h EC50 D. magna Lilius ef al. (1994)
Orphenadrine HCI 
(Mephenamin)
Relaxant; Anti- 
histaminic
45 24h LC50 Artemia salina Calleja et al. 
(1994a)
Orphenadrine HCI 
(Mephenamin)
Relaxant; Anti- 
histaminic
4.3 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Orphenadrine HCI 
(Mephenamin)
Relaxant; Anti- 
histaminic
10.6 24h EC50 D. magna Calleja et al. 
(1994a)
Orphenadrine HCI 
(Mephenamin)
Relaxant; Anti- 
histaminic
5.4 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Oxytetracycline Anti-bacterial >5 24h LC50 Penaeus setiferus Johnson (1976)
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Oxytetracycline
HCI
Anti-bacterial 62.5 24/48/72
/96h
LC50
Morone saxatilis 
(larvae)
Hughes(1973)
Oxytetracycline
HCI
Anti-bacterial 150 24h LC50 Morone saxatilis 
(fingerling)
Hughes (1973)
Oxytetracycline
HCI
Anti-bacterial 125 48h LC50 Morone saxatilis 
(fingerling)
Hughes (1973)
Oxytetracycline
HCI
Anti-bacterial 100 72h LC50 Morone saxatilis 
(fingerling)
Hughes(1973)
Oxytetracycline
HCI
Anti-bacterial 75 96h LC50 Morone saxatilis 
(fingerling)
Hughes (1973)
Oxytetracycline
HCI
Anti-bacterial <200 24/96H
LC50
Salvelinus namay- 
cush
Marking e t al. 
(1988)
Oxytetracycline Anti-bacterial 0.231 EC50 Microcystis aerugi­
nosa
Holten-LUtzhaft 
et al. (1998)
Oxytetracycline Anti-bacterial 5.0 EC50 Selenastrum capri- 
cornutum
Holten-Lützheft. 
et a/. (1998)
Oxytetracycline Anti-bacterial 1.7 EC50 Rhodomonas Holten-Lützhaft 
et a/, (1998)
Paclitaxel Anti-neoplastic >0.74 LC50 baphnia spp. FDA-CDER (1996)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
577 24h LC50 Artemia salina Calleja et al. 
(1994a)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
29.6 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
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Paracetamol/
Acetaminophen
Analgesic;
.Anti-pyretic
55.5 24h EC50 D. magna Calleja et al. 
(1994a)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
5,306 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
13 24h EC50 0. magna Kühn et al. (1989)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
9.2 48h ËC50 D. magna Kühn et al. (1989)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
293 24 EC50 D. magna Henschel et al. 
(1997)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
50.0 48 EC50 0. magna Henschel et al. 
(1997)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
378 48h EC50 Brachydanio rerio 
(embryos)
Henschel et al. 
(1997)
Paracetamol/
Acetaminophen
Analgesic;
Anti-pyretic
134 72h EC50 Scenedesmus sub- 
spicatus
Henschel et al. 
(1997)
Paroxetine HCI Anti­
depressant
3.0 EC50 Daphnia spp: FDA-CDER (1996)
Paroxetine MCI Anti­
depressant
2.0 LC50 Lepomis macrochi- 
rus
FDA-CDER (1996)
Paroxetine HCI Anti­
depressant
3.29 4h LOEC Sphaerium spp. Fong et al. (1998)
Perindopril Erbu- 
mine
Anti­
hypertensive
>1,000 EC50 Daphnia spp. FDA-CDER (1996)
Perindopril Erbu- 
mine
Anti-
hypertensive
>990 LC50 . Lepomis macrochi- 
rus
FDA-CDER (1996)
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Pentobarbital Sedative; Hyp­
notic
49.5 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Phénobarbital Anti­
convulsant; 
Sedative; Hyp­
notic
484 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Phénobarbital
(Phenobarbitone)
Anti­
convulsant; 
Sedative; Hyp­
notic
>10,00
0
24h LC50 Artemia salina Calleja et al. 
(1994a)
Phénobarbital
(Phenobarbitone)
Anti­
convulsant; 
Sedative; Hyp­
notic
1,212 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Phénobarbital
(Phenobarbitone)
Anti­
convulsant; 
Sedative; Hyp­
notic
1,463 24h EC50 0. magna Calleja e t al. 
(1994a)
Phénobarbital
(Phenobarbitone)
Anti­
convulsant; 
Sedative; Hyp­
notic
5,179 24h LC50 Brachionus caly- 
ciflorus
Calleja e t al. 
(1994a)
Porf irmer Sodium Photosensi-
tiser
>994 EC50 Daphnia spp. FDA-CDER (1996)
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Propranolol HCI Anti-
hypertensive;
Anti-anginal;
Anti-
arrhythmic
2.7 24h ECsc D. magna Lilius et al. (1994)
R-(±) Propranolol Anti-
hypertensive;
Anti-anginal;
Anti-
arrhythmic
407 24h LC50 Artemia salina Calleja e t al. 
(1994a)
R-(±) Propranolol Anti-
hypertensive;
Anti-anginal;
Anti-
arrhythmic
1.87 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
R-(±) Propranolol Anti-
hypertensive;
Anti-anginal;
Anti-
arrhythmic
15.87 24h EC50 D: magna Calleja et al. 
(1994a)
R-(±) Propranolol Anti­
hypertensive;
Anti-anginal;
Anti-
arrhythmic
2.59 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
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Quinacrine HCI Anthelminthic;
Anti-malarial
122 48h LC50 Oncorhynchus my- 
kiss
Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
25.0 24h LC50 Salvelinus namay- 
cush
Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
21.0 48h LC50 Salvelinus namay- 
cush
Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
300 24h LC50 Salmo truffa Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
230 48h LC50 Salma truffa Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
196 24h LC50 Ictalurus punctatus Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
70 48h LC50 Ictalurus punctatus Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
230 48h LC50 Salvelinus fon- 
tinalis
Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
120 24h LC50 Lepomis macrochi- 
rus
Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
79 48h LC50 Lepomis macrochi- 
rus
Willford (1966)
Quinacrine HCI Anthelminthic;
Anti-malarial
7.7 24h LC50 Penaeus setiferus Johnson (1976)
Quinidine Sul­
phate
Cardiac de­
pressant (Anti- 
arrhythmic)
60 24h EC50 b. magna Lilius et al. (1994)
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Quinidine Sul­
phate
Cardiac de­
pressant (Anti- 
arrhythmic)
274 24h LC50 Artemia salina Calleja et al. 
(1994a)
Quinidine Sul­
phate
Cardiac de­
pressant (Anti- 
arrhythmic)
8.3 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Quinidine Sul­
phate
Cardiac de­
pressant (Anti- 
arrhythmic)
60 24h EC50 D. magna Calleja et al. 
(1994a)
Quinidine Sul­
phate
Cardiac de­
pressant (Anti- 
arrhythmic)
8.7 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Quinine Bisulphate Anti-malarial; 
Oral sclerosing 
agent
13.1 24h LC50 Penaeus setiferus Johnson (1976)
Quinine HCI Anti-malarial >100 48h LC50 Oncorhynchus my- 
kiss, Salmo trutta, 
Salvelinus 
fontinalis, Ictalu­
rus punctatus, Le­
pomis macrochirus 
4 Salvelinus namay- 
cush
Willford (1966)
Quinine Sulfate Anti-malarial; 
Muscle relax­
ant
13.8 24h LC50 Penaeus setiferus Johnson (1976)
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Ranitidine HCI Anti-ulcerative 650 EC50 Daphnia spp. FDA-CDER (1996)
Risperidone Anti-psychotic 6.0 LC50 Lepomis macrochi­
rus
FDA-CDER (1996)
Risperidone Anti-psychotic 6.0 EC50 Daphnia spp. FDA-CDER (1996)
Salicylic Acid Topical kerato- 
lytic
>1,440 24h EC50 D. magna Bringmann <& Kühn 
(1982)
Salicylic Acid Topical kerato- 
lytic
230 24h EC50 D. magna Wang A Lay 
(1989)
Salicylic Acid Topical kerato- 
lytic
118 EC50 D. magna Henschel et al. 
(1997)
Salicylic Acid Topical kerato- 
lytic
37.0 48h EC50 Brachydanio rerio 
(embryos)
Henschel et al. 
(1997)
Salicylic Acid Topical kerato- 
lytic
>100 72h EC50 Scenedesmus sub- 
spicatus
Henschel et al. 
(1997)
Simethicone Anti-flatulent 44.5 48h TL50 D.magna Hobbs (1975)
Salmeterol Anti-asthmatic 20 EC50 Daphnia spp. FDA-CDER (1996)
Secobarbital, so­
dium salt
Sedative, hyp­
notic
23.6 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Spirapril HCI Anti-
hypertensive
>930 EC50 Daphnia spp. FDA-CDER (1996)
Spirapril HCI Anti-
hypertensive
>970 LC50 Lepomis macrochi­
rus
FDA-CDER (1996)
Stavudine Anti-
(retro)viral
>980 EC50 Daphnia spp. FDA-CDER (1996)
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Sulfadimethoxine Anti-bacterial 1866 24h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Sulfadimethoxine Anti-bacterial 851 48h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Sulfadimethoxine Anti-bacterial 537 72h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Sulfadimethoxine Anti-bacterial 19.5 96h LC50 Artemia salina 
(nauplii)
Brambilla et al. 
(1994)
Sulfadimethoxine Anti-bacterial 1,866 24h LC50 Artemia salina 
(nauplii)
Migliore et al. 
(1993)
Sulfadimethoxine Anti-bacterial 851 48h LC50 Artemia salina 
(nauplii)
Migliore et al. 
(1993)
Sulfadimethoxine Anti-bacterial 537 72h LC50 Artemia salina 
(nauplii)
Migliore et al. 
(1993)
Sulfadimethoxine Anti-bacterial 19.5 96h LC50 Artemia salina 
(nauplii)
Migliore etal. 
(1993)
Sulfamerazine Anti-bacterial >100 48h LC50 Oncorhynchus my- 
kiss, Salmo trutta, 
Salvelinus 
fontinalis, Ictalu­
rus punctatus, Le­
pomis macrochirus 
A Salvelinus namay- 
cush
Willford (1966)
81
Sulfamethazine Anti-bacterial >100 48h LC50
j
Oncorhynchus my- 
kiss, Salmo trutta, 
Salvelinus 
fontinalis, Ictalu­
rus punctatus, Le­
pomis macrochirus 
A Salvelinus namay- 
cush
Willford (1966)
Sulfisoxazole Anti-bacterial >100 48h LC50 Oncorhynchus my- 
kiss, Salmo trutta, 
Salvelinus 
fontinalis, Ictalu­
rus punctatus, Le­
pomis macrochirus 
A Salvelinus namay- 
cush
Willford (1966)
Sumatriptan Suc­
cinate
Anti-mi graine 290 EC50 baphnia spp. FDA-CDER (1996)
Tetracycline Anti-amebic,
Anti-bacterial,
Anti-
ricketettsial
16 72h EC50 Nitzschia closte- 
rium
Peterson et al. 
(1993)
Tetracycline HCI Anti-amebic, 
Anti-bacterial, 
Anti- : 
ricketettsial
220 24/96H
LC50
Salvelinus namay- 
cush
Marking et al. 
(1988)
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Tetracycline HCI Anti-amebic,
Anti-bacterial,
Anti-
ricketettsial
>182 24/48/96 
h LC50
Morone saxatilis Welborn (1969)
Theophylline Bronchodilator 155 24h EC50 0. magna Jlius et al. (1994)
Theophylline Bronchodilator 8,247 24h LC50 Artemia salina Calleja et al. 
(1994a)
Theophylline Bronchodilator 425 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Theophylline Bronchodilator 483 24h EC50 b. magna Calleja et al. 
(1994a)
Theophylline Bronchodilator 3,926 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Thiopental, sodium 
salt
Anesthetic 26.2 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Thiotepa Anti-neoplastic 546 EC50 Oaphnia spp. FDA-CDER (1996)
Thioridazine HCI Anti-psychotic 0.69 24h EC50 Ù. magna Lilius etal. (1994)
Thioridazine HCI Anti-psychotic 14,5 24h LC50 Artemia salina Calleja et al. 
(1994a)
Thioridazine HCI Anti-psychotic 0.33 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Thioridazine HCI Anti-psychotic 4.56 24h EC50 b. magna Calleja et al. 
(1994a)
Thioridazine HCI Anti-psychotic 0.30 24h LC50 Brachionus caly- 
çiflorus
Calleja et al. 
(1994a)
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Tiludronate Diso- 
dium
Metabolic Bone 
Disease
562 24h EC50 D. magna Sanofi (1996)
Tiludronate Diso­
dium
Metabolic Bone 
Disease
320 48h EC50 0. magna Sanofi (1996)
Tolazoline HCI Anti-
adrenergic
354 96h EC50 Pimephales prome- 
las
Russom et al. 
(1997)
Tramadol HCI Analgesic 130 LC50 Unspecified fish FDA-CDER (1996)
Tramadol HCI Analgesic 73 EC50 baphnia spp FDA-CDER (1996)
Verapamil HCI Anti-anginal;
Anti-
arrhythmic
327 24h EC50 b. magna Lilius et al. (1994)
Verapamil HCI Anti-anginal;
Anti-
arrhythmic
356 24h LC50 Artemia salina Calleja et al. 
(1994a)
Verapamil HCI Anti-anginal;
Anti-
arrhythmic
6.24 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Verapamil HCI Anti-anginal;
Anti-
arrhythmic
55.5 24h EC50 D. magna Calleja et al. 
(1994a)
Verapamil HCI Anti-anginal;
Anti-
arrhythmic
10.90 24h LC50 Brachionus caly- 
ciflorus
Calleja et al. 
(1994a)
Warfarin Anti-coagulant 12 96h LC50 Rasbora hetero- 
morpha
Too by et al. 
(1975)
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Warfarin Anti-coagulant 89 24h EC50 Û. magna Lilius et al. (1994)
Warfarin Anti-coagulant 3,638 24h LC50 Artemia salina Calleja etal. 
(1994a)
Warfarin Anti-coagulant 342 24h LC50 Streptocephalus
proboscideus
Calleja et al. 
(1994a)
Warfarin Anti-coagulant 475 24h EC50 D. magna Calleja etal. 
(1994a)
Warfarin Anti-coagulant 444 24h LC50 Brachionus caly- 
ciflorus
Calleja etal. 
(1994a)
Zalcitabine Anti-
(retro)viral
>1,790 EC50 baphnia spp. FDA-CDER (1996)
The distribution of the acute data is presented in Table 2. In collating and summarising the 
data, the most sensitive species/endpoint and most toxic salt were chosen for any given drug 
active.
Table 2. - Summary of available acute ecotoxicity data for human pharmaceuticals.
Ecotoxicity Range Number Frequency (%) Cumulative (%)
<0.1 mg/l 2 1.9 1.9
>0.1-1 mg/l 8 7.5 9.3
>1 -10 mg/l 22 20.3 29.9
>10 -100 mg/l 31 290 58.9
>100 - 1,000 mg/l 37 34.6 93 5
> 1,000 mg/l 7 6.5 100
Total 107 -
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Comparisons of taxa sensitivities (in terms of acute responses) are presented in Table 3 and 
Figures 1 - 3. Fish, Oaphnia magna and algae were chosen as representative of d ifferent tro ­
phic levels. Significant (p<0.05) correlations were observed between all taxa pairs with r val­
ues in the range 0.53 - 0.76. A sensitivity order algae > Oaphnia magna > fish is consistent 
with the results of the regressions.
Table 3. - Paired comparison of relative taxa sensitivity.
Comparison Regression r
Fish v Oaphnia magna 
(n = 40)
Fish Log EC5o (jug/I) = Oaphnia magna EC5o Qvg/I) * 
0.68 + 1.50
0.76
Fish v Algae 
(n = 15)
Fish Log EC5o (pg/\) = Algae EC5o (pg/l) *  0.71 + 0.33 0.53
Oaphnia magna v Algae 
(n=12)
Oaphnia magna Log EC5o Qvg/I) = Algae EC5o Qvg/I) * 
0.87 -0.24
0.66
p<0.05 in all cases. NB: Some algal endpoints are MIC rather than EC5o.
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Figures 1 - 3. - Paired comparison of relative taxa sensitivity.
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The median and range of acute endpoints for selected therapeutic categories for which 
there are two or more different compounds are presented in Figure 4. This allows some in­
terpretation of the relative ecotoxicity of different classes of pharmaceuticals. The most 
ecotoxic of the various therapeutic classes of pharmaceuticals (in terms of observed minima) 
were anti-depressants, anti-bacterials and anti-psychotics, although the range of reported 
responses within each of these categories (and indeed most the other categories) was large 
i.e., typically over several orders of magnitude.
Figure 4. Median and range of acute endpoints for selected therapeutic categories.
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Key: ANL = Analgesic. Anti-Inflammatory, Anti-Pyretic (7); ABA = Anti-Bacterial (18); ADP = Anti-Depressant (5 ex­
cluding Lithium); ADB = Anti-Diabetic (2); AHT = Anti-Hypertensive, Anti-Anginal, Anti-Arrhythmic (9); ANF = Anti- 
Infective (4); AML = Anti-Malarial (4); ANP = Anti-Neoplastic (4); APS = Anti-Psychotic (2); AUL = Anti-Ulcerative 
(5); AVL = Anti-Viral (4); OES = Oestrogen (2); MBD = Metabolic Bone Disease (3); SED = Sedative/Hypnotic (4). 
Figures in brackets denote the number of compounds.
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Chronic Ecotoxicity Dota
The available chronic ecotoxicity database is presented in Table 4. Most endpoints were de­
termined via standard tests with D. magna and algae. Other more sensitive endpoints for 
Ethinyl Oestradiol relate to the induction of plasma vitellogenin, gonadosomatic index (651) 
and spermatogenesis in roach (Rutilus rutilus) and/or rainbow trout (Oncorhynchus mykiss) 
(FWR, 1992; Purdom eta/., 1994; FWR, 1995; Jobling eta/., 1996).
Table 4. - Chronic ecotoxicity data for human pharmaceuticals.
Compound Category Value
(mg/l)
Endpoint/
Duration
Species Reference
Alendronate So­
dium
Metabolic Bone 
Disease
0.5 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Bicalutamide Non-steroidal
Anti-androgen
1 NOEC Unspecified 
blue-green al­
gae
FDA-CDER
(1996)
Bicalutamide Non-steroidal
Anti-androgen
1 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Budenoside Anti­
inflammatory
10 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Cisapride Peristaltic
Stimulant
100 "Effects" Unspecified 
blue-green al­
gae
FDA-CDER
(1996)
Cisapride Peristaltic
Stimulant
320 "Effects" Unspecified 
green algae
FDA-CDER
(1996)
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Clofibrate Antihyper-
lipoproteinemic
0.01
[A/C
1428)
2Id Repro­
duction 
NOEC
D. magna Kopf(1995)
Clofibrate Antihyper-
lipoproteinemic
0.0084 2Id Repro­
duction 
ECio
D. magna Kopf (1995)
Clofibrate Antihyper-
lipoproteinemic
0.106 21d Repro- 
duc-tion
EC50
D. magna Kopf (1995)
Clofibrate Antihyper-
lipoproteinemic
5.4 ECio Unspecified
algae
Kopf (1995)
Diethylstilbestrol Estrogen 0.25/0.5 Fi 21d molt 
frequency 
NOEC/ 
LOEC
b. magna Baldwin etal. 
(1995)
Diethylstilbestrol Estrogen 0.062/0.5
(A/C
17.6)
F2 21d
brood size 
NOEC/ 
LOEC
Ù. magna Baldwin et al. 
(1995)
Diethylstilbestrol Estrogen 0.01 2Id repro­
duction 
NOEC
Tisbe batta- 
gliai
Hutchinson et al. 
(1999)
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Ethinyl Oestradiol Estrogen 1 ng/l lOd Plasma 
vitellogenin 
NOEC 
(9.5*C)
Rutilus rutilus FWR (1992)
Ethinyl Oestradiol Estrogen 1 ng/l lOd Plasma 
vitellogenin 
NOEC 
(9.5*C)
Oncorhynchus
mykiss
FWR (1992)
Ethinyl Oestradiol Estrogen 0.3 ng/l 28wk 
Plasma vi­
tellogenin 
LOEC
Oncorhynchus
mykiss
Sheahan et al. 
(1994)
Ethinyl Oestradiol Estrogen 0.1 ng/l lOd Plasma 
vitellogenin 
LOEC 
(16.5%)
Oncorhynchus
mykiss
Purdom et al. 
(1994)
Ethinyl Oestradiol Estrogen 0.01
(A/C
570)
2Id Repro­
duction 
NOEC
D. magna Kopf (1995)
Ethinyl Oestradiol Estrogen 0.0125 2Id Repro­
duction
ECio
D. magna Kopf (1995)
Ethinyl Oestradiol Estrogen 0.105 2Id Repro­
duction
EC50
D. magna Kopf (1995)
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Ethinyl Oestradiol Estrogen 0.054 ECio Unspecified
algae
Kopf (1995)
Ethinyl Oestradiol Estrogen 2 ng/l 
(A/C 
800,000)
2 Id Sperm­
atogenesis, 
651 4 
plasma vi­
tellogenin 
LOEC
Oncorhynchus
mykiss
FWR (1995)
Ethinyl Oestradiol Estrogen 1 ng/l 2Id Plasma 
vitellogenin 
(positive 
control for 
AP)
Rutilus rutilus FWR (1995)
Ethinyl Oestradiol Estrogen 2 ng/l 2 Id Sperm­
atogenesis, 
GSlâi 
plasma vi­
tellogenin 
(positive 
control for 
AP)
Oncorhynchus
mykiss
Jobling et al. 
(1996)
Ethinyl Oestradiol Estrogen 0387 2Id Repro­
duction 
LOEC
D. magna Schweinfurth et 
a/. (1996)
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Ethinyl Oestradiol Estrogen 10 ng/l 28d Repro­
duction 
LOEC
Pimephales
promelas
Schweinfurth et 
a/. (1996)
Ethinyl Oestradiol Estrogen 1.25 ng/l 50-60d
LOEC
(growth)
Lymnaea stag­
nails
Belfroid & Leo­
nards (1996)
Ethinyl Oestradiol Estrogen 0.125 ng/l 50 -60d
LOEC
(growth)
Bi thy nia ten- 
taculata
Belfroid <& Leo­
nards (1996)
Ethinyl Oestradiol Estrogen 1 ng/l 9 month 
Reproduc­
tion NOEC 
(growth re­
tardation 
LOEC4 
ng/l)
Pimephales
promelas
Lange et al. 
(1997); Lange et 
a/. (2001).
Etidronic Acid Metabolic Bone 
Disease
>12
(A/C
43.9)
28d NOEC D. magna Gledhill <& Feijtel 
(1992)
Etidronic Acid Metabolic Bone 
Disease
1.3 96h NOEC Selenastrum
spp.
Gledhill & Feijtel 
(1992)
Etidronic Acid Metabolic Bone 
Disease
13.2 14d NOEC Selenastrum
spp.
Gledhill <& Feijtel 
(1992)
93
Finasteride Treatment of 
benign 
prostatic hy­
pertrophy
>49 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Fluoxetine HCI Anti­
depressant
0.001 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Fluvoxamine AAale- 
ate
Anti­
depressant
31 NOEC Unspecified 
green algae
FDA-CDER
(1996)
lopromide Diagnostic Aid 
(radiopaque 
medium)
>1,000
(A/C 1.0)
2Id Repro­
duction 
NOEC
D. magna Schweinfurth et 
al. (1996a)
lopromide Diagnostic Aid 
(radiopaque 
medium)
68 NOEC Unspecified 
blue-green al­
gae
FDA-CDER
(1996)
Lomefloxacin Anti-bacterial 2 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Lorcarbef Anti-infective 13 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Losartan K Anti-
hypertensive
556 NOEC Unspecified 
blue-green al­
gae
FDA-CDER
(1996)
Losartan K Anti­
hypertensive
143 NOEC Unspecified 
green algae
FDA-CDER
(1996)
Metronidazole Anti-protozoal 19.9 72hECio Selenastrum
capricornutum
-anzky & Halling- 
Sorenson (1997)
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Metronidazole Anti-protozoal 2.03 72h ECio Chlorella sp. Lanzky & Halling- 
Sorenson (1997)
Nicotine Cholinergic
agonist
0.07
(A/C
429)
LOEC
(length)
D. pulex FDA-CDER
(1996)
Riseperidone Anti-psychotic 100 "Effects" Unspecified 
blue-green al­
gae
FDA-CDER
(1996)
Riseperidone Anti-psychotic 10 "Effects" Unspecified 
green algae
FDA-CDER
(1996)
Salicylic Acid Topical kerato- 
lytic
<20.0 
(A/C 5.9)
21d Repro­
duction 
NOEC
D. magna Wang A Lay 
(1989)
Tiludronate Diso­
dium
Metabolic Bone 
Disease
36.6 14d ECso Selenastrum
capricornutum
Sanofi (1996)
Tiludronate Diso­
dium
Metabolic Bone 
Disease
13.3 21dEC50 Microcystis
aeruginosa
Sanofi (1996)
DISCUSSION
Acute ecotoxicity dota are available for a large number of pharmaceuticals (i.e., >100). The 
results presented here possibly represents the most comprehensive dataset yet collated. 
Most of the data relate to acute ecotoxicity endpoints, although some chronic data are avail­
able. The range of reported acute ecotoxicity endpoints varied from >15,000 mg/l for Atro­
pine Sulphate (Anti-cholinergic/ mydriatic) in a standard 24 hour LC50 Artemia salina test 
(Calleja et al. 1994a) down to 0.003 mg/l for Fluvoxamine (an antidepressant) in a (non­
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standard) study examining the effects of selective serotonin re-uptake inhibitors (55RIs) 
upon parturition (release of juveniles) in fingernail clams (Fong et al., 1998). This corresponds 
to a difference of 6 orders of magnitude. Ten of the compounds had acute endpoints of <1 
mg/l. They were Alendronate (a biphosphonate used in the treatment of metabolic bone dis­
ease), Amitriptyline (an anti-depressant), Carved i loi (an anti-hypertensive and anti-anginal), 
Ethinyl Oestradiol (an oestrogen), Fluticasone (a corticosteroid anti-asthmatic). Fluoxetine 
(an anti-depressant), Fluvoxamine (an anti-depressant). Midazolam (an anesthetic), Paclitexel 
(an anti-neoplastic) and Thioridazine (an anti-psychotic).
In a similar review exercise, the US FDA Center for Drug Evaluation and Research (CDER) 
has performed a retrospective review of toxicity information available in Environmental As­
sessments (EA) previously submitted in support of New Drug Applications (NDA) (FDA-CDER, 
1996). The data showed no observed effects on relevant standard environmental test organ­
isms at drug concentrations below 1 fjg/\ (based on both acute and chronic data from ap­
proximately 60 compounds). The results of the FDA-CDER review provided the justification 
for the 1 /jg/\ cut-off threshold employed in the US FDA environmental risk assessment 
framework for pharmaceuticals (Federal Register 29/07/97 Volume 62, p40569). All acute 
ecotoxicity endpoints considered in this study (which includes the data from the FDA-CDER 
review) were similarly also >1 /yg/l. That the majority of the pharmaceuticals examined are 
limited (90th-percentile >lmg/l) in their acute ecotoxicity is not surprising, given the gener­
ally limited mammalian toxicity required of pharmaceuticals. A relationship between mammal­
ian toxicity and invertebrate ecotoxicity of industrial chemicals and pharmaceuticals has 
similarly been noted elsewhere (e.g., Enslein et al., 1987; Enslein et al., 1989; Calleja et al., 
1993; Calleja et al., 1994b). For perspective, the EU classification criteria for risk phrases 
(677548/EEC) defines compounds with an L(E)Cso mg/l as 'Very toxic to aquatic organ-
/sms'' (R-50), 1 - 10 mg/l as "toxic to aquatic organism^' (R-51) and 10 - 100 mg/l as "harmful 
to aquatic organism^' (R-52).
The comparisons of paired taxa in terms of responses to acute ecotoxicity testing suggests a 
general hierarchy of sensitivity corresponding to algae > baphnia magna > fish. Nevertheless, 
where differences in responses are observed they are typically limited to one order of mag­
nitude. The average difference between fish and baphnia magna is <0.5 log units, between 
fish and algae 1.2 log units and between baphnia magna and algae 1.0 log units. Relative algal 
sensitivity may have resulted in part from the effects of anti-infectives and anti-bacterials 
(such as Oxytetracycline) upon algae.
The most ecotoxic of the various therapeutic classes of pharmaceuticals (in terms of ob­
served minima) were anti-depressants, anti-bacterials and anti-psychotics. The lowest end­
point (3 fjg/\) fo r anti-depressants relates to a test in a freshwater bivalve (Fong et al., 
1998). Even without the inclusion of this non-standard endpoint, anti-depressants would re­
main the most potent therapeutic class in terms of acute ecotoxicity by virtue of an algal 
EC5o of 31 pg/\ fo r Fluoxetine (FDA-CDER, 1996)io. As indicated above, the effects of anti-
bacterials upon algae and in particular blue-green algae (cyanobacteria) accounts for the ex­
tension of the (lower) range of reported responses for anti-bacterials. A fter anti-bacterials, 
the next lowest minima of any category is that of anti-psychotics. In  addition, it is also 
worth noting that the potency of oestrogens in the acute tests reviewed here is reflected in 
the relatively low median value for this category. Variation within each of these categories 
(and indeed most the other categories) was large i.e., typically over several orders of magni-
io There are structural similarities between Fluoxetine and certain phenoxy herbicides such as
Fluazifo-p-butyl, Mecoprop or Difenopenten that may help to explain the apparent sensitivity of mi­
croalgae.
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tude. This presumably reflects the variation in responses of the differing taxa/trophic levels 
(i.e., fish, invertebrates or algae) when exposed to representative compounds from the vari­
ous differing therapeutic classes.
The overall applicability of acute ecotoxicity data in general for environmental risk assess­
ment purposes has been criticised (Hallling-Sorenson et al., 1998). Standard acute bioassays 
with their focus on immediate endpoints such as lethality may not be the most appropriate 
basis for risk assessment given the intended narrow scope of biological activity/effect and 
general potency of pharmaceuticals in general. I t  has consequently been suggested that 
chronic bioassays performed over the I if e-cycle of various organisms from different trophic 
levels may be more appropriate (Halling-Sorenson et al., 1998).
Within this study, chronic ecotoxicity data for aquatic organisms were secured for 20 com­
pounds. The chronic database itself is dominated by data relating to Ethinyl Oestradiol. The 
various endpoints reported for Ethinyl Oestradiol demonstrates the exquisite potency of 
this compound. The ecological significance of some of the various biomarker responses re­
ported for Ethinyl Oestradiol is not known and they are less readily employed in risk charac­
terisation. This contrasts with the more integrative fathead minnow reproduction 
LOEC/NOEC endpoints for Ethinyl Oestradiol reported by Schweinfurth et al. (1996) and 
Lange et al. (1997; 2001). The issue of ecological significance of biomarker responses for 
Ethinyl Oestradiol is discussed further in Lange et al. (2001).
The chronic database for the remaining compounds is dominated by algal endpoints (i.e., 
NOEC or ECio values). Chronic toxicity studies relating to fauna (namely Oaphnia magna or pu­
lex) are limited to Clofibrate, Diethylstilbestrol, Etidronic Acid, lopromide, Nicotine and 
Salicylic Acid. Acute EC5o/Chronic NOEC (A/C) ratios have been calculated for Oaphnia spp.
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(Table 4). Acute/Chronic ratios varied from 1 for lopromide to 1,428 for Clofibrate with a 
median of 43 (n = 7). This does not contrast markedly with A/C ratios in the range of 1.6 to 
1,030 (median 22.1) previously reported for invertebrates for industrial chemicals (ECETOC, 
1993). Whilst not normally considered, A/C ratios can also be calculated for algae 
(EC50/NOEC). In this study values were typically approximately 2 and were limited in all cases 
to one order of magnitude.
Only one example of an Acute/Chronic ratio was available for a fish species (Oncorhynchus 
mykiss) and pertains to Ethinyl Oestradiol^. The A/C ratio was 800,000 and reflects the 
marked difference in the magnitude of the observed endpoints in the respective acute and 
chronic bioassays that results from the endocrine modality of this compound. Such an obser­
vation could be employed as the basis of an argument that would preclude the use of short­
term ecotoxicity testing for the purposes of risk assessment of endocrinologically active 
compounds and oblige chronic testing preferably with vertebrates (i.e., fish). The lack of 
comparative acute and chronic data relating to fish for other (non-oestrogenic) pharmaceuti­
cals precludes the calculation of A/C ratios for such compounds.
CONCLUSIONS
Data relating to the effects of human pharmaceuticals upon aquatic organisms are available, 
although the majority relates to short-term acute responses such as lethality. A review re­
vealed over 360 endpoints in macro-invertebrates, fish and algae for 107 compounds. Over 
90% of the observations were at concentrations >1 mg/l suggesting the relative limited acute 
ecotoxicity of pharmaceuticals in general. All values were > 1 fjg/\. I t  is interesting to note
u Additional data are also presented in OECD (2000). A/C ratios for Medaka (42d) and Zebra fish (300 
d) for Ethinyl Oestradiol are 150,000 and 5,730,000 respectively.
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that the majority of compounds with endpoints in acute bioassays of <1 mg/l are pharmaceu­
ticals intended to impact the human nervous system (i.e., anti-depressant, anti-psychotic or 
anesthetic). The relative sensitivity of tested taxa to pharmaceuticals was algae > baphnia 
magna > fish. Although this trend may reflect the impact of some compounds with intended 
biocidal modes of action (e.g., antibiotics) when tested upon algae. Differences in the re­
sponses of different taxa to the same compound were typically limited to one order of mag­
nitude.
The applicability of the acute ecotoxicity database for environmental risk assessment pur­
poses has been criticised on the basis of the appropriateness of the focus upon immediate 
endpoints such as lethality. Pharmaceuticals are intended to have a narrow scope of biological 
e ffect and it has been suggested that chronic testing may therefore be more appropriate. 
The available chronic ecotoxicity database is more limited and data for only 20 compounds 
are available. The chronic database was dominated by studies upon Ethinyl Oestradiol. The 
remaining endpoints were mostly concerned with algae or baphnia spp. Acute/Chronic ratios 
for baphnia magna and algae were calculated and do not d iffe r markedly from those reported 
elsewhere for industrial chemicals. Whilst the scientific basis for the use of application fac­
tors in risk assessment to derive the PNEC (predicted No-Effect Concentration) from acute 
ecotoxicity data is not contraindicated by the A/C ratios observed for baphnia or algae for 
pharmaceuticals, the absence of relevant chronic data precludes the derivation of A/C ratios 
for fish and a categorical conclusion vis-à-vis the applicability of current risk assessment 
practice to pharmaceuticals. More work relating to the potential chronic effects of pharma­
ceuticals in general and upon fish in particularly is required.
100
REFERENCES
Anon (1993) Acute toxicity to Bluegill (Lepomis macrochirus) of the test substance Ketorolac 
Tromethamine from Radian Corporation in a 96-hr static non-renewal test. Performed for Radian 
Corporation by AnaltiKEM Environmental Lab (Houston, USA). AnalytiKEM Test Number 01628.
Baldwin WS, Milam DL, Leblanc 6A (1995) Physiological and biochemical perturbations in baphnia magna 
following exposure to the model environmental estrogen diethylstilbestrol. Environmental Toxicology <& 
Chemistry 14(6): 945-952.
Belfroid A, Leonards P (1996) Effect of Ethinyl oestradiol on the development of snails and amphibians. 
SETAC 17th Annual Meeting November 1996 Washington DC [Abstract PO/508].
Brambilla G, Civitareale C, Migliore L (1994) Experimental toxicity and analysis of bacitracin, flumequine 
and sulphadimethoxine in terrestrial and aquatic organisms as a predictive model for ecosystem 
damage. Qumica Analitica 13(Suppl. 1): 573-577.
Bringmann G, Kühn R (1982) Ergebnisse der Schadwirkung wassergeftihrdender Stoffe gegen baphnia 
magna in einem weiterentwickelten standardisierten Testverfahren [Results of the harmful effects of 
water pollutants to baphnia magna in a further developed standardized test procedure]. Z  Wasser 
Abwasser Forsch. 15(1): 1-6.
Budavari, 5  (ed.) (1989) The Merck Index - An Encyclopedia of Chemicals, Drugs and Biologicals (11th 
Edition). Merck & Co. Inc. Rahway, N.J. (USA).
Calleja MC, Personne 6, Geladi P (1993) The predictive potential of a battery of ecotoxicological tests 
for human acute toxicity, as evaluated with the firs t 50 MEIC chemicals. ATLA 21: 330-349.
101
Calleja MC, Personne &, Geladi P (1994a) Comparative acute toxicity of the firs t 50 Multi centre 
Evaluation of In  Vitro Cytotoxicity chemicals to aquatic non-vertebrates. Arch. Environ. Contam. 
Toxicol. 26: 69-78.
Calleja MC, Geladi P, Personne G (1994b) Modelling of human acute toxicity from physicochemical 
properties and non-vertebrate acute toxicity of the 38 organic chemicals of the MEIC priority list by 
PL5 regression and neural network. Fd. Chem. Toxic. 32(10): 923-941.
Coats JR, Metcalf RL, Lu P-Y, Brown DD, Williams, JF and Hansen LG (1976) Model ecosystem 
evaluation of the environmental impacts of the veterinary drugs phenothiazine, sulfametazine, clopidol 
and diethylstibestrol. Envir. Health Perspect. 1: 167-197.
Di Delupis GO, Macri A, Civitareale C, Migliore L (1992) Antibiotics of zootechnical use: effects of 
acute high and low dose contamination on baphnia magna Straus. Aquatic Toxicology 22\ 53-60.
ECETOC (1993). Aquatic Toxicity bata Evaluation [Technical Report No. 56]. European Centre for 
Ecotoxicology & Toxicity of Chemicals: Brussels.
Enslein K, Tuzzeo TM, Borgstedt HH, Blake BW, Hart JB (1987) Prediction of rat oral LD5 0  from 
baphnia magna LC5 0  and chemical structure: In: Kaiser KLE (ed) QSAR in Environmental Toxicology - 
I I .  DD Reidel Publishing Company, Dordrecht, pp 91-106.
Enslein K, Tuzzeo TM, Blake BW, Hart JB, Landis WG (1989) Prediction of baphnia magna EC5 0  values 
from rat oral LD5 0  and structural parameters: In: Suter GW, Lewis MA (eds) Aquatic Toxicology and 
Environmental Fate: 11th Volume ASTM STP 1007. American Society for Testing A Materials, 
Philadelphia (PA, USA), pp 397-409.
102
FDA-CDER (1996). Retrospective Review o f Ecotoxicity bata Submitted in Environmental 
Assessessments [bocket No. 96N-0057]. FDA Center for Drug Evaluation and Research: Rockville (MD), 
USA.
Fong PP, Huminski PT, D'Urso LM (1998) Induction and potentiation of parturition in Fingernail Clams 
(Sphaerium striatinum) by selective serotonin re-uptake inhibitors (SSRIs). The Journal o f 
Experimental Zoology 280: 260-264.
FWR (1992) Effects o f Trace Organics on Fish [October 1992 FR/b 0008]. Foundation for Water 
Research, Marlow (Bucks.), UK
FWR (1995) Effects o f Trace Organics on Fish - Phase 2 [July 1995 FR/b 0022] Foundation for Water 
Research, Marlow (Bucks.), UK
Gledhill WE, Feijtel, TCJ (1992) Environmental properties and safety assessment of organic 
phosphonates used for detergent and water treatment: In: de Oude NT (ed) NT betergents - 
Handbook o f Environmental Chemistry Volume 3 Part F, Anthropogenic Compounds. Springer-Verlag, 
New York, Berlin A Heidelberg, pp 261-285.
Hailing-Sorenson B, Nors Nielsen 5, Lanzky PF, Ingerslev F, Holten-Liitzhoft HC, Jorgensen SE (1998) 
Occurrence, fate and effects of pharmaceutical substances in the environment - A review. 
Chemosphere 36(2): 357-393.
Henschel KP, Wenzel A, Diederich M, Fliedner, A (1997) Environmental Hazard Assessment of 
Pharmaceuticals. Regulatory Toxicology <& Pharmacology 25: 220-225.
Hobbs EJ (1975) Toxicity of polydimethylsiloxanes in certain environmental systems. Environmental 
Research 10: 397-406.
103
Holten-Lützhoft H-C, Halling-Sorensen B, Jorgensen, 5.E. (1998). Algal testing of antiobiotics applied in 
Danish fish farming. SETAC-Europe 8th Annual Meeting 14-18th April 1998 Bordeaux [Abstract 
41/004],
Hughes J 5  (1973) Acute Toxicity o f Thirty Chemicals to Stripped Bass (Morone saxatilis). Presented at 
the Western Association of State Game and Fish Commissioners in Salt Lake City, Utah July 1973.
Hutchinson TH, Pounds NA, Hampel M, Williams TD (1999) Life-cycle studies with marine copepods 
(Tisbe battagliai) exposed to 20-hydroxyecdysone and diethylstilbestrol. Environmental Toxicology <£ 
Chemistry 18(12): 2914-2920.
Jobling 5, Sheahan D, Osborne J., Matthiessen P, Sumpter JP (1996) Inhibition of testicular growth in 
rainbow trout (Oncorhynchus mykiss) exposed to estrogenic alkylphenolic chemicals. Environmental 
Toxicology & Chemistry 15(2): 194-202.
Johnson SK (1976) Twenty-Four Hour Toxicity Tests o f Six Chemicals to Mysis Larvae o f Penaeus 
setiferus. Texas A A M University Extension Disease Laboratory, Publication No. FDDL-S8.
Knoll/BASF (1995) Pharmaceutical safety data sheet (Issue/Revision 06 /04 /94 ). Knoll Pharmaceuticals, 
Nottingham, UK. Quoted in Hailing-Sorenson e t a i (1998).
Kdpf W (1995) Wirkung endokriner Stoffe  in Biotests mit Wasserorganismen. Vortag bei der 50. 
Fachtagung des Bayerisches Landesamt fur Wasserwirtschaft: Stoffe mit endokriner Wirkung im 
Wasser (Abstract). [Effects of endocrine substances in bioassays with aquatic organisms. Presentation 
at the 50th Seminar of the Bavarian Association for Waters Supply. Substances with endocrine 
effects in water (Abstract)]. Quoted in Rdmbke e t at. (1995).
Kühn R, Pattard, M, Pernak KD, Winter A (1989) Results of the harmful effects of selected water 
pollutants (anilines, phenols, aliphatic compounds) to baphnia magna. Water Research 23(4): 495-499.
104
Lange R, Hutchinson TH, Croudace CP, Siegmund F, Schweinfurth H, Hampe P, Panther GH, Sumpter JP 
(2001) Effects of the synthetic oestrogen 17a-ethinylestradiol over the life-cycle of the fathead 
minnow (Pimephales promelas). Environmental Toxicology <S Chemistry 20(6): 1216-1227.
Lange R, Schweinfurth H, Croudace C, Panther 6  (1997) Growth and reproduction of fathead minnow 
(Pimephales promelas) exposed to the synthetic steroid hormone Ethinylestradiol in a life cycle test 
(Abstract). Seventh Annual Meeting of SETAC- Europe, Amsterdam, The Netherlands, April 6 - 10, 
1997.
Lanzky PF, Halling-Sarenson B, (1997) The toxic e ffect of the antibiotic metronidazole on aquatic 
organisms. Chemosphere 35(11): 2553-2561.
Li I i us H, Isomaa B, Holmstrdm T  (1994) A comparison of the toxicity of 50 reference chemicals to 
freshly isolated rainbow trout hepatocytes and baphnia magna. Aquatic Toxicology 30: 47-60.
Macri A, Sbardella E (1984) Toxicological evaluation of Nitrofurazone and Furazolidone on Selenastrum 
capricornutum, baphnia magna and Musca domestica. Ecotoxicol. Envir. Safety  8: 115-105.
Marking L , Howe GE, Crowther JR (1988) Toxicity of erythromycin, oxytetracycline and tetracycline 
administered to Lake Trout in water baths, by injection or by feeding. The Progressive Fish-Culturist 
50: 197-201.
Migliore L, Brambilla G, Grassitellis A, Di Delupis GD (1993) Toxicity and bioaccumulation of 
sulphadimethoxine in Artemia (Crustacea, Anostraca). In t. J. Salt Lake Res. 2(2): 141-152.
Migliore L, Civitareale C, Brambilla G, Di Delupis GD (1997) Toxicity of several important agricultural 
antibiotics to Artemia. Wat. Res. 31(7): 1801-1806.
OECD (2000) Record from the 2nd OECD Expert Consultation on Endocrine Disrupters Testing in Fish 
(EDF2) Tokyo 15-16fh March 2000. Test Guidelines Programme Endocrine Disrupters Testing and As­
sessment Task Force (June 2000).
Ranter GH, Thompson R5, Beresford N, Sumpter JP (1999) Transformation of a non-oestrogenic 
steroid metabolite to an oestrogenically active substance by minimal bacterial activity. Chemosphere 
38(15): 3579-3596.
Peterson SM, Batley GE, Scammell, MS (1993) Tetracycline in anti fouling paints. Marine Pollution 
Bulletin 26(2): 96-100.
Purdom CE, Hardi man PA, Bye VJ, Eno NC, Tyler CR, Sumpter JP (1994) Estrogenic effects of effluents 
from sewage treatment works. Chemistry <& Ecology 8: 275-285.
Rodriguez C, Chellman K, Gomez 5, Marple L (1992) Environmental assessment report persuant to 21 
CFR 25.31(a) submitted to the US FDA in support of the New Drug Application (NDA) for naproxen for 
over-the-counter use. Hamilton Pharmaceuticals Limited: Puerto Rico.
Rdmbke J et al. (1996) Minutes of the Round Table Discussion: Medicines in the Environment held at 
the Federal German Bureau of the Environment (Berlin) on 15th December 1995 on behalf of the 
Federal German Bureau of the Environment (UBA).
Russom CL, Bradbury SP, Broderius SJ, Hammermeister DE, Drummond RA (1997) Predicting modes of 
toxic action from chemical structure: Acute toxicity in the fathead minnow (Pimephales promelas). 
Environmental Toxicology <& Chemistry 16(5): 948-967.
Sanofi (1996). Tiludronate Disodium Material Safety Data Sheet SR 41319B Sanofi Research.
106
Schweinfurth H, Ldnge R, ôünzel P (1996) Environmental fate and ecological effects of steroidal 
estrogens. Presentation at the "Oestrogenic Chemicals in the Environment' conference organised by 
1BC Technical Services Ltd in London on the 9th <& 10th May, 1996.
Schweinfurth H, Ldnge R <& Schneider PW (1996a) Environmental risk assessment in the pharmaceutical 
industry. Presentation at the "3rd Eurolab Symposium - Testing and Analysis for Industrial 
Competitiveness and Sustainability' Berlin, 5 - 7th June, 1996.
Sheahan DA, Bucke D, Matthiessen P, Sumpter JP, Kirby MF, Neal I P, Waldock M (1994) The effects of 
low levels of 17 a-ethynylestradiol upon plasma vitellogenin levels in male and female rainbow trout, 
Oncorhynchus mykiss, held at two acclimation temperatures. In: Müller R, Lloyd R (eds) Sublethal and 
Chronic Effects o f Pollutants on Freshwater Fish. Fishing News Books, Blackwell Science, Oxford, 99- 
112.
Tooby TE, Hursey PA, Alabaster JS (1975) The acute toxicity of 102 pesticides and miscellaneous 
substances to fish. Chemistry and Industry 2 lst June 1975: 523-526.
Wang WH, Lay JP (1989) Fate and effects of salicylic acid compounds in freshwater systems. 
Ecotoxicology and Environmental Safety  17(3): 308-316.
Welborn TL (1969) The toxicity of nine therapeutic and herbicidal compounds to stripped bass. The 
Progressive Fish Culturist 31(1): 27-32.
Wilford WA (1966) Toxicity o f 22 Therapeutic Compounds to Six Fishes. US Dept, of the Interior, 
Fish & Wildlife Service, Bureau of Sports Fisheries & Wildlife - Resource Publication 35. Washington 
DC December 1966.
Zou E, Fingerman (1997) Synthetic estrogenic agents do not interfere with sex differentiation but do 
inhibit molting of the cladoceran Oaphnia magna. Bull. Environ. Contam. Toxicol. 58: 596-602.
107
APPENDIX
Fish:
Brachyderio (=Danio) rerio - Zebra fish 
Gambusia affinis - Mosquito fish 
Ictalurus punctatus- Channel catfish 
Lepomis macrochirus - Bluegill sunfish 
Morone saxatilis - Striped bass 
Oncorhynchus mykiss - Rainbow trout 
Pimephales promelas - Fathead minnow 
Rasbora heteromorpha - Harlequin fish 
Rutilus rutilus - Roach 
Salmo tru tta  - Brown trout 
Salvelinus fontinalis - Brook trout 
Salvelinus namaycush - Lake trout
Invertebrates:
Acartia tonsa - Copepod crustacean
Artemia salina - Anostracan crustacean
Brachionus calyciflorus - Rotifer
Bithynia tentaculata - Gastropod mollusc
baphnia magna - Cladoceran crustacean (Water flea)
Hyalella azteca - Amphipod crustacean
Lymnaea stagnalis - Gastropod mollusc (Pond snail)
Panaeus setiferus - Decapod crustacean (White shrimp)
Physa sp. - Gastropod mollusc (Bladder Snail)
Sphaerium striatinum  -  Bivalve mollusc (Fingernail clam) 
Streptocephalus proboscideus - Anostracan crustacean 
Tisbe battaglia i -  Copepod crustacean
Algae:
Scenedesmus subspicatus - Green algae 
Selenastrum capricornutum  - Green algae 
N itzschia closterium -  Marine diatom 
Skeletonema costatum -  Marine diatom 
Chlorella spp. - Green algae 
M icrocystis aeruginosa -  Blue-green algae
CHAPTER 4 
AQUATIC RISK CHARACTERISATION
This chapter has been published in "Pharmaceuticals in the Environment -  Sources, Fate, 
E ffects  and Risks" (Ed. K. Kiimmerer) under the title "A Oata Based Perspective on the  
Environmental Risk Assessment o f Human Pharmaceuticals H  -  Aquatic Risk Assessment' 
pp 203- 219 (Springer, 2001).
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INTRODUCTION
Environmental risk assessment (ERA) evaluates the likelihood that adverse ecological effects 
result from exposure to a substance. I t  therefore requires a consideration of both exposure 
and effects in relevant environmental compartments. The exposure assessment considers the 
fate of a substance released to the environment and predicts the environmental concentra­
tion or PEC Predicted Environmental Concentration"). The effects assessment considers 
data relating to the effects of the substance upon representative biota and uses such data 
to predict the no-effect concentration or PNEC {"Predicted No-Effect Concentration") for 
the various environmental compartments (i.e., surface waters, sediment, soil, etc.). The PEC 
and PNEC are combined in order to characterise the risk, i.e., calculation of the PEC/PNEC 
ratio (see Figure 1). Decisions regarding the safety of the substance depend upon the value 
of this quotient.
Figure 1. - Risk assessment framework within the aquatic environment for human
pharmaceuticals.
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Risk assessment conventionally proceeds in an iterative/tiered process, employing simple and 
conservative assumptions to estimate PEC and PNEC at initial tiers and progressing through 
subsequent tiers by employing more realistic or representative assumptions when estimating
in
PEC and PNEC. Conservatism is incorporated into both the PEC (via the assumptions used to 
estimate the exposure) and PNEC (via use of assessment factors to extrapolate from labora­
tory derived-data to the ecosystem). The exposure and effects assessments do not have to 
simultaneously progress to successive tiers, and e ffo rt can be focused on those data that 
potentially have the largest impact upon the risk quotient or will reduce uncertainties.
I f  the environmental concentration in a compartment is less than the concentration causing 
"n o -e ffe c t' to that compartment, i.e., PEC/PNEC <1, then it is assumed that use of the sub­
stance carries little  risk of an adverse environmental effect. I f  the PEC/PNEC >1, then a de­
cision must be made either to further refine the data upon which the risk characterisation is 
based (i.e., progress to a subsequent tier), to manage the risk by limiting the amount of the 
substance released to the environment or to accept the level of risk following risk-benefit 
analysis. This latter option may be particularly pertinent to pharmaceuticals. Environmental 
(and human) risk assessment of both new and existing industrial substances in the European 
Union are conducted according to the Technical Guidance Document or TGD (CEC, 1996).
By means of a new directive (93/39/EEC), the Council of the European Union amended 
65/65/EEC {"Council b irective  6 5 /6 5 /E E C  o f  26 January 1965 on the approximation o f  pro­
visions laid down by law, regulation or administration action relating to medicinal product^'). 
Article 4.6 of the amendment states " I f  applicable, reasons fo r any precautionary and s a fe ty  
measures to be taken fo r the storage o f  the medicinal product, its  administration to patients  
and fo r  the disposal o f  waste products, together with an indication o f  any potential risks  
presented by the medicinal product fo r the environment' (93/39/EEC). The amendment e f­
fectively requires an environmental risk assessment (ERA) be submitted with marketing au­
thorisation applications (MAA) for pharmaceutical products containing novel compounds. EU 
member states were required to implement necessary regulations by January 1st, 1995.
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However, technical guidelines for the Environmental Risk Assessment (ERA) of pharmaceuti­
cal products for human use have yet to be finalised and are still subject to change. Drafts 
were prepared in 1994-95 under the aegis of several technical committees, including a task 
force under DG I I I  (the European Commission's Industry Directorate) providing comment to 
the CPMP Committee for Proprietary Medicinal Product^'). The nature and implications of 
the draft European guidelines from 1994-1995 are more fully reviewed elsewhere (see Hus­
sain and Hennessy, 1995; Olejniczak, 1995; Webb, 1995). Development of the EU guidance 
was halted pending clarification and further information from the US Food and Drug Admini­
stration (FDA) with respect to their experience of the value of environmental assessments 
(EAs). This followed the FDA's declaration that EA requirements for pharmaceuticals were 
to be simplified and that the number of EAs required to be submitted to the FDA for review 
would be reduced (FDA, 1995). This conclusion was based on the fact that virtually all EAs 
submitted to the FDA have been issued with a "Finding O f No Significant Impact' (FONSI). 
Following finalisation of the FDA's EA requirements, there is now a categorical exclusion for 
New Drug Actives (NDA) if the estimated concentration of the substance at the point of en­
try  into the aquatic environment (i.e., in sewage effluent) is below 1 pg/\ (US FDA Final Rule - 
Federal Register 29/07/97 Vo I 62 No 145 p40569-40600). This corresponds to a de facto 
threshold of ~41 t/a  in the USA. Guidance on the FDA's EA requirements can be found in an 
FDA-CDER publication entitled: "Guidance for Industry - Environmental Assessment o f Hu­
man Drugs and Biologies Application^' (FDA-CDER, 1998). Recently, a discussion paper on EU 
guidelines has been circulated by the EU Committee for Proprietary Medicinal Products 
(CPMP, 2001). Proposed guidelines are essentially similar to those proposed in 1994-1995. The 
action limit in the aquatic environment is 0.01 pg/\. This corresponds to a de facto threshold 
of 3 tonnes/annum within the EU before ecotoxicity data will be required. Commentary on 
the CPMP proposal has been provided in the form of an opinion of the EU Scientific Commit­
tee on Toxicity, Ecotoxicity and the Environment (C5TEE, 2001).
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This study brings together collated data relating to the usage and ecotoxicity of existing 
pharmaceuticals. Where possible, these data were employed in preliminary ERAs of com­
pounds in the aquatic compartment (which is assumed to be predominantly relevant) in a fash­
ion consistent with that prescribed by the draft European Guidelines. The intention is to pro­
vide perspective that will prove useful during the further development of any assessment 
criteria.
METHODS
In general, there is a paucity of readily accessible data relating to the consumption of phar­
maceuticals. This has hitherto precluded attempts at the systematic analysis of the potential 
impacts of pharmaceuticals upon the environment. The most comprehensive survey of drug 
usage to date was conducted by Richardson and Bowron (1985), who examined drug prescrip­
tion patterns in the UK for the years 1975-76 (see Table 1). Of a total of 1,600 compounds 
considered, approximately 170 were used at >1 tonne/annum. Of these 170, it is possible to 
derive consumption values for 141 compounds from the publication. The distribution of the 
data is summarised in Table 2. The corresponding overall consumption totals <6,700 ton­
nes/annum.
Usage data for 10 drugs in Germany (1995) is presented in Ternes (1998). Some limited drug 
consumption data for Sweden, the Netherlands and Denmark are presented in Eckerman and 
Martineus (1997), Van Der Heide and Hueck-Van Der Plas (1984) and Halling-Sorenson et ai, 
(1998). Within the EU there are almost 2000 pharmaceutical manufacturers operating at up 
to 400 sites. The number of pharmaceutical preparations produced and sold within the EU is 
estimated at up to 10,000 (CEC, 1992).
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Table 1. - Profile of highest use compounds (derived from Richardson & Bowron, 1985).
Rank Drug Category UK Use (t/a)i2
1 Paracetamol (Acetaminophen) Analgesic; Anti-pyretic 2,329
2 Aspirin Analgesic; Anti-pyretic; 
Anti-inflammatory
1,103
3 Methyldopa Anti-hypertensive 120
4 Ibuprofen Anti-inflammatory 65
5 Benorylate Analgesic; Anti­
inflammatory; Anti-pyretic
63
6 Karaya Gum Cathartic 63
7 Ampicillin Anti-bacterial 54
8 Sulphamethoxazole Anti-bacterial; Anti- 
pneumocystis
49
9 Oxytetracycline Anti-bacterial 46
10 Clofibrate Anti-hyperlipoproteinemic 43
11 Dimethicone Anti-flatulent 30
12 Inositol Nicotinamide Vasodilator 26
13 Dextroproproxyphene Narcotic analgesic 22
14 Tetracycline Anti-amebic; Anti-bacterial; 
Anti-ricketettsial
20
15 Meprobamate Anxiolytic 18
12 Based on the assumption that use of a drug at the level of 1 tonne/annum in the UK corresponds to a
maximum predicted concentration of -0.15 pg/l in the River Lee. For example, quoted proprietary use 
of Aspirin at 1,000 tonnes/annum corresponds to a predicted concentration of 146 pg/l. All other pre­
dicted river water concentrations are in multiples of 0.146 pg/l (Richardson pers. comm.).
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Table 2. - Summary of UK consumption data (derived from Richardson & Bowron, 1985).
Tonnes/annum 1 - 10 10
<20
20 - 
<30
30 - 
<40
40 - 
<50
50 - 
<100
> 100 Total
>1
Number 115 13 3 0 3 4 3 141
Frequency (%) 82 9 2 0 2 3 2 100
Given the absence of recently published usage data, an audit of 1995 UK pharmaceutical us­
age was commissioned from IMS (pharmacies, dispensing general practitioners and hospital 
pharmacies. Intercontinental Medical Statistics - UK and Ireland Ltd). Approximately 60 
compounds were selected for audit on the basis of the availability of ecotoxicity data 
(thereby allowing risk characterisation).
The results of the audit are presented in Table 4 and reflect sales of all products containing 
these compounds (irrespective of salt and including combination products) into retail Data 
relating to the UK usage of OTC analgesics were obtained from the Paracetamol Information 
Centre (Brandon pers. comm.)^ and the European Aspirin Foundation (Hopkins pers. comm.)14.
Data are summarised in Table 3. Where data are available for both drug consumption and 
ecotoxicity, an aquatic risk characterisation was undertaken for human pharmaceuticals. A 
review of short-term/acute ecotoxicity data for macro-invertebrates, fish and algae for 
over 100 human pharmaceuticals is presented in Chapter 3 (Webb, 2001).
i3 1950 - 2000 tonnes. Based on 3.9 - 4.0 billion (109) tablet equivalent units of 500 mg (Paracetamol 
Information Centre).
h 770 tonnes. Declining sales of Aspirin can be attributed to the increased availability of other OTC 
analgesics such as Ibuprofen (European Aspirin Foundation).
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Table 3. - Summary of 1995 UK consumption data [commissioned from IM S].
Tonnes/annum <1 1 - 10 1 0 -
<20
20 - 
<30
3 0 -
<40
4 0 -
<50
5 0 -
<100
> 100
Number 38 14 3 3 1 1 4 3
Frequency (%) 57 21 4.5 4.5 1.5 1.5 6 4.5
Although the results o f the risk characterisation are specific to the  United Kingdom, they  
are probably equally applicable to other countries with similarly developed healthcare provi­
sions and wastewater treatm ent in frastructure. Sewage influent concentrations are calcu­
lated throughout on th e  basis o f a UK population of 57.6 million and a specific w ater con­
sumption of 259  litres /cap ita /d ay  (W SA , 1994). The assumptions of no human metabolism, 
passage of all material to  drain, no removal during wastew ater trea tm en t (via biodégradation, 
sorption or volatilisation) and no surface w ater dilution of e fflu en t th a t were used to calcu­
late the  PEC are all conservative. Collectively, they can be thought of as "worst-case" (see 
Figure 2). The PNEC values are derived using an assessment fac to r o f 1,000 with the  relevant 
acute data. This is consistent with th e  approach employed fo r  other chemical compounds in 
the  EU Technical Guidance Document (CEC, 1996).
Figure 2. - " Worst-case” PEC estimation for pharmaceuticals 
Pharmaceutical Use Wastewater Treatment Surface Waters
Si!
No metabolism 
100% loss to drain
No removal No dilution
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RESULTS
The results of the preliminary assessment for over 60 compounds are presented in Table 4 
and summarised in Figure Sis. Together, these compounds will probably account for over half
of all known pharmaceuticals consumption in tonnage terms. The PEC/PNEC ratio was <1 in all 
but eight cases. PEC/PNEC ratios less than unity are taken as indicative of a negligible risk of 
an adverse environmental effect. The exceptions were Paracetamol (Acetaminophen), Aspirin, 
Dextropropoxyphene, Fluoxetine, Oxytetracycline, Propranolol, Amitriptyline and 
Thioridazine. I t  is notable that Paracetamol and Aspirin are the two most commonly 
consumed pharmaceutical compounds. One possible caveat to the approach adopted is the 
implicit assumption of homogenous distribution of use in the UK. Certain drugs such as 
antineoplastics may only be used in hospitals on an in-patient basis. Further refinement of 
the risk assessment is therefore required for Paracetamol, Aspirin, Dextropropoxyphene, 
Fluoxetine, Oxytetracycline, Propranolol, Amitriptyline, and Thioridazine. Chronic ecotoxicity 
data -which would have allowed use of an alternative assessment factor to calculate the 
PNEC - are not available for most of the drugs and the initial effects assessments were 
therefore retained.
Table 4. - Initial aquatic risk assessment for selected pharmaceuticals in the UK.
Name UK Use (t/a)i6 PEC 0/g/l) PNEC G/g/l)i7 PEC/PNEC
Paracetamol -2,000 367.3 9.2 39.92
Aspirin 770 141.4 141 1.00
is These results were originally presented at SETAC-Europe 1998 (Webb, 1998).
16 Quoted figures are all assumed to refer to the organic parent molecule (although in some cases the
active will actually be the salt and the values will therefore be overestimates).
17 Asterisk denotes adjustment for molar equivalent of organic parent molecule.
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Metformin 106.1 19.49 101* 0.19
Cimetidine 72.0 13.22 740 0.02
Ranitidine 69.0 12.67 582* 0.02
Erythromycin 67.7 12.43 >74 <0.17
Naproxen 60.6 11.13 128* 0.09
Dextropropoxyphene 42.5 7.81 3.79* 2.06
Oxytetracycline 33.7 6.19 0.23 26.8
Quinine 29.7 5.45 10.1* 0.54
Theophylline 21 3.86 155 0.02
Lithium Salts 20.518 0.35 (Li) 4.18 (Li) 0.08
Metronidazole 15.5 2.85 12.5 0.23
lopromide 11.9 2.19 >92 <0.01
Propranolol 11.8 2.17 1.87 1.16
Verapamil 9.9 1.82 5.78* 0.31
Amitriptyline 5.5 1.01 0.78 1.29
Tetracycline 4.7 0.86 16.0 0.05
Omeprazole 3.9 0.72 88 <0.01
Thioridazine 3.8 0.70 0.27* 2.59
Chloroquine 2.9 0.53 2.72* 0.20
Gabapentin 2.6 0.48 >1100 <0.01
Etidronic Acid 2.1 0.39 3.0 0.13
Fluoxetine 2.0 0.37 0.026* 14.19
Phénobarbital 1.7 0.31 484 <0.01
is Includes 16.89 tonnes/annum Lithium Citrate and 3.54 tonnes/annum Lithium Carbonate. PEC and 
PNEC values are adjusted to the Lithium ion.
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Tramadol 1.7 0.31 64* <0.01
Clofibrate 1.5 0.28 12.0 0 .02
Paroxetine 1.3 0.24 1.8* 0.13
Orphenadrine 1.1 0 .20 3.82* 0.05
Diazepam 0.957 0.18 4.3 0.04
Acarbose 0.918 0.17 >1000 <0.01
Isoniazid 0.690 0.13 24.4 <0.01
Nefazodone 0.618 0.11 *6.5 0.02
Quinidine 0.601 0.11 7.2* 0.02
Sumatriptan 0.521 0.10 207* <0.01
Aminosidin/Neomycin E 0.487 0.09 340* <0.01
Warfarin 0.476 0.09 12.0 <0.01
Lansoprazole 0.434 0.08 18.0 <0.01
Cisapride 0.413 0.08 1000 <0.01
Chloramphenicol 0.377 0.07 305 <0.01
Famciclovir 0.286 0.05 820 <0.01
Azithromycin 0.276 0.05 120 <0.01
Cetirizine 0.273 0.05 278* <0.01
Famotidine 0.246 0.05 398 <0.01
Ceftibuten 0.095 0.017 >520 <0.01
Lorsatan 0.087 0.016 331 <0.01
Budesonide 0.081 0.015 >19 <0.01
Finasteride 0.067 0.012 20 <0.01
Perindopril 0.047 0.009 >990* <0.01
Didanosine 0,039 0.007 >1021 <0.01
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Midazolam 0.037 0.007 0.2 0.04
Fluticasone 0.034 0.006 0.48* 0.01
Digoxin 0.031 0.006 24 <0.01
Ethinyl Oestradiol 0.029 0.005 0.84 <0.01
Risperidone 0.021 0.004 6 <0.01
Atropine 0.016 0.003 221* <0.01
Carvedilol 0.008 0.001 1 <0.01
Salmeterol 0.007 0.001 20 <0.01
Bicalutamide 0.007 0.001 >1 <0.01
Alendronic Acid 0.007 0.001 0.46* <0.01
Dorzolamide 0.004 0.001 604* <0.01
Diethystilbestrol 0.002 <0.001 1.09 <0.01
Paclitaxel 0.001 <0.001 0.74 <0.01
Zalcitabine <0.001 <0.001 >1790 <0.01
Thiotepa <0.001 <0.001 546 <0.01
Flumazenil <0.001 <0.001 >500 <0.01
Milrinone <0.001 <0.001 223* <0.01
Figure 3. - Initial preliminary risk characterisation.
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Refinement was consequently confined to the exposure assessments (i.e., PECs). This re­
quired a consideration of the likely degree of removal during wastewater treatment (via bio­
dégradation^, adsorption or volatilisation) and/or surface water dilution of sewage effluent.
From a regulatory perspective, any further discussion of removal during wastewater treat­
ment of Aspirin, Dextropropoxyphene, Propranolol, Amitriptyline and Thioridazine is aca­
demic as a consideration of surface water dilution alone is sufficient to ensure a PEC/PNEC 
<1. This assumes a dilution factor 10, which is the default from the EU Technical Guidance 
Document (CEC, 1996).
Paracetamol: A high degree of elimination (98%) of Paracetamol during activated sludge 
wastewater treatment has been reported by Ternes (1998). This is not surprising given the 
biodégradation profile of Paracetamol (Richardson and Bowron, 1985). An estimated 
Paracetamol "worst-case" (i.e., no human metabolism) sewage influent concentration of 367 
f/g/litre would therefore be reduced to an effluent concentration of 7.3 j/g/l following acti­
vated sludge treatment. The corresponding PEC after l-in-10 dilution of effluent in surface 
water would be 0.7 jt/g/l. A PNEC of 9.2 fjg/\ can be derived for Paracetamol by the applica­
tion of an assessment factor of 1,000 to the lowest of 3 acute endpoints in algae, fish and 
baphnia (Henschel et ai, 1997; Kühn et al., 1989). The résultant PEC/PNEC ratio is 0.08 and 
environmental safety is assumed (even without any consideration of human metabolism). I t  is 
notable that Paracetamol was not detected in the environmental matrices examined by
i9 Biodégradation data were available for five of the compounds (or a closely related analogue in the
case of Oxytetraceycline). The likely biodégradation profile of all the compounds was also predicted 
using the group contribution method of Boethling et al., (1994). Biodégradation of Paracetamol, Aspirin, 
Oxytetracycline and Amitriptyline as predicted via the group contribution method was comparable with 
that reported by Richardson & Bowron (1985). Only in the case of Dextroproproxyphene did reported biodég­
radation d iffer from the predicted profile. The group contribution algorithm suggests that Dextropropoxyphene is 
not recalcitrant and may even be readily biodegradable.
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Richardson and Bowron (1985) or in German surface waters (LOD 0.15 fjg/\) by Ternes (1998). 
Concentrations in treated sewage effluents in Germany were similarly less than the detection 
limit (LOD 0.5 A/g/l) at the 90th-percentile (Ternes, 1998). Risk characterisation based the 
measured (rather than predicted) environmental concentrations (MEC) from Ternes (1998) 
would yield MEC/PNEC ratios <0.02.
Fluoxetine: The likely biodégradation profile of Fluoxetine can be predicted using the group 
contribution method of Boethling e t a/., (1994). The linear model predicts rapid biodégrada­
tion. A degree of elimination via biodégradation of Fluoxetine during wastewater treatment is 
therefore likely. A removal of >91% can be predicted for readily biodegradable substances 
(regardless of Ko*) from the WWTP removal defaults in the appendices of the TGD (CEC, 
1996). Incorporation of such an elimination rate and a consideration of surface water dilution 
of effluent (dilution factor 10) would yield a revised PEC for Fluoxetine of 0.003 fjg/\. The 
initial PNEC for Fluoxetine of 0.026 fjg/\ is derived from an application of an assessment fac­
tor to the lowest (algae) of three acute endpoints (FDA-CDER, 1996). A revised PEC/PNEC 
based upon the above exposure and effects scenarios would be 0 .12.
Oxytetracycline: Human metabolism of Oxytetracycline is limited (Dollery, 1991). Biodégra­
dation is also likely to be limited (based on observations for Tetracycline from Richardson 
and Bowron, 1985). As such the initial assumptions of 100% loss to drain (i.e., no metabolism) 
and 0% removal during wastewater treatment is retained. The estimated sewage influent and 
effluent concentrations remain at 6.2 /yg/l. With surface water dilution of effluent (dilution 
factor 10) this corresponds to a PEC of 0.62 fjg/\. A PNEC of 0.23 fjg/\ can be derived from 
the use of an application factor of 1,000 on an algal EC5o (Holtzen-Lützhoft et  a/.,1998). The 
revised PEC/PNEC is 2.7 and nominally requires further refinement. I t  is notable that Tetra­
cycline is photodegradable in surface waters with a half-life in terms of hours (Peterson et
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al., 1993). Photodegradation may help to explain why Oxytetracycline was not detected (90%- 
tile <LOD 0.05 fjg/\) in German rivers by Hirsch et al., (1999). Similarly, the complexing prop­
erties of tetracyclines with calcium and other similar ions have also been highlighted as a 
possible reason to explain their absence from the water column (Hirsch et al., 1999). Risk 
characterisation based on measured concentrations from Hirsch et nal., (1999) yield 
MEC/PNEC ratios <0.22.
Ethinyl Oestradiol: Although initial risk characterisation of Ethinyl Oestradiol yielded 
PEC/PNEC ratios <1, specific concerns have been raised around the possible effects of this 
compound following observations in environmental matrices. These concerns can also be ad­
dressed via risk characterisation based on (i) actual monitoring data rather than predicted 
concentrations and (ii) a PNEC derived from chronic endpoints. Acute/short term ecotoxicity 
endpoints for Ethinyl Oestradiol initially employed to derive a PNEC are (i) algal EC5o 0.84 
mg/l (Kdpf, 1995) (ii) Oncorhynchus mykiss LC5o 1.6 mg/l (Schweinfurth et al., 1996) and (iii) 
baphnia magna EC5o 6.4 mg/l (Schweinfurth et al., 1996). In contrast, sub-lethal responses in 
baphnia and algae (Kdpf, 1995) were at concentrations 1 - 3 orders of magnitude less. Even 
more sensitive endpoints for Ethinyl Oestradiol exist for fish. They include plasma vitel­
logenin bioassay effect concentrations of <1 ng/l in rainbow trout (Oncorhynchus mykiss) and 
a spermatogenesis/gonadosomatic index (GSI) e ffect concentration of 2 ng/l in roach (Ruti­
lus rutilus) and rainbow trout (Purdom et al., 1994; FWR, 1995). Although the ecological sig­
nificance of responses in these biomarkers is unclear, other more readily interpretable end­
points are available. For example, Schweinfurth et al. (1996) also detail preliminary chronic 
test data from studies conducted with fathead minnows (Pimephales promelas). These include 
a 28d LOEC of 10 ng/l fo r inhibited egg production. A subsequent study revealed a 9-month 
reproduction NOEC of 1 ng/l (Ldnge et al., 1997; 2001). With an appropriate assessment fac­
tor (i.e., 10), the corresponding PNEC is therefore 0.1 ng/l.
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At a consumption figure of 29 kg/annum in the UK - equivalent to ~2.65 million daily doses of 
30 fjg - the predicted influent concentration is ~5 ng/l. This excludes human metabolism. 
Less than 1% of Ethinyl Oestradiol is excreted unchanged. The major pathway of metabolism 
is 2-hydroxylation. Hydroxylated metabolites have little oestrogenic activity. Up to 30% is 
excreted unoxidised as glucuronide or sulphate conjugates in urine and bile (Dollery, 1991). 
However, this assumption of no human metabolism is somewhat vindicated by the recent ob­
servation that non-oestrogenic steroids metabolites (i.e., Oestradiol-3-glucuronide) can be 
readily biotransformed into biologically active oestrogens via microbial activity (Ranter et a/., 
1999).
Incorporation of a consideration of removal during waste water treatment (78% by activated 
sludge treatment and 64% by trickling filte r treatment - Ternes et al., 1999) and effluent 
dilution in surface water (l-in-10) results in a surface water PEC of 0.03 - 0.05 ng/l. This can 
be compared with values of 2 - 15 ng/l reported in UK rivers by Aherne and Briggs (1989). 
However, other authorities have doubted the veracity of such observations following subse­
quent monitoring studies (FWR, 1995). This is supported by the most recent observations 
from studies detailing (i) German surface water concentrations where values were all <0.2 
ng/l (Kalbfus, 1995) and (ii) how Ethinyl Oestradiol was undetectable (<0.2 ng/l) in more than 
half of UK sewage effluents sampled and where detectable was usually below 1 ng/l (Desbrow 
et al., 1996). With sufficient surface water dilution of the effluent (i.e., l-in-10), the PEC 
would typically range from <0.02 ng/l to <0.1 ng/l, and the environmental safety of Ethinyl 
Oestradiol could be assumed. Only under low dilution scenarios (i.e., <l-in-2 where effluent 
concentrations are above the detection limit of 0.2  ng/l) will risk characterisation yield 
PEC/PNEC ratios >1.
However, it should also be noted that Desbrow et al. (1996) also details how the majority 
(90%) of oestrogenic activity in sewage effluent in the UK is accounted for by the presence 
of the natural oestrogens, Estrone and 17(3-Estradiol. The source of these natural oestrogens 
appears to be excretion from women, particularly pregnant women. I t  is suspected that the 
conjugated forms of Estrone and 17p-Estradiol that are excreted by women are metabolised 
by bacterial 6-glucuronidase enzymes to produce active hormones. Desbrow et al. (1996) 
therefore concluded that although Ethinyl Oestradiol may contribute to the overall oestro- 
genicity of sewage effluents, it appears likely that natural oestrogens are responsible for 
the majority of the feminised responses observed in fish populations exposed to sewage 
efluents. The corollary of this observation is that additivity can be assumed for steroids. 
Thorpe et al. (2001) demonstrates that binary mixtures of oestrogenic chemicals are addi­
tive in vivo in juvenile rainbow trout.
Clofibrate/Clofibric Acid: Acute/short term ecotoxicity endpoints for Clofibrate/Clofibric 
Acid ranged from 12 mg/l to 89 mg/l (Kdpf, 1995). The initial PNEC value was 12 //g/l (based 
on algal EC5o from Kdpf, 1995) and the PEC was 0.28 fjq/\. Risk characterisation yielded a 
PEC/PNEC ratio of 0.02. For comparison, the PNEC value that can be derived from chronic 
data is 0.2 fjg/\. This is based on a 21d NOEC in baphnia magna of 10 //g/l (Kdpf, 1995) with an 
assessment factor of 50 (algal and baphnia chronic endpoints). The PEC could be further re­
fined by an incorporation of the reported degree of elimination (51%) of Clofibric Acid dur­
ing wastewater treatment (Ternes, 1998) and surface water dilution of effluent (dilution 
factor 10). This would yield a PEC of 0.014 //g/l. The maximum reported environmental con­
centrations (MEC) of Clofibric Acid in surface waters in Germany is 1.75 //g/l with a 90- 
percentile of 0.72 //g/l (Ternes, 1998). MEC/PNEC ratios are therefore 8.75 and 3.6 respec­
tively. Further revision of the effects assessment to generate a third chronic endpoint for 
fish would allow an assessment factor of 10. This may improve the MEC/PNEC ratio at the
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90-percentile. Differences between the PECs for the UK and reported concentrations of 
Clofibric Acid in German surface waters in part reflect differing use patterns in the two 
countries, i.e., 1.5 t/a  in the UK compared with 16 t/a  reported for Germany by Ternes 
(1998).
Other Drugs: Observations of surface water concentrations are available for several other 
pharmaceuticals (see Table 5). Maximal measured environmental concentrations (MECs) for 
most compounds were generally less than the corresponding "worst-case" PECs from Table 3. 
Although in several cases, the difference was less than one order of magnitude. Whilst many 
of the measured observations relate to German surface waters, they may be considered in­
dicative of the conservatism employed in this study when deriving the PECs. The surface wa­
ter concentrations can also be compared with a PNEC to derive MEC/PNEC ratios. In all 
cases, MEC/PNEC ratios are <1. I t  is notable that Aspirin, Dextroproproxyphene and Pro­
pranolol were also amongst those compounds highlighted for further refinement of the risk 
assessment following initial characterisation under the "worst-case" exposure assessment as­
sumptions (see Table 4).
Table 5. - Comparison of maximal measured environmental concentrations (MEC) with 
predicted no-effect concentrations (PNEC).
Drug/Metabolite MEC (ng/l) PNEC (ng/l)2o MEC/PNEC Ratio
Aspirin 340 (i) 141,000 <0.01
Chloroamphenicol 60 (ii) 305,000 <0.01
Dextroproproxyphene 1,000 (iii) 3,790 0.26
Diazepam <30 (i) 4,300 <0.01
20 See Chapter 3 (Webb, 2001) for ecotoxicological data for substances marked with an asterisk (*).
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Erythromycin 1,700 (ii) >74,000 <0 .02
Ibuprofen 530 (i) 7,100* 0.07
Methotrexate <6.25 (iv) 85,000* <0.01
Naproxen 390 (i) 128,000 <0.01
Oxytetracycline <50 (ii) 230 <0.22
Propranolol 590 (i) 1,870 0.32
Sulfamethazine <20 (ii) >100,0 0 0 * <0.01
Tetracycline 1,000 (v) 16,000 0.06
Theophylline 1,000 (v) 155,000 <0.01
Source: (i) Ternes (1998); (ii) Hirsch et al. (1999); (iii) Richardson <& Bowron (1995); (iv) 
Aherne e t al. (1985); (v) Watts et al. (1983).
DISCUSSION
The general lack of public domain usage data had previously precluded estimates of the envi­
ronmental concentrations of pharmaceuticals. Data presented in this study allowed the 
aquatic exposure assessment of a large number of compounds from across a wide variety of 
therapeutic classes. Initial risk characterisation utilising acute ecotoxicity data and conser­
vative fate assumptions (including no human metabolism, no removal during wastewater 
treatment and no surface water dilution of effluent) demonstrated the nominal environ­
mental safety (i.e., PEC/PNEC <1) of all but eight of the greater than 60 pharmaceutical com­
pounds considered. The exceptions were Paracetamol, Aspirin, Dextropropoxyphene, Fluoxet­
ine, Oxytetracycline, Propranolol, Amitriptyline, and Thioridazine. Incorporation of their 
likely fate following use (i.e., removal during wastewater treatment and/or surface water di­
lution of effluent) yielded a marked reduction in the surface water PEC values, and the resul­
tant PEC/PNEC ratios were generally less than unity when the PNEC was based on acute data. 
This use of acute ecotoxicity data for risk assessment purposes for pharmaceuticals has
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been criticised (Halling-Serenson et al., 1998). Standard acute bioassays with their focus on 
immediate endpoints such as lethality may not be the most appropriate basis for risk assess­
ment given the intended narrow scope of biological activity/effect and general potency of 
pharmaceuticals in general. I t  has consequently been suggested that chronic bioassays per­
formed over the life-cycle of various organisms from different trophic levels may be more 
appropriate (Halling-Sorenson et ai, 1998). A limited amount of data relating to the effects 
of pharmaceuticals upon chronic ecotoxicity endpoints was available. I t  is interesting to note 
that in this study when PNECs were derived from this chronic data set, values were less than 
the corresponding values derived from acute data (i.e., in the case of Ethinyl Oestradiol and 
Clofibrate). MEC/PNEC ratios based on maximal measured surface water concentrations 
rather than PECs were similarly less than unity. In  general, these maximal MECs were less 
than the "worst-case" PECs and this was interpreted as confirmation of the conservative na­
ture of the underlying assumptions used to derive the PECs.
Following use, most human drugs (or their metabolites) will tend to enter the environment by 
excretion (via urine and/or faeces) from patients. Incorporation of a consideration of human 
metabolism during the exposure assessment would therefore have the potential to reduce 
PEC values. Even though it has not proven necessary to include a consideration of metabolism 
to demonstrate nominal environmental safety of parent compounds, reported metabolism of 
many drugs is known to be considerable. Where metabolism does take place, metabolites in 
general will tend to be more polar and water soluble. Metabolism is also often associated with 
a loss of pharmacological action and detoxification. For example, Richardson and Bowron 
(1985) noted that a significant number of pharmaceuticals undergo mammalian metabolism to 
yield conjugates, and that the toxicity and pharmacological activity of these conjugates is 
likely to be much lower than that of the parent compounds. However, any effects on solubil­
ity may also have a concomitant influence on removal via adsorption during wastewater trea-
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ment. A full consideration of the fate and effects of all the metabolites of each drug con­
sidered in this study would clearly be prohibitive. Risk characterisation was therefore exclu­
sively conducted on the parent drug substance as representative of substances potentially 
entering the environment. Alternative practices may need to be applied for drugs where 
there are clear indications that the fate of the metabolites d iffe r from the parent com­
pound or that the metabolites could adversely e ffect the environment to a greater extent 
than the parent drug substance. In some cases, incorporation of a consideration of metabo­
lism when estimating exposure may even be inadvisable, as there is a suggestion that some 
drug conjugates have the potential to be reactivated during biological wastewater treatment 
(FWR, 1995). Similarly, Henschel et al. (1997) speculate whether Paracetamol and Salicylic 
Acid conjugates can be reactivated via microbial p-gluconidase or su If at ase. Most recently, 
Ranter et al. (1999) demonstrated the transformation of a non-oestrogenic steroid metabo­
lite to an oestrogenically active substance via bacterial activity. I t  is interesting to note that 
both Clofibrate and Ethinyl Oestradiol - two pharmaceuticals that have attracted particular 
attention following observations in environmental samples - are excreted in considerable 
amounts as conjugates in the urine or faeces (Dollery, 1981). Some 50 - 85% of dosed Clof- 
brate is excreted in the urine as the glucuronic conjugate of Clofibric Acid. In  the case of 
Ethinyl Oestradiol, considerable amounts (~30%) are excreted in urine and bile as the pri­
mary glucuronide and sulphate conjugates.
One potential issue that has not been directly addressed is that of bioaccumulation. The po­
tential to bioaccumulate is driven by lipophilicity. Octanol-water partition coefficient (Kqw) is 
a surrogate measure of lipophilicity and has frequently been correlated with bioaccumulation 
in non-polar/non-ionisable substances, e.g., Mackay (1982) and Veith and Kosian (1983). A 
quantitative inclusion of a consideration of bioaccumulation into the risk assessment process 
is described by Cowan et al. (1995). One important aspect of the integrated assessment
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framework relating to bioaccumulation was whether the duration of ecotoxicity tests are 
sufficient to achieve maximal body burdens and elicit potential ecotoxic effects upon test 
organisms. Based on a consideration of such an issue, the study also proposed an initial action 
threshold for a tiered bioaccumulation assessment of a fish bioconcentration factor (BCF) of 
1,000. Both Mackay (1982) and Veith and Kosian (1983) predict a BCF of 1,000 at log K0w 
~4.3. Such models typically overestimate actual bioaccumulation and may trigger unjustifiable 
concerns (ECETOC, 1995). Deviations from predicted bioaccumulation will occur with (i) sub­
stances of molecular weight greater than ~700, thereby inhibiting or excluding penetration 
of biological membranes, (ii) substances that are ionizable, surface active or polar or (iii) 
where active biotransformation of the substance to a more hydrophilic derivative occurs 
(ECETOC, 1995).
Of particular importance in reducing the bioconcentration and bioaccumulation of substances 
within aquatic organisms is biotransformation (ECETOC, 1995). Two types of biotransforma­
tion reactions are observed in aquatic organisms and these have been classified as Phase I  
and Phase I I  reactions. Phase I  reactions are the primary phase of metabolism involving oxi­
dation, reduction or hydrolysis of functional groups. Phase I I  reactions involve conjugation, 
whereby substances or their metabolites are bound to other substances such as sulphate or 
glucuronic acid. Several cases of the influence of metabolism on measured BCFs have been 
reported, and it is evident that biotransformation is crucial in reducing the bioconcentration 
and bioaccumulation of substances within aquatic organisms (see ECETOC, 1995). Significant 
discrepancies can exist between measured and calculated BCF values, and these become more 
pronounced with increasing log Kq w  (ECETOC, 1995). Therefore, where biotransformation is 
known to occur, log Kq w  cannot be reliably used to predict actual potential to bioconcentrate.
Log Kqw data are available for a large number of pharmaceuticals (e.g., Bowman and Rand, 
1980; Dollery, 1991; Hansch et al., 1995; Hoekman 1997). Of those considered in this study, 
only four compounds had log Kqw values >4.3. These were Amitriptyline, Chloroquine, Diethyl- 
stibestrol and Thioridazine. All have molecular weights <700. I t  is known that lower verte­
brates and invertebrates maintain many of the same systems to biotransform xenobiotics 
which are present in mammals (ECETOC, 1995). Mammalian metabolism studies may therefore 
have some value as a firs t indication of the potential of fish to metabolise a substance. 
Mammalian metabolism of Diethylstibestrol, Amitriptyline and Thioridazine is similarly re­
ported by Dollery (1991). Only in the case of Chloroquine (K q w  4.63) is mammalian metabolism 
limited. Excretion is slow with a plasma half-life of 30 - 60 days and Chloroquine may persist 
in tissues for months or even years after discontinuation of therapy (Reynolds, 1996). Sub­
stantial amounts (35%) are excreted unchanged in the urine (Dollery, 1991). However, biocon­
centration of Chloroquine is unlikely to be an issue. With pKc values of 8.4 and 10.8 it will be 
mainly present as the ionised di-cation moiety at ambient pH in surface waters, and this is 
likely to limit bioconcentration.
Given that (i) few pharmaceuticals appear to have log Kq w  values >4.3, (ii) many pharmaceuti­
cals are weak acids/bases and exist as the ionised moiety under conditions of ambient pH, 
(iii) many pharmaceuticals are readily metabolised to more polar metabolites such as conju­
gates, (iv) the relatively low levels of pharmaceuticals likely to occur in the environment and 
(v) the lack of reported examples, it is suggested that the bioaccumulation of human pharma­
ceuticals will generally not be an issue. This stance is supported by explicit statements from 
the US FDA that similarly suggest bioaccumulation is not an issue for human pharmaceuticals, 
i.e.,
"In  general, pharmaceuticals tend not to be very lipophilic and are produced/used in
relatively low quantities compared to industrial chemicals. In  humans, the majority
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of pharmaceuticals are metabolized to some extent in humans to SRSs (structurally 
related substances) that are more polar, less toxic and less pharmacologically active 
than the parent compound. This suggests that there is a low potential for bioac­
cumulation or bioconcentration o f pharmaceuticals..." (FDA-CEDR, 1998).
"The vast majority o f drugs do not have the physical or chemical characteristics 
that would allow them to bioaccumulate in tissue because this would raise safety 
concerns for use in humans. I f  a drug does have the physical or chemical character­
istics that would allow i t  to bioaccumulate, there has to be some mechanism for the 
human body to metabolize the compound to a substance that has lower bioaccumula­
tion potential so that i t  is cleared from the body. In  the environmental assessments 
that COER reviewed, bioaccumulation has not been an issue." (FDA, 1996).
Many pharmaceuticals are weak acids or bases and therefore subject to ionisation (Newton 
and Kluza, 1978; Raymond and Born, 1986). The degree of ionisation can greatly affect both 
their fate and the effects as the hydrophobicity, adsorption, volatilisation, bioconcentration, 
and ecotoxicity of the ionised moiety may d iffe r markedly from the unionised or neutral moi­
ety. These processes will be particularly sensitive to changes in pH in the case of substances 
with pKa values within the range of environmentally relevant pHs (i.e., 5-9). This therefore 
necessitates that due attention be given to the role of ionisation in determining the effects 
and fate behaviour of pharmaceuticals subject to ERA. The general lack of empirical study in 
this respect needs to be rectified.
Environmental risk assessment in this study has focused upon the water column and has ig­
nored other compartments such as soil and sediment. Most pharmaceuticals tend to have low 
Kow values and are often metabolised to more polar (and hence more water soluble) moieties.
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As such, the soil and sediment compartments may be less important, although they should not 
and indeed cannot be ignored.
Given the increasing number of observations of pharmaceutical compounds in sewage, surface 
waters and drinking water, the environmental fate of pharmaceuticals cannot be ignored and 
should be considered in the development process. Whilst relative metabolic recalcitrance in 
humans may be necessary for the pharmacological e ffect of some compounds (e.g., ethinyl 
substitution in the case of Ethinyl Oestradiol), it will likely correspond to a poorer biodégra­
dation profile in the environment. As such it may not always be possible to design "biodegrad­
able" pharmaceuticals. Under such circumstances, other degradation mechanisms could per­
haps be considered. For example, it may be possible to develop photolabile analogues of com­
pounds which otherwise resist metabolism as well as biodégradation per se. One example of a 
drug where photodegradation is known to be the major elimination pathway in surface waters 
is Diclofenac (Buser et al., 1998; Poiger et al., 2001). Kummerer et al., (2000) similarly high­
light how it is potentially feasible to reduce the impact of pharmaceuticals on the aquatic en­
vironment by the development of biodegradable structural analogues of existing anti­
neoplastic compounds.
CONCLUSIONS
There are a growing number of observations of pharmaceuticals in environmental matrices 
such as sewage influent, effluent, surface waters and potable water. This implies exposure of 
aquatic biota and necessitates risk assessment. The general lack of public domain usage data 
had previously precluded estimates of the environmental concentrations of pharmaceutical. 
Data presented in this study allowed the aquatic exposure assessment of a large number of 
compounds (>60) from across a wide variety of therapeutic classes. Risk characterisation
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based on acute ecotoxicity data and "worst-case" conservative fate assumptions 
demonstrated the nominal environmental safety (i.e., PEC/PNEC <1) of the large majority of 
pharmaceuticals considered. For the remainder, the incorporation of their likely fate 
following use (i.e., likely removal during wastewater treatment and/or surface water dilution 
of effluent), yielded a marked reduction in the surface water PEC values, and the resultant 
PEC/PNEC ratios were generally less than unity for most of the compounds. Further 
refinement of the risk assessment is required for relatively few drugs. An important caveat 
to this conclusion relates to the assumption that the standard ecotoxicity tests that 
constitute the acute aquatic database are appropriate to the assessment of compounds with 
specific modes of action. Risk characterisation was exclusively conducted on the parent drug 
substance as representative of substances entering the environment. Whilst human 
metabolism is a mechanism that will potentially reduce environmental exposure, phase I I  
human metabolism of pharmaceuticals to produce conjugates may be reversible if the 
metabolites are exposed to microbial activity (i.e., in sewage). This potential re-release of 
biologically active parent compounds has to be considered in any exposure assessment. 
Metabolites per se should also not be ignored if their fate or effects d iffe r markedly from 
that of the parent compound. The potential bioaccumulation/bioconcentration of 
pharmaceuticals was also considered, although it was deemed not to be a general issue.
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CHAPTER 5 
INDIRECT HUMAN EXPOSURE
This chapter has been published in "Pharmaceuticals in the Environment - Sources, Fate, 
E ffects  and Risks" (Ed. K. Kummerer) under the title "A Oata Based Perspective on the 
Environmental Risk Assessment o f Human Pharmaceuticals XU - In d ire c t Human Expo­
sure" pp 221-230 (Springer, 2001).
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INTRODUCTION
Concerns have previously been expressed over the possibility of adverse human effects aris­
ing from indirect exposure to pharmaceuticals via drinking water supplies (e.g., Richardson & 
Bowron, 1985; Christensen, 1998). This follows numerous observations of pharmaceuticals (or 
their metabolites) as contaminants in wastewater, surface water and groundwater following 
normal usage (e.g., Rurainski et al., 1977; Aherne et al., 1985; Aherne & Briggs, 1989; Aherne 
et al., 1990; Stan et al., 1994; Stumpf et al., 1996; Ternes, 1998; Hirsch et al., 1999). At pre­
sent there is no regulatory guidance as to how the significance of the potential presence of 
pharmaceuticals at trace concentrations in drinking water supplies may be assessed. Risk as­
sessment of pharmaceuticals for marketing authorisation purposes within both the United 
States and European Union do not address this point (Olejniczak, 1995; FDA-CDER, 1998). In 
order to provide some perspective on this issue, quantitative estimates of potential worse 
case indirect exposure to pharmaceuticals via drinking water have been undertaken. Potential 
effects endpoints against which to benchmark such exposure include daily therapeutic dos­
age.
METHODS
I 7o values based on the life-time (i.e., 70 years) ingestion of 2 litres/day of water were cal­
culated using the "worst-case" predictions for UK surface water concentrations from Chap­
ter 4 (Webb, 2001) with the additional assumption of no drug removal during drinking water 
treatment (Figure 1). In the absence of a readily available comparable mammalian no-effects 
endpoints database, the I 70 values were compared with minimum adult or paediatric daily 
therapeutic doses (Dollery, 1991; Reynolds 1996). The I 7o concept was firs t employed by 
Richardson & Bowron (1985).
Figure 1. " Worst-casé' estimation of indirect human exposure to pharmaceuticals via
drinking water supplies.
Pharm aceutical W astewater Surface W aters Drinking W ater
Use Treatm ent Treatm ent
• No metabolism • No removal • No dilution • No removal
• 100% loss to Drain
RESULTS
Details of the analysis are presented in Table 1 and summarised in Table 221. The calculated
'worst-case" lifetime ingestion of a pharmaceutical compound via potable water is of the or­
der of <1 days therapeutic dose fo r at least 80% of the compounds assessed. For illustration, 
the calculated 'worst-case" I 70 values fo r Paracetemol, Diazepam and Clofibrate were nine 
times the daily dose, one and half times the daily dose and one-hundreth of the daily dose 
respectively. Ethinyl Oestradiol represented the extreme case with a "worst-case" I 7o of 26 
times the daily dose.
Table 1. - "Worst-case" lifetime drinking water exposure.
Compound UK Use PEC Dose 170 I 70
(t/a) (//g/l) (mg/d) (mg) (daily dose)
Paracetamol -2,000 367.3 2,000 (analgesia) 18769 9.38
Aspirin 770 141.4 1,200 (analgesia) 7226 6.02
Metformin 106.1 19.49 500 (type 2 diabetes) 996 1.99
21 These results were originally presented at SETAC 1998 (Webb, 1998).
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Cimetidine 72 13.22 800 (gastric/duodenal ul­
ceration)
676 0.84
Ranitidine 69 12.67 300 (gas­
tric/duodenal/stomal ulcera­
tion)
647 2.16
Erythromycin 67.7 12.43 1,000 (bacterial infection) 635 0.64
Naproxen 60.6 11.13 500 (analgesia) 569 1.14
Dextroproproxyphene 42.5 7.81 175 (analgesia) 399 2.28
Oxytetracycline 33.7 6.19 1,000 (microbial infection) 316 0.32
Quinine 29.7 5.45 1,500 (malaria) 279 0.18
Theophylline 21 3.86 240 (bronchospasm in 
asthma)
197 0.82
Lithium Salts 20.5 0.35
(Li)
75 (manic depression) 17.9 0.23
Metronidazole 15.5 2.85 1,200 (protozoal infections) 146 0.12
lopromide 11.9 2.19 20,000
(angiography/urography/ ar­
thrography contrast medium)
112 <0.01
Propranolol 11.8 2.17 80 (hypertension/angina) 111 1.39
Verapamil 9.9 1.82 120 (supraventricular ar­
rhythmia)
93 0.78
Amitriptyline 5.5 1.01 75 (depression) 52 0.69
Tetracycline 4.7 0.86 1,000 (bacterial infection) 44 0.04
Omeprazole 3.9 0.72 20 (duodenal/gastric ulcera­
tion)
37 1.84
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Thioridazine 3.8 0.7 150 (schizophrenia) 36 0.24
Chloroquine 2.9 0.53 40 (malarial prophylaxis) 27 0.68
Cabapentin 2.6 0.48 <2,400 (treatment of partia 
epileptic seizures)
25 0.01
Etidronic Acid 2.1 0.39 275 (paget's disease) 20 0.07
Fluoxetine 0.37 20 (depressive disorder) 19 0.95
Phénobarbital 1.7 0.31 60 (antiepileptic) 16 0.26
Tramadol 1.7 0.31 50 (analgesia) 15.84 0.32
Clofibrate 1.5 0.28 2,000 (type I I I  hyperlipo- 
proteinaemia)
14.31 0.01
Paroxetine 1.3 0.24 20 (depression) 12.26 0.61
Orphenadrine 1.1 0.2 150 (parkinsonism) 10.22 0.07
Diazepam 0.957 0.18 6 (insomnia/anxiety) 9.20 1.53
Acarbose 0.918 0.17 300 (type I / I I  diabetes) 8.69 0.03
Isoniazid 0.69 0.13 300 (tuberculosis) 6.64 0.02
Nefazodone 0.618 0.11 400 (depression) 5.62 0.01
Quinidine 0.601 0.11 500 (atrial fibrillation) 5.62 0.01
Sumatriptan 0.521 0.1 6 (migraine) 5.11 0.85
Aminosidin/ 
Neomycin E
0.487 0.09 500 (intestinal amoebiasis) 4.60 <0.01
Warfarin 0.476 0.09 3 (thrombo-embolic disor­
ders)
4.60 1.53
Lansoprazole 0.434 0.08 30 (peptic ulcer) 4.09 0.14
Cisapride 0.413 0.08 30 (gastro-oesophageal re­
flux disease)
4.09 0.14
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Chloramphenicol 0.377 0.07 3,000 (bacterial infection) 3.58 <0.01
Famciclovir 0.286 0.05 750 (genital herpes & herpes 
zostera)
2.56 <0.01
Azithromycin 0.276 0.05 1,000 (Chlamydia infection) 2.56 <0.01
Cetirizine 0.273 0.05 10 (hypersensitivity) 2.56 0.26
Famotidine 0.246 0.05 40 (duodenal ulceration) 2.56 0.06
Ceftibuten 0.095 0.017 400 (urinary/respiratory 
tract infection)
0.87 <0.01
Lorsatan 0.087 0.016 50 (hypertension) 0.82 0.02
Budesonide 0.081 0.015 0.4 (asthma) 0.77 1.92
Finasteride 0.067 0.012 5 (benign prostatic hyperpla­
sia)
0.61 0.12
Perindopril 0.047 0.009 2 (hypertension) 0.46 0.23
Didanosine 0.039 0.007 400 (HIV infection) 0.36 <0.01
Midazolam 0.037 0.007 15 (hypnotic) 0.36 0.02
Fluticasone 0.034 0.006 0.5 (asthma prophylaxis) 0.31 0.61
Digoxin 0.031 0.006 0.125 (congestive heart fail­
ure)
0.31 2.48
Ethinyl Oestradiol 0.029 0.005 0.010 (menopausal symptoms) 0.26 26
Risperidone 0.021 0.004 4 (schizophrenia/ 
psychoses)
0.20 0.05
Atropine 0.016 0.003 0.2 (gastrointestinal disor­
ders)
0.15 0.03
Carved i loi 0.008 0.001 25 (hypertension) 0.05 <0.01
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Alendronic Acid 0.007 0.001 10 (post menopausal osteopo­
rosis)
0.05 <0.01
Bicalutamide 0.007 0.001 50 (prostatic cancer) 0.05 <0.01
Salmeterol 0.007 0.001 0.1 (chronic asthma) 0.05 0.5
Dorzolamide 0.004 0.001 20
(glaucoma & ocular hyperten­
sion)
0.05 <0.01
Diethystilbestrol 0.002 0.001 1 (prostate carcinoma) 0.05 0.05
Paclitaxel 0.001 0.001 350 (malignant neoplasms) 0.05 <0.01
Flumazenil <0.001 0.001 0.5 (reversal of benzodi­
azepine-induced sedation)
0.05 0.10
Milrinone <0.001 0.001 ~80 (1.13/kg/day (severe 
heart failure)
0.05 <0.01
Thiotepa <0.001 0.001 60 (bladder cancer) 0.05 <0.01
Zalcitabine <0.001 0.001 2.25 (HIV infection) 0.05 0.02
Table 2. - Summary of "Worst-case" lifetime drinking water exposure.
I70 (Daily Dose 
Equivalent)
I70 (Fraction Daily 
Dose)
Number Cumulative Fre­
quency (%)
>10 <V  2,500 1 1.5
>5 <1/ 5,000 2 4.5
>1 <725,000 10 19.4
>0.5 <750,000 10 34.3
>0.1 <7250,000 13 53.7
>0.05 <7500,000 4 59.7
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>0.01 <V 2,500,000 9 73.1
<=0.01 >1/ 2,500,000 18 100
Total - 67 100
DISCUSSION
Within the European Union, the quality of water for human consumption is determined by the 
Drinking Water Directive (Council Directive 98/93/EC on the quality of water intended for 
human consumption). None of the 48 parameters within the directive relate to pharmaceuti­
cals. The most comprehensive consideration of the potential long-term public health risk of 
the ingestion of drinking water contaminated with human pharmaceuticals was undertaken by 
Richardson A Bowron (1985). I 7o values based on the life-time (i.e., 70 years) ingestion of 2 
litres/day of water were similarly calculated using "worst-case" predictions for surface wa­
ter concentrations. These I 7o values were also similarly compared with typical adult and pae­
diatric therapeutic doses. The calculated ingested quantities were small and a lifetime inges­
tion of a pharmaceutical compound via potable water would typically be of the order of one 
days recommended therapeutic dose. The calculated I 70 values for Paracetemol, Diazepam 
and Clofibrate were four times the daily dose, one daily dose and one-sixth the daily dose re­
spectively. Similar results for I 70 were observed in this study with large differences be­
tween I 70 values and therapeutic doses. More recently, Christensen (1998) estimated "worst- 
case" environmental fate and human exposure of Ethinyl Oestradiol (oestrogen), Phenoxy- 
methylpenicillin (antibiotic) and cyclophosphamide (antineoplastic) employing the EUSES 
software (see http://ecb.ei.jrc.it/existing-chemicals). The results yielded a "negligible" hu­
man risk connected to predicted human exposure based on diffuse emissions from the use 
phase via drinking water and diet (vegetables, fish, meat and dairy produce). The effects 
benchmarks were male endogenous oestrogen production, tolerable food residues based an 
allergic reactions and genotoxic carcinogenicity thresholds respectively.
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Relatively few attempts have been made to detect pharmaceuticals in potable water supplies. 
Data for a number of compounds are presented in Table 3. These include observations for 
Bleomycin (Aherne et al., 1990), Clofibric Acid (Stan et al., 1994; Heberer et al., 1997), Di­
azepam (Waggott, 1981), Diethylstilbestrol (Rurainski et al., 1977), Ethinyl Oestradiol (Ru­
ral nski et al., 1977; Aherne et al., 1985; Aherne & Briggs, 1989; Kalbfus, 1995; James et al., 
1998), Fenofibrate (Heberer et al., 1997), Ibuprofen (Heberer et al., 1997), Methotrexate 
(Aherne et al., 1985), Norethisterone (Aherne et al., 1985; Aherne <& Briggs, 1989), Penicillins 
(Richardson & Bowron, 1985), Phenazone (Heberer et al., 1997) and Propyphenazone (Heberer 
etal., 1997).
Table 3. - Observations of human pharmaceuticals in potable water supplies.
Compound Concentration (ng/l) Reference
Bleomycin (i) range <5 - 13 
(ii) mean 8.7
Aherne et al. (1990)
Clof ibric Acid 10 -165 Stan et al. (1994)
Clof ibric Acid 70 - 7,300* Heberer et al. (1997)
Diazepam -1 0 Waggott (1981)
Diclofenac <LOD - 380* Heberer et al. (1997)
Diethylstilbestrol (i) range 0  - 0.8  
(ii) mean 0.11 - 0.24
Rurainski etal. (1977)
Ethinyl Oestradiol (i) range 0 - 22.5 
(ii) mean 0.69 - 3.18
Rurainski et al. (1977)
Ethinyl Oestradiol < 5 Aherne, English A Marks 
(1985)
Ethinyl Oestradiol <1-4 Aherne & Briggs (1989)
Ethinyl Oestradiol <0.2 Kalbfus (1995)
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Ethinyl Oestradiol <0.4 James et al. (1998)
Fenofibrate <LOD - 45* Heberer et al. (1997)
Ibuprofen <LOD - 200* Heberer et al. (1997)
Methotrexate <6.25 Aherne, English & Marks 
(1985)
Norethisterone < 10 Aherne, English A Marks 
(1985)
Norethisterone <2 -<10 Aherne A Briggs (1989)
"Penicilloyl Groupé' < 10 Richardson A Bowron (1985)
Phenazone <10 - 1,250* Heberer et al. (1997)
Propylphenazone <LOD - 1,465* Heberer et al. (1997)
* groundwater supply to drinking water treatment plant
One of the studies relating to occurrence of pharmaceuticals in water supplies concerns ob­
servations of Clofibric Acid in German potable water. Concentrations ranged from 10 - 165 
ng/l (Stan et al., 1994). The corresponding refined I 7o value based on measured observations 
would be 0.5 - 8.4 mg. This can be compared to a daily maintenance dose for Clofibrate of up 
to 2,000 mg to give an I 70 value expressed as 0.004 days. A similar calculation can be made 
for Ethinyl Oestradiol on the basis of the most recent observed concentrations of <0.4 ng/l 
and <0.2 ng/l in UK and German potable water supplies (James et al., 1998; Kalbfus, 1995). 
This compares to the nworst-case" PEC of 5 ng/l employed here. The refined I 70 value of 
0.02  mg can be compared with a minimum daily therapeutic dose of 0.01 mg used in the 
treatment of menopausal symptoms. This equates to an I 7o value of 2 days when expressed as 
daily dose. Although concerns have been expressed over the possibility of adverse effects on 
human reproductive biology arising from the presence of oestrogenic substances in drinking 
water (Ginsburg et al., 1994), a review of international water use patterns highlighted a lack
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of homogeneity and suggested that drinking water is consequently unlikely to be a significant 
factor (Fawell <& Wilkinson, 1994). The lack of a vitellogenin response on the part of caged 
fish in UK raw water storage reservoirs, in contrast to sewage effluent discharges, may simi­
larly be interpreted as supporting this conclusion (FWR, 1995). A fter Ethinyl Oestradiol, the 
compound with the highest initial "worst-case" I 7o value when expressed as daily dose was 
Paracetamol (9 days). This ignores a high degree (98%) of elimination during wastewater 
treatment (Ternes, 1998) and surface water dilution (default l-in-10) of treated wastewater 
effluent. Incorporation of these factors would yield a refined PEC of 0.7 pg/\ compared to 
the "worst-case" 367 fjg/\ employed here. Refinement of the I 7o on this basis would result in 
a value of 35.8 mg or 0.02 days. The conservatism of the initial "worst-case" PEC for 
Paracetamol is confirmed by the lack of observation of Paracetamol at detectable concentra­
tions in surface waters in the UK (Richardson A Bowron, 1985), Germany (Ternes, 1998) and 
the Netherlands (Van Hoof et al., 2000).
Also contributing to the discrepancy between observed concentrations of pharmaceuticals in 
potable water and the "worst-case" concentrations employed here will be drinking water 
treatment processes. For example, Hutchinson et al. (1996) details the efficacy of a number 
of drinking water treatment processes (chlorination, ozonation, coagulation and powdered ac­
tivated carbon) on a range of steroids on a laboratory scale. Chlorination, ozonation and pow­
dered activated carbon were effective at removing steroids, but coagulation with aluminium 
sulphate had little effect. A subsequent study (James et al., 1998) employing similar method­
ologies confirmed the efficacy of chlorination, ozonation and powdered activated carbon 
(>95% steroidal removal) and the ineffectiveness of coagulation. I t  additionally, demon­
strated that filtration was ineffective but aeration was quite effective. Ternes (2000) simi­
larly confirmed the general efficacy of drinking water treatment for a large number of 
pharmaceuticals.
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In considering the fate of pharmaceuticals, several studies have highlighted cytotoxic drugs 
such as anti-neoplastics (e.g., Aherne et al., 1985; Richardson <& Bowron, 1985; Lee, 1988; 
Aherne e t al., 1990). Many of these are carcinogenic, mutagenic, embryotoxic or teratogenic 
and concerns have been expressed over potential risks to potable water supplies. However, 
where observations from environmental samples are available, concentrations of cytotoxic 
drugs are limited. For example, concentrations of Methotrexate in river water and potable 
water samples were all found to be <6.25 ng/l. This can be compared to a concentration of 1 
jug/1 found in a sewer immediately downstream of an oncology clinic (Aherne et al., 1985). 
Sewage and water treatment, dilution and degradation effectively reduced this level in the 
river and potable samples. Methotrexate itself is known to be readily metabolised and to un­
dergo hydrolytic decomposition. Bleomycin was chosen for study by Aherne et al. (1990) on 
the basis of its relative stability. Concentrations of this cytotoxic drug varied from 11 - 19 
ng/l in effluents to <5 - 17 ng/l in river and potable water samples. Aherne et al. (1990) con­
cluded that any risk to public health from such levels of Bleomycin in drinking water was 
unlikely. This followed the calculation that consumption of 2 litres/day of such water would 
result in the ingestion of one-millionth of the daily adult dose of 20 - 30 mg/day. Other anti­
neoplastics detected in the aquatic environment (but not drinking water) include Ifosamide 
and Cyclophosphamide (Steger-Hartmann et al., 1996; Kümmerer et al. 1997). One major con­
cern with anti-neoplastics is the possibility that a cancer risk may exist at any level of expo­
sure (i.e., there is no threshold dose). In  the case of other carcinogenic compounds, mathe­
matical models have been developed to try  and predict the hypothetical incremental cancer 
rate at low doses. These models require the selection of an acceptable cancer risk - typically 
1 x 10"5 to 1 x 10"6 (i.e., one-in-one hundred thousand to one-in-one million). Such an approach 
may be appropriate in determining limits on anti-neoplastics (and other potentially carcino­
genic pharmaceuticals) in drinking water supplies. Sources of data relating to the careino-
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genicity (or otherwise) of pharmaceuticals in general include IARC (1974; 1977; 1979; 1980; 
1981; 1990; 1996; 1999)and Fung etal. (1995).
Implicit in the calculation of I 7o values is a life-time exposure over 70 years i.e., 25,550 days. 
For the large majority (80%) of compounds with I 7o values equivalent to <1 days daily thera­
peutic dose, this implies a margin of >25,000 (2.5 x 104) between indirect exposure and e ff i­
cacious therapeutic dosage. Refinement of the exposure for the remaining compounds with 
"worst-case" I 7o values equivalent >1 days daily therapueutic dose would undoubtedly lead to 
smaller values if based on more realistic fate scenarios or measured concentrations. Witness 
the reduction in the refined I 70 value for Ethinyl Oestradiol, Clofibrate or Paracetamol. The 
relevance of the use of therapeutic dosage as a benchmark can undoubtedly be questioned, 
but the absence of a readily available comprehensive chronic mammalian NOEL (no-observed- 
e ffect level) database for pharmaceuticals obliged its use in this study and by Richardson <& 
Bowron (1995). Similarly, caveats need to be voiced concerning the potential issues associ­
ated with potential life-long exposure at low sub-therapeutic levels and what risk assessment 
paradigm should apply under such circmustances. A sub-set of the population that are poten­
tially exposed to low sub-therapeutic levels of a pharmaceutical over extended periods are 
workers from the pharmaceutical industry. One approach used to derive occupational expo­
sure limits (OELs) for pharmaceuticals is based on the application of a safety factor to the 
lowest recommended therapeutic dose in order to determine a therapeutically non-effective 
dose (Ku, 2000). This safety factor is typically 100. Whilst there are some issues associated 
with this approach (i.e., cases of compounds where toxicity is unrelated to pharmacological 
effects or compounds used in life threatening situations where significant toxicities are ac­
ceptable), it does offer some useful perspective and perhaps a base from which to derive an 
acceptable exposure limit for the population as a whole. I f  an additional safety factor of 10 
were applied to OELs in order to derive general population exposure limits, a margin of
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safety would still apply to all compounds with I 7o values <25 days. In the case of an additional 
safety factor of 100, a margin of safety would apply to all those compounds with I 7o values 
<2.5 days.
CONCLUSIONS
Numerous observations of pharmaceuticals (or their metabolites) in wastewater, surface wa­
ter and groundwater have given rise to concerns over the possibility of adverse human e f­
fects arising from indirect exposure to pharmaceuticals via drinking water. In the absence of 
regulatory guidance as to how the significance of such contamination to human health may be 
assessed, quantitative estimates of potential life-time "Worse Case" indirect exposure to 
pharmaceuticals via drinking water have been undertaken and benchmarked against daily 
therapeutic dosage. Calculated "worst-case" life-time (70 years) ingestion for pharmaceutical 
compounds via potable water is <1 day therapeutic dose for at least for 80% of the com­
pounds assessed. This implies a margin of at least 25,000 between indirect exposure and e f­
ficacious therapeutic dosage. For compounds where "worst-case" life-time ingestion was >1 
day therapeutic dose, refinement of the exposure for several compounds (i.e.. Paracetamol, 
Clofibrate and Ethinyl Oestadiol) demonstrated the degree of conservatism associated with 
the exposure estimations. Overall it appears that indirect exposure to pharmaceuticals via 
the potable water supply is unlikely to represent a general objective safety issue. I t  is how­
ever, an area that requires further attention.
REFERENCES
Aherne GW, Briggs R (1989) The relevance of the presence of certain synthetic steroids in the aquatic 
environment. J. Pharm. Pharmacol. 41: 735 - 736.
155
Aherne 6W , English J, Marks V (1985) The role of immunoassay in the analysis of micro-contaminants in 
water samples. Ecotoxicology and Environmental Safety 9: 79-83.
Aherne GW, Hardcastle A, Nield AH (1990) Cytotoxic drugs and the aquatic environment: estimation of 
bleomycin in river and water samples. J. Pharm. Pharmacol. 42: 741-742.
Christensen FM (1998) Pharmaceuticals in the environment - A human risk? Regulatory Toxicology <& 
Pharmacology 28: 212-221.
Dollery CT (ed) (1991) Therapeutic brugs - Volume 1 <St 2. Churchill Livingstone, Edinburgh.
Fawell JK, Wilkinson MJ (1994) Oestrogenic substances in water: a review. J. Water S R T- Aqua 43(5): 
219-221.
FDA-CDER (1998) Guidance for Industry - Environmental Assessment o f Human brugs and Biologies 
Applications. July 1998 CMC6 Revision 1. FDA Center for Drug Evaluation and Research, Rockville (MD), 
USA. [http://www.fda.gov/cder/guidance/index.htm]
Fung VA, Barrett JC, Huff J (1995) The carcinogenesis bioassay in perspective: application in identify­
ing human cancer hazards. Environ. Health Perspect. 103(7-8): 680-683.
FWR (1995) Effects o f Trace Organics on Fish - Phase 2 [July 1995 FR/b 0022], Foundation for Water 
Research, Marlow (Bucks.), UK.
Ginsburg J, Okolo S, Prelevic G, Hardi man P (1994) Residence in the London area and sperm density. 
Lancet 343: 230.
Heberer T, Dünnbier U, Reilich C, Stan HJ (1997) Detection of drugs and drug metabolites in 
groundwater samples of a drinking water treatment plant. Fresenius Environ. Bull. 6: 438-443.
156
Hirsch R, Ternes T, Haberer K, Kratz KL (1999) Occurrence of antibiotics in the aquatic environment. 
Sci. Tot. Env. 225: 109-118.
Hutchinson J, Harding L, Car I i le P, Hart J, Fielding AA, Kanda R (1996) Effect o f water treatment 
processes on oestrogenic chemicals. DW-05 Drinking Water Quality & Health. UK Water Industry 
Research Limited (UKWIR), London.
IARC (1974) IARC Cancer AAonographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans - 
Sex Hormones (Volume 6). World Health Organisation International Agency for Research, Lyon, France.
IARC (1977) IARC Cancer AAonographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans - 
Some AAiscellaneous Pharmaceutical Substances (Volume 13). World Health Organisation International 
Agency for Research, Lyon, France.
IARC (1979) IARC Cancer AAonographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans - 
Sex Hormones ( I I )  (Volume 21). World Health Organisation International Agency for Research, Lyon, 
France.
IARC (1980) IARC Cancer AAonographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans - 
Some Pharmaceutical Drugs (Volume 24). World Health Organisation International Agency for Re­
search, Lyon, France.
IARC (1981) IARC Cancer AAonographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans - 
Some Antineoplastic and Immunosuppressive Agents (Volume 26). World Health Organisation Interna­
tional Agency for Research, Lyon, France.
IARC (1990) IARC Cancer AAonographs on the Evaluation of Carcinogenic Risks to Humans - Pharmaceu­
tical Drugs (Volume 50). World Health Organisation International Agency for Research, Lyon, France.
157
IARC (1996) IARC Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans - Some Phar­
maceutical Drugs (Volume 66). World Health Organisation International Agency for Research, Lyon, 
France.
IARC (1999) IARC Cancer Monographs on the Evaluation of Carcinogenic Risks to Humans - Hormonal 
Contraception and Post-Menopausal Hormonal Therapy (Volume 72). World Health Organisation In te r­
national Agency for Research, Lyon, France.
James HA, Fielding M, Franklin O, Williams D, Lunt D (1998) Steroid Concentrations in Treated Sewage 
Effluents and Water Courses - Implications for Water Supplies. Report Ref. No. 98/TX /01/1 . UK 
Water Industry Research Limited (UKWIR), London.
Kalbfus, W. (1995) Belastung bayerisches Gewdsser durch synthetische Ostrogene. Vortag bei der 50. 
Fachtagung des Bayerisches Landesamt fur Wasserwirtschaft: Stoffe mit endokriner Wirkung im 
Wasser (Abstract). [Effects in Bavarian watercourses through synthetic oestrogens. Presentation at 
the 50th Seminar of the Bavarian Association for Waters Supply: Substances with endocrine effects in 
water (Abstract)].
Ku RH (2000) An overview of setting occupational exposure limits (OELs) for pharmaceuticals. Chemical 
Health A Safety 7(1)'. 34-37.
Kümmerer K, Steger-Hartmann T, Meyer M (1997) Biodegradability of the anti-tumour agent ifosamide 
and its occurrence in hospital effluents and sewage. Water Research 31: 2705-2710.
Lee MG (1988) The environmental risks associated with the use and disposal of pharmaceuticals in 
hospitals. In: Richardson ML (ed) Risk Assessment o f Chemicals in the Environment. The Royal Society 
of Chemistry, London, pp 491-504.
158
Olejniczak J (1995) Environmental risk assessment for medicinal products in the EU, Phase I .  In: Wolf 
PU (ed) Environmental Risk Assessment for Pharmaceuticals and Veterinary Medicines. Proceedings of 
the International RCC Workshop held in Basle, Switzerland, February 1 1995. RCC Group: Itingen 
(Switzerland), pp 58-66.
Reynolds JEF (ed) (1996) Martindale - The Extra Pharmacopoeia [Electronic Version]. The Royal 
Pharmaceutical Society of Great Britain. Micromedex Inc., Engel wood, CO (USA).
Richardson ML, Bowron JM  (1985) The fate of pharmaceutical chemicals in the aquatic environment. J. 
Pharm. Pharmacol. 37: 1-12.
Rurainski R, Theiss HJ, Zimmermann W (1977) Uber das vorkommen von ndturlichen und synthetischen 
oestrogenen im trinkwasser [Concerning the occurrence of natural and synthetic oestrogens in drinking 
water]. Gwf-Wasser/Abwasser 118(6): 288-291.
Stan HJ, Heberer T, Linkerhdgner M. (1994) Vorkommen von clofibrinsdure im aquatischen System - 
Fiihrt die therapeutische Anwendung zu einer Belastung von Oberflldchen-, Grund- und Trinkwasser? - 
[Occurrence of clofibric acid in the aquatic system - Is  the use in human medical care the source of 
the contamination of surface, ground and drinking water?]. Vom Wasser 83: 57-68.
Steger-Hartmann T, Kümmerer K, Schecker J (1996) Trace analysis of the antineoplastics ifosamide 
and cyclophosphamide in sewage water by two-step solid phase extraction and gas chromatography- 
mass spectrometry. Journal o f Chromatography A 726: 179-184.
Stumpf M, Ternes TA, Haberer K, Seel P, Baumann W (1996) Nachweis von arzneimittelrückstanden in 
kldranlagen und fliessgewdssern. Vom Wasser 86: 291-303.
Ternes, TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. Water Research 
32(11): 3245-3260.
159
Ternes TA (2000) Pharmaceuticals: Occurrence in rivers, groundwater and drinking water. In: 
Proceedings o f International Seminiar on Pharmaceuticals in the Environment March 9th 2000 
(Brussels). Technological Institute (KVIV), Brussels, Belgium.
Van Hoof F, Van Genderen J, Mans M, Claeys C (2000) Perspective of the drinking water industry. In: 
Proceedings o f International Seminiar on Pharmaceuticals in the Environment March 9th 2000 
(Brussels). Technological Institute (KVIV), Brussels, Belgium.
Waggott, A (1981) Trace organic substances in the River Lee - In: Cooper WJ (ed) Chemistry in Water 
Reuse. Ann. Arbor Publishers Inc., Ann Arbor, M I (USA), pp 55-99.
Webb SF (1998) A data-based perspective on the environmental risk assessment (ERA) of human 
pharmaceuticals [Abstract]. SETAC 19th Meeting The Natural Connection: Environmental Integrity and 
Human Health. November 15-19,1998, Charlotte, NC (USA).
Webb SF (2001) A data-based perspective on the environmental risk assessment of human 
pharmaceuticals I I  - Aquatic risk characterisation. In: Kümmerer K (ed) Pharmaceuticals in the 
Environment, (pp 203-219) Springer, Berlin.
160
CHAPTER 6 
GENERAL DISCUSSION
AQUATIC EXPOSURE
The general lack of public domain usage data had previously precluded a systematic analysis 
of the potential impacts of pharmaceuticals. In contrast, data presented in this study have 
allowed the estimation of environmental concentrations of >60 compounds from across a wide 
variety of therapeutic classes. When coupled with the available ecotoxicity data, this 
permitted risk characterisation. The assumptions employed in calculating "worst-case" PECs 
(i.e., no human metabolism, loss of all material to drain, no removal during waste water 
treatment and no surface water dilution) ensured that estimates were generally 
conservative. This is confirmed by comparison of MEC values with the PEC values, especially 
for extensively metabolised and readily biodegradable compounds. The differences tend to 
be less pronounced for more recalcitrant (i.e., less extensively metabolised/non- 
biodegradable) compounds such as Tetracycline and Ethinyl Oestradiol. The availability of 
measured data relating to human pharmaceuticals is increasing rapidly. Over 60 compounds 
are detailed in Table 3 of Chapter 2. Ternes (1998) alone deals with nearly 40 compounds.
Following use, most human drugs (or their metabolites) will tend to enter the environment by 
excretion (as urine and/or faeces) from patients. Incorporation of a consideration of human 
metabolism during the exposure assessment would therefore have the potential to reduce 
PEC values. Even though it has not proven generally necessary to include a consideration of 
metabolism in order to demonstrate environmental safety of parent compounds, reported 
metabolism of many drugs is known to be considerable. Where metabolism does take place, 
metabolites in general will tend to be more polar and water soluble and therefore less toxic 
than the parent compounds. For example, Richardson A Bowron (1985) noted that a signifi­
cant number of pharmaceuticals undergo mammalian metabolism to yield conjugates and that 
the toxicity and pharmacological activity of these conjugates is likely to be much lower than 
that of the parent compounds. However, any effects on solubility may also have a concomi-
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tant influence on removal via adsorption during wastewater treatment. A full consideration of 
the fate and effects of all the metabolites of each drug considered here would clearly be 
prohibitive. In  this study, risk characterisation has been exclusively conducted on the parent 
drug substance (with the exception of Clofibric Acid) as representative of substances enter­
ing the environment. Alternative practices may need to be applied for drugs where there are 
clear indications that the fate of the metabolites differs from the parent compound or that 
the metabolites could adversely effect the environment to a greater extent than the parent 
drug substance. In  some cases, incorporation of a consideration of metabolism when estimat­
ing exposure may even be inadvisable, as there is a suggestion that some drug conjugates 
have the potential to be reactivated during biological wastewater treatment (FWR 1995; 
Henschel et al., 1997; Ranter et al., 1999). I t  is interesting to note that both Clofibrate and 
Ethinyl Oestradiol - two pharmaceuticals that have attracted particular attention following 
observations in environmental samples - are excreted in considerable amounts as conjugates 
in the urine or faeces. Some 50 - 85% of dosed Clofibrate is excreted in the urine as the 
glucuronic conjugate of Clofibric Acid. In the case of Ethinyl Oestradiol, considerable 
amounts (~30%) are excreted in urine and bile as the primary glucuronide and sulphate con­
jugates (Dollery, 1981).
AQUATIC EFFECTS
All acute ecotoxicity endpoints considered in this study were >1 pg/\. In  a similar exercise, 
the US FDA Center for Drug Evaluation and Research (CDER) has performed a retrospective 
review of toxicity information available in EAs previously submitted in support of NDA (FDA- 
CDER, 1996). These data showed that no observed effects on relevant standard environ­
mental test organisms at drug concentrations below 1 //g/l. Whilst many classes of compound 
are represented in the acute ecotoxicity database reviewed here, other classes of com­
pounds will not be represented. A general lack of chronic ecotoxicity data was also noted. In
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the case of Ethinyl Oestradiol, significant differences in magnitude between acute and 
chronic endpoints were noted for fish. The acute ECso/chronic NOEC ratio for Oncorhyn- 
chus mykiss (Rainbow Trout) was 800,000. This observation could be employed as the basis 
of an argument that would preclude the use of short-term ecotoxicity testing for the pur­
poses of risk assessment of endocrinologically active compounds and oblige chronic testing at 
least in the context of vertebrates (i.e., fish). Acute/Chronic ratios for Daphnia varied from 
1 for lopromide to 1,428 for Clofibrate with a median of ~43 (n = 7). The Acute/Chronic ra­
tio for Ethinyl Oestradiol in Daphnia was 570. These observations do not contrast markedly 
with A/C ratios in the range of 1.6 to 1,030 (median 22.1) previously reported for inverte­
brates based on endpoints from the general ecotoxicity database (ECETOC, 1993).
The vast majority of acute ecotoxicity endpoints identified by this study were >0.1 mg/1 
(with the exception of endpoints for two SSRIs in non-standard bioassays i.e., Fluvoxamine 
and Fluoxetine). An implied PNEC of 0.1 pg/\ can be derived from an acute ecotoxicity end­
point of 0.1 mg/l with an acute assessment factor of 1,000. The corollary is that the risk of 
adverse environmental effects from these compounds is assumed to be low if the PEC values 
are <0.1 //g/l. Under the risk assessment paradigm, an environmental concentration threshold 
of 0.1 //g/l would therefore generally be protective of aquatic biota against the effects of 
most of the pharmaceuticals considered here.
This can be compared with the "concentration o f no concern" of 0.01 //g/l in the aquatic com­
partment promulgated in the draft EU Phase I  guidelines in both 1995 (Olejniczak, 1995) and 
2001 (CPMP, 2001). Assuming no removal during wastewater treatment and 1 in-10 surface 
water dilution of effluent, this corresponds to a de facto usage threshold of ~3 ton­
nes/annum in the 15 member state EU (Table 1).
Table 1. - De facto  drug usage thresholds based on a "concentration o f no concerri1 of 
0.01 //g/l in the aquatic compartment (from Webb, 1995).
European Union 
Member States
Population
(millions)
Water Consumption
(1 itres/capita/day)22
De Facto Threshold 
(kg)
Austria 7.86 261 75
Belgium 10.02 166 61
Denmark 5.15 257 49
Finland 5.05 279 52
France 56.80 225 467
Germany 78.30 199 569
Greece 10.10 200 74
Holland 14.83 213 116
Ireland 3.50 200 25
Ita ly 57.52 277 582
Luxembourg 0.39 274 4
Portugal 10.40 200 76
Spain 38.81 192 272
Sweden 8.64 291 92
UK 57.60 259 545
EU15 364.97 230 3,065
The EIC ("Environmental Introduction Concentration") Tier 0 limit for sewage effluent de­
tailed in the US FDA guidance for environmental assessment of human drugs is 1 //g/l (FDA -
22 WSA (1994). In  the absence of data, a figure of 200 litres/capita/day is assumed for Greece, I r e ­
land and Portugal.
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CDER, 1998). With a dilution factor of 10, this corresponds to a surface water concentration 
of 0.1 fjg/\. The limit equates to a de facto usage threshold of approximately 40 ton­
nes/annum in the USA (cf. Europe). There is no regulatory requirement to generate fate and 
effects data below this threshold. The justification for the limit arose from the retrospec­
tive observation (FDA-CDER, 1996). The findings of this study substantiate the experience 
of the US FDA-CDER in this respect - at least with regard to acute data. The implicit as­
sumption on the part of the FDA that pharmaceuticals will not exert an effect at <0.1 //g/l 
can obviously be challenged for Ethinyl Oestradiol where the chronic NOEC is 1 ng/l. An em­
pirically based threshold, rather than an arbitrary value, should form the focus for any in­
ternational horizontal harmonisation of environmental assessment regulations for human 
pharmaceuticals.
AQUATIC RISK
Following initial "worst-case" risk characterisation, only eight compounds had PEC/PNEC ra­
tios >1. In each case, further refinement of the PEC via a consideration of likely fate during 
wastewater treatment and/or surface water dilution of sewage effluent resulted in a mark­
edly reduced PEC/PNEC ratio and generally lead to an assumption of negligible risk of an en­
vironmental e ffect (i.e., PEC/PNEC <1.0). Further refinement was necessary in the case of 
Paracetamol, Fluoxetine and Oxytetracycline. In  all cases refinement reduced the PEC/PNEC 
ratios markedly. Earlier caveats about the applicability of acute ecotoxicity data in the con­
text of risk assessment should be repeated here. The only other compounds of any concern 
highlighted by the study were Ethinyl Oestradiol and Clofibric Acid. In the case of Ethinyl 
Oestradiol, some potential for an effect in the environment under conditions of low effluent 
dilution was suggested following a comparison of chronic endpoints with measured effluent 
concentrations. However, it has been suggested that the oestrogenic activity of sewage e f­
fluent is predominantly associated with the presence of natural steroidal oestrogens rather
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than Ethinyl Oestradiol (Desbrow et al., 1996). A similar comparison of observed German sur­
face water concentrations of Clofibric Acid with the PNEC also revealed some potential for 
effect and further refinement (i.e., provision of additional chronic data) was recommended.
The general lack of impacts suggested by the outcome of the risk assessments in this study 
(albeit based on acute data), mirrors recent US FDA conclusions. Based upon experience in 
assessing environmental assessments (EA) that accompany the applications for drug approval 
submitted by industry, the FDA has concluded that it can eliminate the need for EAs in al­
most all cases (FDA, 1995). This decision is based on that fact that virtually all EAs prepared 
in recent years have been issued with a "finding o f no significant impact1 (FON5I) by the 
FDA. Only one product in recent years, Taxol, has been identified as presenting any poten­
tially significant environmental concerns. Moreover, these concerns were unrelated to manu­
facturing or use and related to harvesting of endangered Pacific Yew trees.
INDIRECT HUMAN EXPOSURE
I 70 values based on the life-time (i.e., 70 years) ingestion of 2 litres/day of water were 
calculated using the "worst-case" predictions for surface water concentrations. These I 7o 
values were then compared with typical adult and paediatric doses. The calculated ingested 
quantities were small and a lifetime ingestion of a pharmaceutical compound via potable water 
would typically be of the order of one days recommended therapeutic dose. Prior to this 
study, the most comprehensive consideration of the potential long term public health risk of 
the ingestion of drinking water contaminated with human pharmaceuticals was undertaken by 
Richardson & Bowron (1985) who employed a similar methodology. More recently, Christensen 
(1998) examined human risk in relation to indirect exposure to Ethinyl Oestradiol, Phenoxy- 
methylpenicillin and Cyclophosphamide from drinking water and diet. The risk was found to be 
"negligible". Other comparisons between measured observations of pharmaceutical compounds
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in drinking water and potable water supplies confirmed the conservative nature of the 
"worst-case" exposure calculations. For example, marked reductions in the I 7o values for 
Ethinyl Oestradiol and Clofibrate were noted when measured values were employed.
The relevance of therapeutic dosage as a benchmark can be questioned, but the absence of a 
comprehensive chronic mammalian effects database obliged its use. Similarly, caveats need 
to be voiced concerning the potential issues associated with potential life-long exposure at 
low levels and whether the traditional risk assessment paradigm applies under such 
circumstances. Nevertheless, it intuitively appears that indirect exposure to pharmaceuticals 
via the potable water supply is unlikely to represent a safety issue. I t  is however, an area 
that requires further attention.
BACTERIAL RESISTANCE
One potential indirect e ffect of drug use not yet highlighted in this study is bacterial resis­
tance to antimicrobials. I t  is known that the frequency of bacterial strains resistant to an­
timicrobial agents in the environment can be high (e.g., Ohba et al., 1999). This is attributed 
to the widespread use of such drugs. Bacteria with the highest level of resistance are typi­
cally isolated from selective environments contaminated with anti-microbial agents e.g., sew­
age effluents and wastewaters from livestock and fish farms. Whilst the debate whether 
the development of resistance is possible at the concentrations reported in the environment 
continues, many studies have identified antibiotics in sewage influents, effluents, surface 
waters and groundwaters (e.g., Hirsch et al., 1999). Hirsch et al. (1999) also report how a 
large proportion of antibiotics are excreted unchanged or as glucuronide conjugates following 
human administration. The microbial reactivatiion of conjugated antibiotics (Chloroampheni- 
col <& Sulfamethazine) has been reported by Berger et al. (1986). These two factors un­
doubtedly help to explain the occurrence of antibiotics in the environment.
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Recently, the possibility of the transfer of resistant genes between bacteria via conjugation 
and transfer of plasmids in natural environments has attracted particular attention (Kruse <& 
Serum, 1994; Sandaa & Enger, 1994; AAcKeon et al., 1996). Calls have been made for some re­
strictions on the use of anti-microbials with the aim of reducing the frequency of resistance 
among bacteria in the environment at large (Kruse A Serum, 1994). The ultimate concern is 
the reduced efficacy of drug treatment for human and animal diseases caused by resistant 
pathogens and the resultant public health hazard. Mckeon et al. (1996) reports on antibiotic 
resistance (AR) and multiple antibiotic resistance (MAR) of more than 250 coliform and non- 
coliform environmental isolates from rural untreated groundwater supplies to sixteen antibi­
otics. Widespread resistance to several of the antimicrobials considered in the study was ob­
served (i.e.. Tetracycline 32%, Chloroamphenicol 16.9%, Neomycin <10% and Sulfisoxazole 
<10%). More than 90% of the isolates were resistant to at least one of the antibiotics 
tested. MAR was expressed by 78% of all isolates.
Most recently, Backhaus A Grimme (1999) have presented data on the toxicity of antibiotic 
agents to the bacterium Vibrio fischeri as determined in the chronic bioluminescence inhibi­
tion assay (24h) They also discussed the potential for impacts on natural microbial communi­
ties following human, veterinary and aquacluture applications of such compounds and specu­
late that direct effects are to be expected under certain circumstances (e.g., fish farms). 
Where possible, comparisons can be made between the EQo values obtained by Backhaus A 
Grimme (1999) and the observations of antibiotic agents in sewage effluents and receiving 
surface waters made by Hirsch et al. (1999). For example, the ECio for Chloroamphenicol is 
0.0187 mg/l. This can be compared with reported maximal concentrations of Chloroampheni­
col of 0.56 fi/g/l in effluents and 0.06 //g/l in surface water. The respective MEC/ECio ratios 
are 0.03 and <0.01. Similarly, an ECi0 of 0.0046 mg/l for Tetracycline can be compared with
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maximal concentrations of <0.05 /vg/l in both sewage effluent and surface waters. The resul­
tant MEC/ECio ratios are both 0 .01. Assuming that the response of Vibrio fischeri is repre­
sentative of natural microbial communities as a whole, the MEC/ECio ratios (for Chloroam­
phenicol and Tetracycline) appear to indicate that selective pressure is unlikely in the com­
partments considered. This may not apply to other situations such as fish farms or veteri­
nary applications, which may result in high local concentrations in sediments or manure.
RISK MANAGEMENT
Medicinal products have historically been exempted from the European legislative framework 
dealing with the risk management of industrial chemicals. For example, Article 2 paragraph 
2(a) of 67/548/EEC (Directive on the approximation of the law, regulations and administra­
tive provisions relating to the classification, packaging and labelling of dangerous substances) 
lists nmedicinal products for human or veterinary use, as defined in directive 65/65/EEC..." 
as being exempt from the directive. Similarly, Article 1 paragraph 3(a) of 88/379/EEC (Di­
rective on the approximation of the law, regulations and administrative provisions relating to 
the classification, packaging and labelling of dangerous preparations) exempts "medicinal or 
veterinary products as defined by Directive 65/65/EEC...". Most recently, 94/904/EC (Coun­
cil Decision of 22 December 1994 establishing a list of hazardous waste pursuant to article 
1(4) of Council Directive 91/689/EEC on hazardous waste) does not include unused medicines.
Following the obligation to indicate potential risks presented by medicines to the environ­
ment (i.e., via 93/39/EEC) there remains some debate over the form of risk management 
measures for medicines within the EU. Whilst manufacturers have adequate control over 
emissions during formulation of product (CEC, 1992), they do not have any control over the 
emissions resulting from the use and disposal of the product. In  the absence of any regula­
tions, they are obliged to persuade suppliers and users to accept and implement relevant risk
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management processes. I t  is notable that no human medicinal product has been refused mar­
keting authorisation on the basis of ecotoxicological risk potentials. Indeed, it is unlikely
that the current societal paradigm will allow this at present, even though there is increasing 
intolerance of environmental contamination. Moreover, no mechanism exists whereby envi­
ronmental risk can effectively be weighed against the value to society from a new or existing 
medicine. One could therefore argue that while it remains to be decided how the risk man­
agement of medicines will take place, all discussions regarding their environmental risk as­
sessment are moot. Accordingly, an extreme stance would be that if no medicine will ever be 
denied authorisation on environmental grounds, then environmental risk assessment would be 
unnecessary as the outcome would have no relevance. I t  is therefore suggested that the na­
ture of a risk management framework for human medicines urgently needs to be addressed 
before the European environmental risk assessment guidelines are finalised.
Although unlikely in practice, current European legislative provisions do appear to allow an au­
thorisation for a human medicinal product to be declined or revoked on the basis of ecotoxi­
cological risk potential (assuming implementation into respective national legislations). Article 
5 of 65/65/EEC (Directive on the approximation of provisions laid down by law, regulation or 
administrative action relating to proprietary medicinal products) states that "The authorisa­
tion...shall be refused, i f  a fte r verification o f the particulars and documents listed in Article 
4, it  proves that the proprietary medicinal product is harmful in the normal conditions o f use, 
or that its therapeutic efficacy is lacking or is insufficiently substantiated by the applicant, 
or that its qualitative and quantitative composition is not as declared'.
23 Use of certain anti-neoplastic drugs is restricted to in-patient facilities, although this is probably
mainly a result of human safety concerns rather than ecotoxicological risk (see Lee, 1988). I t  does 
however remain as one possible option with which to mitigate the environmental effects of a given 
drug.
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A similar provision in Article 11 allows an authorisation to be revoked and states "the compe­
tent authorities o f the member states shall suspend or revoke an authorisation to place a 
proprietary medicinal product on the market where the product proves to be as harmful in 
the normal conditions o f use, or where its therapeutic efficacy is lacking, or where its quali­
tative and quantitative composition is not as declared. An authorisation shall also be sus­
pended or revoked where the particulars supporting the application as provided for in Article 
4 are found to be incorrect...
Following 93/39/EEC (Directive amending Directives 65/65/EEC, 75/318/EEC and 
75/319/EEC in respect of medicinal products). Article 4 of 65/65 now contains reference to 
potential environmental risks. Article 4.6 of the amendment states " I f  applicable, reasons 
for an precautionary and safety measure to be taken for the storage o f the medicinal prod­
uct, its administration to patients and for the disposal o f waste products, together with an 
indication o f any potential risks presented by the medicinal product for the environment'. I t  
therefore follows that an indication of potential harmful effects arising from environmental 
exposure or the provision of incorrect data to support environmental safety are sufficient to 
deny, suspend or revoke human medicinal drug authorisations.
Whilst the debate continues, it is likely that the extent of risk management of human medi­
cines will be limited to the provision of the advice relating to their proper use and disposal 
via some form of appropriate labelling or other means of hazard identification. Provisions to 
permit this are already in place Article 2 paragraph 1 of 92/27/EEC (Directive on the label­
ling of medicinal products for human use and on packaging leaflets) indicates that "The fol­
lowing particulars shall appear on the outer packaging o f medicinal products or, where there 
is no outer packaging, on the immediate packaging" and included in the list is "(j) special pre-
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cautions for disposal o f unused medicinal products or waste materials derived from such 
products, i f  appropriate". Article 2 paragraph 2 states that "The outer packaging may include 
symbols or pictograms designed to clarify certain information mentioned in paragraph 1 and 
other information compatible with the summary o f the product characteristics which is use­
ful for health education...".
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CHAPTER 7  
SUMMARY
There are a growing number of observations of pharmaceuticals in environmental matri­
ces such as sewage influent, effluent, surface waters and potable water. This implies ex­
posure of aquatic biota and/or indirect human exposure and necessitates risk assess­
ment.
Where acute aquatic data are available, the degree of aquatic ecotoxicity of the large ma­
jority  of pharmaceuticals is limited. This is not unexpected given the low mammalian toxic­
ity that is required of pharmaceuticals in general. All acute ecotoxicity endpoints were 
>ljL/g/l. A lack of published ecotoxicity data was noted for certain classes of compounds. 
Similarly, the chronic ecotoxicity database is limited.
The general lack of public domain usage data had previously precluded estimates of the 
environmental concentrations of pharmaceutical. Data presented in this study allowed the 
aquatic exposure assessment of a large number of compounds from across a wide variety 
of therapeutic classes. Where available, surface water MEC values were generally less 
than "worst-case" exposure predictions.
Risk characterisation utilising acute ecotoxicity data and "worst-case" conservative fate 
assumptions (including no human metabolism, no removal during wastewater treatment and 
no surface water dilution of effluent) demonstrated the apparent environmental safety 
(i.e., PEC/PNEC <1) of all but 8 of the pharmaceuticals considered. The exceptions were 
Paracetamol (Acetaminophen), Aspirin, Dextroproproxyphene, Fluoxetine, Oxytetracy- 
cline, Propranolol, Amitriptyline and Thioridazine. Incorporation of their likely fate fo l­
lowing use (removal during wastewater treatment and/or surface water dilution of e fflu ­
ent but not human metabolism), yielded a marked reduction in the surface water PEC val­
ues and the resultant PEC/PNEC ratios were less than unity for most of the compounds.
Further refinement of the risk assessment is required for Paracetamol, Oxytetracycline 
and Fluoxetine. Risk characterisation was exclusively conducted on the parent drug sub­
stance as representative of substances entering the environment. As a result of the risk 
characterisation it is concluded that there is no basis for assuming widespread environ­
mental effects on the part of pharmaceuticals in general. An important caveat to this 
conclusion relates to the assumption that the standard ecotoxicity tests that constitute 
the acute aquatic database are appropriate to the assessment of compounds with specific 
modes of action. Large Acute/Chronic ratios fo r certain compounds could be used to ar­
gue that chronic ecotoxicity testing with endpoints tailored to the specific modes of ac­
tion be required in the risk assessment of pharmaceuticals. This would entail obvious im­
plications regarding the cost of testing strategies.
• Human metabolism is a mechanism that will potentially reduce environmental exposure. 
However, Phase I I  human metabolism of pharmaceuticals to produce conjugates may be 
reversible if the metabolites are exposed to microbial activity (i.e., in sewage). This po­
tential release of biologically active parent compound has to be considered in any expo­
sure assessment.
• Many pharmaceuticals are weak acids or bases and therefore subject to ionisation. The 
degree of ionisation can greatly affect both their fate and the effects as the hydropho- 
bicity, adsorption, volatilisation, bioconcentration and ecotoxicity of the ionised moiety 
may d iffe r markedly from the unionised or neutral moiety. These processes will be par­
ticularly sensitive to changes in pH in the case of substances with pK* values within the 
range of environmentally relevant pHs (i.e., 5 - 9). This therefore necessitates that due 
attention be given to the role of ionisation in determining the effects and fate behaviour
of pharmaceuticals subject to ERA. The general lack of empirical study in this respect 
needs to be rectified.
Environmental risk assessment in this study has focused upon the water column and has 
ignored other compartments such as soil and sediment. Most pharmaceuticals tend to 
have low Kow values and are often metabolised to more polar (and hence more water solu­
ble) moieties. As such the soil and sediment compartments may be less important, al­
though they should not and indeed cannot be ignored.
Given that (i) few pharmaceuticals appear to have sufficiently elevated K0w values, (ii) 
many are weak acids/bases and exist as the ionised moiety under conditions of ambient 
pH, (iii) many are readily metabolised to more polar metabolites such as conjugates, (iv) 
relatively low levels are likely to occur in the environment and (v) there is a lack of re­
ported examples, it is suggested that the bioaccumulation of human pharmaceuticals will 
not generally be an issue and may effectively be ignored in the risk assessment of the 
majority of compounds.
Although concerns have been expressed over the possibility of adverse human effects 
arising from the presence of pharmaceuticals in drinking water supplies, quantitative 
comparisons reveal that potential lifetime ingestion of pharmaceuticals is limited relative 
to daily therapeutic doses. Further work based on benchmarking predicted exposure with 
the mammalian toxicological database rather than therapeutic dosing regimes (which by 
definition illicit an effect) is desirable.
Given the increasing number of observations of pharmaceutical compounds in sewage, 
surface waters and drinking water, the environmental fate of pharmaceuticals cannot be
ignored and should be considered in the development process. Whilst relative metabolic 
recalcitrance in humans may be necessary for the pharmacological effect of some com­
pounds (e.g., ethinyl substition in the case of Ethinyl Oestradiol), it will likely correspond 
to a poor biodégradation profile in the environment. As such it may not always be possible 
to design "biodegradable" pharmaceuticals. Under such circumstances, other degradation 
mechanisms could perhaps be considered. For example, it may be possible to design 
photolabile analogues of compounds, which resist biodégradation perse.
• A consideration of risk management concluded that current European legislative provi­
sions would allow a drug marketing authorisation to be declined, suspended or revoked on 
the basis of ecotoxicological risk, although in practice this was deemed unlikely. Any risk- 
benefit consideration relates directly to human health and will undoubtedly be fraught 
with difficulties. I t  was therefore suggested that the nature of a risk management 
framework for human medicines urgently needs to be addressed in addition to the Euro­
pean environmental risk assessment guidelines.
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